Separate indirect from direct evidence (SIDE) using back-calculation method

cardiac_serious

Random effects model: 

                                          comparison k prop   nma         95%-CI direct        95%-CI indir.         95%-CI  RoR         95%-CI     z p-value
                     Afatinib:Afatinib + Cetuximab 1 1.00  0.98 [0.06;  15.87]   0.98 [0.06; 15.87]      .              .    .              .     .       .
                   Afatinib:Afatinib + HMGCR inhibitor 1 1.00  3.38 [0.13;  86.01]   3.38 [0.13; 86.01]      .              .    .              .     .       .
                               Afatinib:Almonertinib 0    0  0.44 [0.07;   2.68]      .             .   0.44 [0.07;   2.68]    .              .     .       .
                   Afatinib:Amivantamab  +  Lazertinib 0    0  0.38 [0.12;   1.22]      .             .   0.38 [0.12;   1.22]    .              .     .       .
                               Afatinib:Chemotherapy 2 0.17  0.92 [0.46;   1.86]   0.35 [0.07;  1.90]   1.13 [0.52;   2.45] 0.31 [0.05;   1.98] -1.23  0.2171
                                Afatinib:Dacomitinib 0    0  1.56 [0.67;   3.60]      .             .   1.56 [0.67;   3.60]    .              .     .       .
                             Afatinib:DHFR inhibitor 0    0  1.28 [0.25;   6.50]      .             .   1.28 [0.25;   6.50]    .              .     .       .
                                  Afatinib:Erlotinib 1 0.63  0.99 [0.56;   1.74]   1.01 [0.50;  2.05]   0.96 [0.38;   2.44] 1.05 [0.33;   3.38]  0.08  0.9367
                     Afatinib:Erlotinib + chemotherapy 0    0  0.76 [0.24;   2.38]      .             .   0.76 [0.24;   2.38]    .              .     .       .
                   Afatinib:Erlotinib + COX2 inhibitor 0    0  3.09 [0.12;  81.33]      .             .   3.09 [0.12;  81.33]    .              .     .       .
                   Afatinib:Erlotinib + HER3 inhibitor 0    0  0.38 [0.07;   1.95]      .             .   0.38 [0.07;   1.95]    .              .     .       .
                    Afatinib:Erlotinib + IGF-1R inhibitor 0    0  0.77 [0.23;   2.55]      .             .   0.77 [0.23;   2.55]    .              .     .       .
                    Afatinib:Erlotinib + MET inhibitor 0    0  0.90 [0.39;   2.07]      .             .   0.90 [0.39;   2.07]    .              .     .       .
                    Afatinib:Erlotinib + MMP inhibitor 0    0  0.10 [0.01;   2.05]      .             .   0.10 [0.01;   2.05]    .              .     .       .
                   Afatinib:Erlotinib + antiangiogenesis 0    0  0.77 [0.37;   1.63]      .             .   0.77 [0.37;   1.63]    .              .     .       .
                              Afatinib:Furmonertinib 0    0  0.79 [0.20;   3.12]      .             .   0.79 [0.20;   3.12]    .              .     .       .
                                  Afatinib:Gefitinib 1 0.41  1.12 [0.53;   2.34]   0.99 [0.31;  3.15]   1.21 [0.46;   3.18] 0.82 [0.18;   3.67] -0.26  0.7934
                        Afatinib:Gefitinib/Erlotinib 0    0  1.28 [0.36;   4.59]      .             .   1.28 [0.36;   4.59]    .              .     .       .
                     Afatinib:Gefitinib + chemotherapy 0    0  0.35 [0.03;   3.88]      .             .   0.35 [0.03;   3.88]    .              .     .       .
                   Afatinib:Gefitinib + PARP inhibitor 0    0  0.37 [0.01;   9.97]      .             .   0.37 [0.01;   9.97]    .              .     .       .
                                   Afatinib:Icotinib 0    0  0.16 [0.01;   3.37]      .             .   0.16 [0.01;   3.37]    .              .     .       .
                                 Afatinib:Lazertinib 0    0  0.54 [0.17;   1.74]      .             .   0.54 [0.17;   1.74]    .              .     .       .
                                Afatinib:Osimertinib 0    0  0.63 [0.24;   1.66]      .             .   0.63 [0.24;   1.66]    .              .     .       .
                   Afatinib:Osimertinib + chemotherapy 0    0  0.41 [0.11;   1.57]      .             .   0.41 [0.11;   1.57]    .              .     .       .
                 Afatinib:Osimertinib + antiangiogenesis 0    0  0.12 [0.02;   0.90]      .             .   0.12 [0.02;   0.90]    .              .     .       .
                                    Afatinib:Placebo 1 0.29  1.27 [0.64;   2.52]   2.38 [0.68;  8.39]   0.98 [0.43;   2.21] 2.43 [0.54;  10.87]  1.16  0.2460
                                Afatinib:Rociletinib 0    0  0.63 [0.09;   4.31]      .             .   0.63 [0.09;   4.31]    .              .     .       .
                             Afatinib:antiangiogenesis 0    0  0.19 [0.07;   0.49]      .             .   0.19 [0.07;   0.49]    .              .     .       .
                               Afatinib:Zorifertinib 0    0  0.47 [0.07;   3.02]      .             .   0.47 [0.07;   3.02]    .              .     .       .
     Afatinib + Cetuximab:Afatinib + HMGCR inhibitor 0    0  3.46 [0.05; 248.19]      .             .   3.46 [0.05; 248.19]    .              .     .       .
                 Afatinib + Cetuximab:Almonertinib 0    0  0.45 [0.02;  12.48]      .             .   0.45 [0.02;  12.48]    .              .     .       .
     Afatinib + Cetuximab:Amivantamab  +  Lazertinib 0    0  0.39 [0.02;   8.04]      .             .   0.39 [0.02;   8.04]    .              .     .       .
                 Afatinib + Cetuximab:Chemotherapy 0    0  0.95 [0.05;  16.78]      .             .   0.95 [0.05;  16.78]    .              .     .       .
                  Afatinib + Cetuximab:Dacomitinib 0    0  1.59 [0.09;  29.33]      .             .   1.59 [0.09;  29.33]    .              .     .       .
               Afatinib + Cetuximab:DHFR inhibitor 0    0  1.31 [0.05;  33.05]      .             .   1.31 [0.05;  33.05]    .              .     .       .
                    Afatinib + Cetuximab:Erlotinib 0    0  1.01 [0.06;  17.45]      .             .   1.01 [0.06;  17.45]    .              .     .       .
       Afatinib + Cetuximab:Erlotinib + chemotherapy 0    0  0.78 [0.04;  15.82]      .             .   0.78 [0.04;  15.82]    .              .     .       .
     Afatinib + Cetuximab:Erlotinib + COX2 inhibitor 0    0  3.16 [0.04; 232.68]      .             .   3.16 [0.04; 232.68]    .              .     .       .
     Afatinib + Cetuximab:Erlotinib + HER3 inhibitor 0    0  0.39 [0.02;   9.82]      .             .   0.39 [0.02;   9.82]    .              .     .       .
      Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor 0    0  0.79 [0.04;  16.37]      .             .   0.79 [0.04;  16.37]    .              .     .       .
      Afatinib + Cetuximab:Erlotinib + MET inhibitor 0    0  0.92 [0.05;  16.94]      .             .   0.92 [0.05;  16.94]    .              .     .       .
      Afatinib + Cetuximab:Erlotinib + MMP inhibitor 0    0  0.11 [0.00;   6.29]      .             .   0.11 [0.00;   6.29]    .              .     .       .
     Afatinib + Cetuximab:Erlotinib + antiangiogenesis 0    0  0.79 [0.04;  14.20]      .             .   0.79 [0.04;  14.20]    .              .     .       .
                Afatinib + Cetuximab:Furmonertinib 0    0  0.80 [0.04;  18.06]      .             .   0.80 [0.04;  18.06]    .              .     .       .
                    Afatinib + Cetuximab:Gefitinib 0    0  1.15 [0.06;  20.50]      .             .   1.15 [0.06;  20.50]    .              .     .       .
          Afatinib + Cetuximab:Gefitinib/Erlotinib 0    0  1.32 [0.06;  28.20]      .             .   1.32 [0.06;  28.20]    .              .     .       .
       Afatinib + Cetuximab:Gefitinib + chemotherapy 0    0  0.36 [0.01;  14.30]      .             .   0.36 [0.01;  14.30]    .              .     .       .
     Afatinib + Cetuximab:Gefitinib + PARP inhibitor 0    0  0.38 [0.01;  28.36]      .             .   0.38 [0.01;  28.36]    .              .     .       .
                     Afatinib + Cetuximab:Icotinib 0    0  0.16 [0.00;  10.18]      .             .   0.16 [0.00;  10.18]    .              .     .       .
                   Afatinib + Cetuximab:Lazertinib 0    0  0.56 [0.03;  11.41]      .             .   0.56 [0.03;  11.41]    .              .     .       .
                  Afatinib + Cetuximab:Osimertinib 0    0  0.64 [0.03;  12.29]      .             .   0.64 [0.03;  12.29]    .              .     .       .
     Afatinib + Cetuximab:Osimertinib + chemotherapy 0    0  0.42 [0.02;   9.29]      .             .   0.42 [0.02;   9.29]    .              .     .       .
   Afatinib + Cetuximab:Osimertinib + antiangiogenesis 0    0  0.12 [0.00;   3.81]      .             .   0.12 [0.00;   3.81]    .              .     .       .
                      Afatinib + Cetuximab:Placebo 0    0  1.31 [0.07;  23.05]      .             .   1.31 [0.07;  23.05]    .              .     .       .
                  Afatinib + Cetuximab:Rociletinib 0    0  0.65 [0.02;  19.14]      .             .   0.65 [0.02;  19.14]    .              .     .       .
               Afatinib + Cetuximab:antiangiogenesis 0    0  0.20 [0.01;   3.72]      .             .   0.20 [0.01;   3.72]    .              .     .       .
                 Afatinib + Cetuximab:Zorifertinib 0    0  0.49 [0.02;  13.80]      .             .   0.49 [0.02;  13.80]    .              .     .       .
               Afatinib + HMGCR inhibitor:Almonertinib 0    0  0.13 [0.00;   5.29]      .             .   0.13 [0.00;   5.29]    .              .     .       .
   Afatinib + HMGCR inhibitor:Amivantamab  +  Lazertinib 0    0  0.11 [0.00;   3.53]      .             .   0.11 [0.00;   3.53]    .              .     .       .
               Afatinib + HMGCR inhibitor:Chemotherapy 0    0  0.27 [0.01;   7.49]      .             .   0.27 [0.01;   7.49]    .              .     .       .
                Afatinib + HMGCR inhibitor:Dacomitinib 0    0  0.46 [0.02;  13.04]      .             .   0.46 [0.02;  13.04]    .              .     .       .
             Afatinib + HMGCR inhibitor:DHFR inhibitor 0    0  0.38 [0.01;  14.15]      .             .   0.38 [0.01;  14.15]    .              .     .       .
                  Afatinib + HMGCR inhibitor:Erlotinib 0    0  0.29 [0.01;   7.83]      .             .   0.29 [0.01;   7.83]    .              .     .       .
     Afatinib + HMGCR inhibitor:Erlotinib + chemotherapy 0    0  0.22 [0.01;   6.94]      .             .   0.22 [0.01;   6.94]    .              .     .       .
   Afatinib + HMGCR inhibitor:Erlotinib + COX2 inhibitor 0    0  0.91 [0.01;  90.97]      .             .   0.91 [0.01;  90.97]    .              .     .       .
   Afatinib + HMGCR inhibitor:Erlotinib + HER3 inhibitor 0    0  0.11 [0.00;   4.20]      .             .   0.11 [0.00;   4.20]    .              .     .       .
    Afatinib + HMGCR inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.23 [0.01;   7.16]      .             .   0.23 [0.01;   7.16]    .              .     .       .
    Afatinib + HMGCR inhibitor:Erlotinib + MET inhibitor 0    0  0.27 [0.01;   7.53]      .             .   0.27 [0.01;   7.53]    .              .     .       .
    Afatinib + HMGCR inhibitor:Erlotinib + MMP inhibitor 0    0  0.03 [0.00;   2.50]      .             .   0.03 [0.00;   2.50]    .              .     .       .
   Afatinib + HMGCR inhibitor:Erlotinib + antiangiogenesis 0    0  0.23 [0.01;   6.33]      .             .   0.23 [0.01;   6.33]    .              .     .       .
              Afatinib + HMGCR inhibitor:Furmonertinib 0    0  0.23 [0.01;   7.83]      .             .   0.23 [0.01;   7.83]    .              .     .       .
                  Afatinib + HMGCR inhibitor:Gefitinib 0    0  0.33 [0.01;   9.15]      .             .   0.33 [0.01;   9.15]    .              .     .       .
        Afatinib + HMGCR inhibitor:Gefitinib/Erlotinib 0    0  0.38 [0.01;  12.30]      .             .   0.38 [0.01;  12.30]    .              .     .       .
     Afatinib + HMGCR inhibitor:Gefitinib + chemotherapy 0    0  0.10 [0.00;   5.86]      .             .   0.10 [0.00;   5.86]    .              .     .       .
   Afatinib + HMGCR inhibitor:Gefitinib + PARP inhibitor 0    0  0.11 [0.00;  11.07]      .             .   0.11 [0.00;  11.07]    .              .     .       .
                   Afatinib + HMGCR inhibitor:Icotinib 0    0  0.05 [0.00;   4.02]      .             .   0.05 [0.00;   4.02]    .              .     .       .
                 Afatinib + HMGCR inhibitor:Lazertinib 0    0  0.16 [0.01;   5.00]      .             .   0.16 [0.01;   5.00]    .              .     .       .
                Afatinib + HMGCR inhibitor:Osimertinib 0    0  0.18 [0.01;   5.43]      .             .   0.18 [0.01;   5.43]    .              .     .       .
   Afatinib + HMGCR inhibitor:Osimertinib + chemotherapy 0    0  0.12 [0.00;   4.04]      .             .   0.12 [0.00;   4.04]    .              .     .       .
 Afatinib + HMGCR inhibitor:Osimertinib + antiangiogenesis 0    0  0.04 [0.00;   1.60]      .             .   0.04 [0.00;   1.60]    .              .     .       .
                    Afatinib + HMGCR inhibitor:Placebo 0    0  0.38 [0.01;  10.30]      .             .   0.38 [0.01;  10.30]    .              .     .       .
                Afatinib + HMGCR inhibitor:Rociletinib 0    0  0.19 [0.00;   8.06]      .             .   0.19 [0.00;   8.06]    .              .     .       .
             Afatinib + HMGCR inhibitor:antiangiogenesis 0    0  0.06 [0.00;   1.64]      .             .   0.06 [0.00;   1.64]    .              .     .       .
               Afatinib + HMGCR inhibitor:Zorifertinib 0    0  0.14 [0.00;   5.84]      .             .   0.14 [0.00;   5.84]    .              .     .       .
               Almonertinib:Amivantamab  +  Lazertinib 0    0  0.87 [0.12;   6.46]      .             .   0.87 [0.12;   6.46]    .              .     .       .
                           Almonertinib:Chemotherapy 0    0  2.10 [0.34;  12.85]      .             .   2.10 [0.34;  12.85]    .              .     .       .
                            Almonertinib:Dacomitinib 0    0  3.55 [0.54;  23.35]      .             .   3.55 [0.54;  23.35]    .              .     .       .
                         Almonertinib:DHFR inhibitor 0    0  2.92 [0.28;  30.80]      .             .   2.92 [0.28;  30.80]    .              .     .       .
                              Almonertinib:Erlotinib 0    0  2.26 [0.37;  13.63]      .             .   2.26 [0.37;  13.63]    .              .     .       .
                 Almonertinib:Erlotinib + chemotherapy 0    0  1.73 [0.22;  13.37]      .             .   1.73 [0.22;  13.37]    .              .     .       .
               Almonertinib:Erlotinib + COX2 inhibitor 0    0  7.03 [0.18; 281.72]      .             .   7.03 [0.18; 281.72]    .              .     .       .
               Almonertinib:Erlotinib + HER3 inhibitor 0    0  0.86 [0.08;   9.18]      .             .   0.86 [0.08;   9.18]    .              .     .       .
                Almonertinib:Erlotinib + IGF-1R inhibitor 0    0  1.75 [0.22;  14.11]      .             .   1.75 [0.22;  14.11]    .              .     .       .
                Almonertinib:Erlotinib + MET inhibitor 0    0  2.05 [0.31;  13.72]      .             .   2.05 [0.31;  13.72]    .              .     .       .
                Almonertinib:Erlotinib + MMP inhibitor 0    0  0.23 [0.01;   7.34]      .             .   0.23 [0.01;   7.34]    .              .     .       .
               Almonertinib:Erlotinib + antiangiogenesis 0    0  1.76 [0.27;  11.36]      .             .   1.76 [0.27;  11.36]    .              .     .       .
                          Almonertinib:Furmonertinib 0    0  1.79 [0.24;  13.50]      .             .   1.79 [0.24;  13.50]    .              .     .       .
                              Almonertinib:Gefitinib 1 1.00  2.55 [0.49;  13.28]   2.55 [0.49; 13.28]      .              .    .              .     .       .
                    Almonertinib:Gefitinib/Erlotinib 0    0  2.93 [0.37;  23.42]      .             .   2.93 [0.37;  23.42]    .              .     .       .
                 Almonertinib:Gefitinib + chemotherapy 0    0  0.81 [0.05;  13.43]      .             .   0.81 [0.05;  13.43]    .              .     .       .
               Almonertinib:Gefitinib + PARP inhibitor 0    0  0.84 [0.02;  31.14]      .             .   0.84 [0.02;  31.14]    .              .     .       .
                               Almonertinib:Icotinib 0    0  0.36 [0.01;  10.77]      .             .   0.36 [0.01;  10.77]    .              .     .       .
                             Almonertinib:Lazertinib 0    0  1.23 [0.17;   9.05]      .             .   1.23 [0.17;   9.05]    .              .     .       .
                            Almonertinib:Osimertinib 0    0  1.42 [0.21;   9.65]      .             .   1.42 [0.21;   9.65]    .              .     .       .
               Almonertinib:Osimertinib + chemotherapy 0    0  0.94 [0.11;   7.81]      .             .   0.94 [0.11;   7.81]    .              .     .       .
             Almonertinib:Osimertinib + antiangiogenesis 0    0  0.27 [0.02;   3.67]      .             .   0.27 [0.02;   3.67]    .              .     .       .
                                Almonertinib:Placebo 0    0  2.90 [0.48;  17.69]      .             .   2.90 [0.48;  17.69]    .              .     .       .
                            Almonertinib:Rociletinib 0    0  1.44 [0.11;  18.82]      .             .   1.44 [0.11;  18.82]    .              .     .       .
                         Almonertinib:antiangiogenesis 0    0  0.43 [0.06;   3.02]      .             .   0.43 [0.06;   3.02]    .              .     .       .
                           Almonertinib:Zorifertinib 0    0  1.08 [0.09;  12.85]      .             .   1.08 [0.09;  12.85]    .              .     .       .
               Amivantamab  +  Lazertinib:Chemotherapy 0    0  2.41 [0.77;   7.56]      .             .   2.41 [0.77;   7.56]    .              .     .       .
                Amivantamab  +  Lazertinib:Dacomitinib 0    0  4.05 [1.19;  13.83]      .             .   4.05 [1.19;  13.83]    .              .     .       .
             Amivantamab  +  Lazertinib:DHFR inhibitor 0    0  3.33 [0.51;  21.83]      .             .   3.33 [0.51;  21.83]    .              .     .       .
                  Amivantamab  +  Lazertinib:Erlotinib 0    0  2.58 [0.86;   7.75]      .             .   2.58 [0.86;   7.75]    .              .     .       .
     Amivantamab  +  Lazertinib:Erlotinib + chemotherapy 0    0  1.97 [0.45;   8.64]      .             .   1.97 [0.45;   8.64]    .              .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + COX2 inhibitor 0    0  8.03 [0.27; 242.07]      .             .   8.03 [0.27; 242.07]    .              .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor 0    0  0.98 [0.15;   6.53]      .             .   0.98 [0.15;   6.53]    .              .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor 0    0  2.00 [0.43;   9.22]      .             .   2.00 [0.43;   9.22]    .              .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor 0    0  2.35 [0.67;   8.26]      .             .   2.35 [0.67;   8.26]    .              .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor 0    0  0.27 [0.01;   6.17]      .             .   0.27 [0.01;   6.17]    .              .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis 0    0  2.01 [0.60;   6.72]      .             .   2.01 [0.60;   6.72]    .              .     .       .
              Amivantamab  +  Lazertinib:Furmonertinib 0    0  2.04 [0.40;  10.36]      .             .   2.04 [0.40;  10.36]    .              .     .       .
                  Amivantamab  +  Lazertinib:Gefitinib 0    0  2.91 [0.94;   9.00]      .             .   2.91 [0.94;   9.00]    .              .     .       .
        Amivantamab  +  Lazertinib:Gefitinib/Erlotinib 0    0  3.34 [1.14;   9.77]      .             .   3.34 [1.14;   9.77]    .              .     .       .
     Amivantamab  +  Lazertinib:Gefitinib + chemotherapy 0    0  0.92 [0.07;  11.70]      .             .   0.92 [0.07;  11.70]    .              .     .       .
   Amivantamab  +  Lazertinib:Gefitinib + PARP inhibitor 0    0  0.96 [0.03;  28.94]      .             .   0.96 [0.03;  28.94]    .              .     .       .
                   Amivantamab  +  Lazertinib:Icotinib 0    0  0.41 [0.02;   9.87]      .             .   0.41 [0.02;   9.87]    .              .     .       .
                 Amivantamab  +  Lazertinib:Lazertinib 1 0.93  1.41 [0.63;   3.15]   1.35 [0.59;  3.09]   2.69 [0.13;  57.87] 0.50 [0.02;  11.98] -0.43  0.6684
                Amivantamab  +  Lazertinib:Osimertinib 1 0.96  1.63 [0.81;   3.25]   1.68 [0.83;  3.39]   0.74 [0.02;  29.17] 2.27 [0.05;  95.51]  0.43  0.6684
   Amivantamab  +  Lazertinib:Osimertinib + chemotherapy 0    0  1.07 [0.34;   3.37]      .             .   1.07 [0.34;   3.37]    .              .     .       .
 Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis 0    0  0.31 [0.05;   2.07]      .             .   0.31 [0.05;   2.07]    .              .     .       .
                    Amivantamab  +  Lazertinib:Placebo 0    0  3.32 [1.21;   9.11]      .             .   3.32 [1.21;   9.11]    .              .     .       .
                Amivantamab  +  Lazertinib:Rociletinib 0    0  1.65 [0.19;  13.99]      .             .   1.65 [0.19;  13.99]    .              .     .       .
             Amivantamab  +  Lazertinib:antiangiogenesis 0    0  0.50 [0.13;   1.88]      .             .   0.50 [0.13;   1.88]    .              .     .       .
               Amivantamab  +  Lazertinib:Zorifertinib 0    0  1.24 [0.22;   6.88]      .             .   1.24 [0.22;   6.88]    .              .     .       .
                            Chemotherapy:Dacomitinib 0    0  1.69 [0.73;   3.90]      .             .   1.69 [0.73;   3.90]    .              .     .       .
                         Chemotherapy:DHFR inhibitor 0    0  1.39 [0.27;   7.00]      .             .   1.39 [0.27;   7.00]    .              .     .       .
                              Chemotherapy:Erlotinib 7 0.69  1.07 [0.62;   1.86]   1.07 [0.55;  2.08]   1.07 [0.40;   2.87] 1.00 [0.31;   3.28] -0.00  0.9999
                 Chemotherapy:Erlotinib + chemotherapy 1 0.36  0.82 [0.28;   2.41]   0.97 [0.16;  5.79]   0.74 [0.19;   2.87] 1.31 [0.14;  12.24]  0.24  0.8127
               Chemotherapy:Erlotinib + COX2 inhibitor 0    0  3.34 [0.13;  87.83]      .             .   3.34 [0.13;  87.83]    .              .     .       .
               Chemotherapy:Erlotinib + HER3 inhibitor 0    0  0.41 [0.08;   2.10]      .             .   0.41 [0.08;   2.10]    .              .     .       .
                Chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  0.83 [0.25;   2.75]      .             .   0.83 [0.25;   2.75]    .              .     .       .
                Chemotherapy:Erlotinib + MET inhibitor 0    0  0.98 [0.43;   2.22]      .             .   0.98 [0.43;   2.22]    .              .     .       .
                Chemotherapy:Erlotinib + MMP inhibitor 0    0  0.11 [0.01;   2.21]      .             .   0.11 [0.01;   2.21]    .              .     .       .
               Chemotherapy:Erlotinib + antiangiogenesis 0    0  0.84 [0.40;   1.75]      .             .   0.84 [0.40;   1.75]    .              .     .       .
                          Chemotherapy:Furmonertinib 0    0  0.85 [0.21;   3.38]      .             .   0.85 [0.21;   3.38]    .              .     .       .
                              Chemotherapy:Gefitinib 2 0.44  1.21 [0.58;   2.54]   0.99 [0.32;  3.04]   1.41 [0.53;   3.79] 0.70 [0.16;   3.13] -0.46  0.6450
                    Chemotherapy:Gefitinib/Erlotinib 0    0  1.39 [0.39;   4.92]      .             .   1.39 [0.39;   4.92]    .              .     .       .
                 Chemotherapy:Gefitinib + chemotherapy 0    0  0.38 [0.03;   4.20]      .             .   0.38 [0.03;   4.20]    .              .     .       .
               Chemotherapy:Gefitinib + PARP inhibitor 0    0  0.40 [0.01;  10.80]      .             .   0.40 [0.01;  10.80]    .              .     .       .
                               Chemotherapy:Icotinib 0    0  0.17 [0.01;   3.65]      .             .   0.17 [0.01;   3.65]    .              .     .       .
                             Chemotherapy:Lazertinib 0    0  0.59 [0.18;   1.87]      .             .   0.59 [0.18;   1.87]    .              .     .       .
                            Chemotherapy:Osimertinib 1 0.21  0.68 [0.26;   1.77]   0.34 [0.04;  2.83]   0.81 [0.27;   2.39] 0.42 [0.04;   4.52] -0.72  0.4712
               Chemotherapy:Osimertinib + chemotherapy 0    0  0.45 [0.12;   1.68]      .             .   0.45 [0.12;   1.68]    .              .     .       .
             Chemotherapy:Osimertinib + antiangiogenesis 0    0  0.13 [0.02;   0.97]      .             .   0.13 [0.02;   0.97]    .              .     .       .
                                Chemotherapy:Placebo 0    0  1.38 [0.67;   2.84]      .             .   1.38 [0.67;   2.84]    .              .     .       .
                            Chemotherapy:Rociletinib 0    0  0.69 [0.10;   4.65]      .             .   0.69 [0.10;   4.65]    .              .     .       .
                         Chemotherapy:antiangiogenesis 0    0  0.21 [0.08;   0.53]      .             .   0.21 [0.08;   0.53]    .              .     .       .
                           Chemotherapy:Zorifertinib 0    0  0.51 [0.08;   3.24]      .             .   0.51 [0.08;   3.24]    .              .     .       .
                          Dacomitinib:DHFR inhibitor 0    0  0.82 [0.16;   4.34]      .             .   0.82 [0.16;   4.34]    .              .     .       .
                               Dacomitinib:Erlotinib 1 0.75  0.64 [0.33;   1.24]   0.79 [0.37;  1.72]   0.33 [0.09;   1.24] 2.41 [0.52;  11.17]  1.12  0.2617
                  Dacomitinib:Erlotinib + chemotherapy 0    0  0.49 [0.15;   1.63]      .             .   0.49 [0.15;   1.63]    .              .     .       .
                Dacomitinib:Erlotinib + COX2 inhibitor 0    0  1.98 [0.07;  53.25]      .             .   1.98 [0.07;  53.25]    .              .     .       .
                Dacomitinib:Erlotinib + HER3 inhibitor 0    0  0.24 [0.04;   1.30]      .             .   0.24 [0.04;   1.30]    .              .     .       .
                 Dacomitinib:Erlotinib + IGF-1R inhibitor 0    0  0.49 [0.14;   1.73]      .             .   0.49 [0.14;   1.73]    .              .     .       .
                 Dacomitinib:Erlotinib + MET inhibitor 0    0  0.58 [0.23;   1.43]      .             .   0.58 [0.23;   1.43]    .              .     .       .
                 Dacomitinib:Erlotinib + MMP inhibitor 0    0  0.07 [0.00;   1.34]      .             .   0.07 [0.00;   1.34]    .              .     .       .
                Dacomitinib:Erlotinib + antiangiogenesis 0    0  0.50 [0.22;   1.14]      .             .   0.50 [0.22;   1.14]    .              .     .       .
                           Dacomitinib:Furmonertinib 0    0  0.50 [0.11;   2.21]      .             .   0.50 [0.11;   2.21]    .              .     .       .
                               Dacomitinib:Gefitinib 1 0.11  0.72 [0.29;   1.78]   0.99 [0.06; 15.87]   0.69 [0.26;   1.81] 1.43 [0.08;  26.99]  0.24  0.8126
                     Dacomitinib:Gefitinib/Erlotinib 0    0  0.82 [0.22;   3.14]      .             .   0.82 [0.22;   3.14]    .              .     .       .
                  Dacomitinib:Gefitinib + chemotherapy 0    0  0.23 [0.02;   2.64]      .             .   0.23 [0.02;   2.64]    .              .     .       .
                Dacomitinib:Gefitinib + PARP inhibitor 0    0  0.24 [0.01;   6.68]      .             .   0.24 [0.01;   6.68]    .              .     .       .
                                Dacomitinib:Icotinib 0    0  0.10 [0.00;   2.27]      .             .   0.10 [0.00;   2.27]    .              .     .       .
                              Dacomitinib:Lazertinib 0    0  0.35 [0.10;   1.21]      .             .   0.35 [0.10;   1.21]    .              .     .       .
                             Dacomitinib:Osimertinib 0    0  0.40 [0.14;   1.16]      .             .   0.40 [0.14;   1.16]    .              .     .       .
                Dacomitinib:Osimertinib + chemotherapy 0    0  0.26 [0.07;   1.07]      .             .   0.26 [0.07;   1.07]    .              .     .       .
              Dacomitinib:Osimertinib + antiangiogenesis 0    0  0.08 [0.01;   0.60]      .             .   0.08 [0.01;   0.60]    .              .     .       .
                                 Dacomitinib:Placebo 1 0.34  0.82 [0.38;   1.78]   0.40 [0.11;  1.49]   1.20 [0.46;   3.11] 0.33 [0.06;   1.69] -1.33  0.1845
                             Dacomitinib:Rociletinib 0    0  0.41 [0.06;   2.86]      .             .   0.41 [0.06;   2.86]    .              .     .       .
                          Dacomitinib:antiangiogenesis 0    0  0.12 [0.04;   0.34]      .             .   0.12 [0.04;   0.34]    .              .     .       .
                            Dacomitinib:Zorifertinib 0    0  0.30 [0.05;   2.02]      .             .   0.30 [0.05;   2.02]    .              .     .       .
                            DHFR inhibitor:Erlotinib 1 1.00  0.77 [0.17;   3.55]   0.77 [0.17;  3.55]      .              .    .              .     .       .
               DHFR inhibitor:Erlotinib + chemotherapy 0    0  0.59 [0.10;   3.69]      .             .   0.59 [0.10;   3.69]    .              .     .       .
             DHFR inhibitor:Erlotinib + COX2 inhibitor 0    0  2.41 [0.07;  85.17]      .             .   2.41 [0.07;  85.17]    .              .     .       .
             DHFR inhibitor:Erlotinib + HER3 inhibitor 0    0  0.29 [0.03;   2.58]      .             .   0.29 [0.03;   2.58]    .              .     .       .
              DHFR inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.60 [0.09;   3.84]      .             .   0.60 [0.09;   3.84]    .              .     .       .
              DHFR inhibitor:Erlotinib + MET inhibitor 0    0  0.70 [0.14;   3.64]      .             .   0.70 [0.14;   3.64]    .              .     .       .
              DHFR inhibitor:Erlotinib + MMP inhibitor 0    0  0.08 [0.00;   2.20]      .             .   0.08 [0.00;   2.20]    .              .     .       .
             DHFR inhibitor:Erlotinib + antiangiogenesis 0    0  0.60 [0.12;   2.99]      .             .   0.60 [0.12;   2.99]    .              .     .       .
                        DHFR inhibitor:Furmonertinib 0    0  0.61 [0.08;   4.75]      .             .   0.61 [0.08;   4.75]    .              .     .       .
                            DHFR inhibitor:Gefitinib 0    0  0.87 [0.16;   4.70]      .             .   0.87 [0.16;   4.70]    .              .     .       .
                  DHFR inhibitor:Gefitinib/Erlotinib 0    0  1.00 [0.14;   7.07]      .             .   1.00 [0.14;   7.07]    .              .     .       .
               DHFR inhibitor:Gefitinib + chemotherapy 0    0  0.28 [0.02;   4.69]      .             .   0.28 [0.02;   4.69]    .              .     .       .
             DHFR inhibitor:Gefitinib + PARP inhibitor 0    0  0.29 [0.01;  10.84]      .             .   0.29 [0.01;  10.84]    .              .     .       .
                             DHFR inhibitor:Icotinib 0    0  0.12 [0.00;   3.75]      .             .   0.12 [0.00;   3.75]    .              .     .       .
                           DHFR inhibitor:Lazertinib 0    0  0.42 [0.06;   2.81]      .             .   0.42 [0.06;   2.81]    .              .     .       .
                          DHFR inhibitor:Osimertinib 0    0  0.49 [0.08;   2.88]      .             .   0.49 [0.08;   2.88]    .              .     .       .
             DHFR inhibitor:Osimertinib + chemotherapy 0    0  0.32 [0.04;   2.36]      .             .   0.32 [0.04;   2.36]    .              .     .       .
           DHFR inhibitor:Osimertinib + antiangiogenesis 0    0  0.09 [0.01;   1.14]      .             .   0.09 [0.01;   1.14]    .              .     .       .
                              DHFR inhibitor:Placebo 0    0  1.00 [0.20;   5.08]      .             .   1.00 [0.20;   5.08]    .              .     .       .
                          DHFR inhibitor:Rociletinib 0    0  0.49 [0.05;   5.37]      .             .   0.49 [0.05;   5.37]    .              .     .       .
                       DHFR inhibitor:antiangiogenesis 0    0  0.15 [0.03;   0.82]      .             .   0.15 [0.03;   0.82]    .              .     .       .
                         DHFR inhibitor:Zorifertinib 0    0  0.37 [0.03;   3.96]      .             .   0.37 [0.03;   3.96]    .              .     .       .
                    Erlotinib:Erlotinib + chemotherapy 2 0.78  0.77 [0.28;   2.11]   0.65 [0.21;  2.06]   1.34 [0.15;  11.66] 0.49 [0.04;   5.69] -0.57  0.5685
                  Erlotinib:Erlotinib + COX2 inhibitor 1 1.00  3.11 [0.12;  78.18]   3.11 [0.12; 78.18]      .              .    .              .     .       .
                  Erlotinib:Erlotinib + HER3 inhibitor 1 1.00  0.38 [0.08;   1.78]   0.38 [0.08;  1.78]      .              .    .              .     .       .
                   Erlotinib:Erlotinib + IGF-1R inhibitor 2 1.00  0.77 [0.27;   2.24]   0.77 [0.27;  2.24]      .              .    .              .     .       .
                   Erlotinib:Erlotinib + MET inhibitor 3 1.00  0.91 [0.49;   1.68]   0.91 [0.49;  1.68]      .              .    .              .     .       .
                   Erlotinib:Erlotinib + MMP inhibitor 1 1.00  0.10 [0.01;   1.96]   0.10 [0.01;  1.96]      .              .    .              .     .       .
                  Erlotinib:Erlotinib + antiangiogenesis 9 1.00  0.78 [0.48;   1.28]   0.78 [0.48;  1.28]      .              .    .              .     .       .
                             Erlotinib:Furmonertinib 0    0  0.79 [0.20;   3.11]      .             .   0.79 [0.20;   3.11]    .              .     .       .
                                 Erlotinib:Gefitinib 0    0  1.13 [0.55;   2.30]      .             .   1.13 [0.55;   2.30]    .              .     .       .
                       Erlotinib:Gefitinib/Erlotinib 0    0  1.30 [0.38;   4.40]      .             .   1.30 [0.38;   4.40]    .              .     .       .
                    Erlotinib:Gefitinib + chemotherapy 0    0  0.36 [0.03;   3.89]      .             .   0.36 [0.03;   3.89]    .              .     .       .
                  Erlotinib:Gefitinib + PARP inhibitor 0    0  0.37 [0.01;  10.01]      .             .   0.37 [0.01;  10.01]    .              .     .       .
                                  Erlotinib:Icotinib 0    0  0.16 [0.01;   3.39]      .             .   0.16 [0.01;   3.39]    .              .     .       .
                                Erlotinib:Lazertinib 0    0  0.55 [0.18;   1.68]      .             .   0.55 [0.18;   1.68]    .              .     .       .
                               Erlotinib:Osimertinib 0    0  0.63 [0.25;   1.57]      .             .   0.63 [0.25;   1.57]    .              .     .       .
                  Erlotinib:Osimertinib + chemotherapy 0    0  0.42 [0.11;   1.51]      .             .   0.42 [0.11;   1.51]    .              .     .       .
                Erlotinib:Osimertinib + antiangiogenesis 0    0  0.12 [0.02;   0.88]      .             .   0.12 [0.02;   0.88]    .              .     .       .
                                   Erlotinib:Placebo 3 0.51  1.29 [0.72;   2.29]   1.44 [0.65;  3.23]   1.14 [0.50;   2.61] 1.27 [0.40;   4.02]  0.40  0.6879
                               Erlotinib:Rociletinib 1 1.00  0.64 [0.10;   4.00]   0.64 [0.10;  4.00]      .              .    .              .     .       .
                            Erlotinib:antiangiogenesis 2 0.93  0.19 [0.09;   0.42]   0.22 [0.10;  0.49]   0.03 [0.00;   0.64] 6.48 [0.31; 136.02]  1.20  0.2292
                              Erlotinib:Zorifertinib 0    0  0.48 [0.08;   2.94]      .             .   0.48 [0.08;   2.94]    .              .     .       .
     Erlotinib + chemotherapy:Erlotinib + COX2 inhibitor 0    0  4.07 [0.14; 119.32]      .             .   4.07 [0.14; 119.32]    .              .     .       .
     Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor 0    0  0.50 [0.08;   3.15]      .             .   0.50 [0.08;   3.15]    .              .     .       .
      Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor 0    0  1.01 [0.23;   4.39]      .             .   1.01 [0.23;   4.39]    .              .     .       .
      Erlotinib + chemotherapy:Erlotinib + MET inhibitor 0    0  1.19 [0.36;   3.88]      .             .   1.19 [0.36;   3.88]    .              .     .       .
      Erlotinib + chemotherapy:Erlotinib + MMP inhibitor 0    0  0.14 [0.01;   3.04]      .             .   0.14 [0.01;   3.04]    .              .     .       .
     Erlotinib + chemotherapy:Erlotinib + antiangiogenesis 0    0  1.02 [0.33;   3.14]      .             .   1.02 [0.33;   3.14]    .              .     .       .
                Erlotinib + chemotherapy:Furmonertinib 0    0  1.04 [0.19;   5.55]      .             .   1.04 [0.19;   5.55]    .              .     .       .
                    Erlotinib + chemotherapy:Gefitinib 0    0  1.47 [0.44;   4.94]      .             .   1.47 [0.44;   4.94]    .              .     .       .
          Erlotinib + chemotherapy:Gefitinib/Erlotinib 0    0  1.69 [0.35;   8.14]      .             .   1.69 [0.35;   8.14]    .              .     .       .
       Erlotinib + chemotherapy:Gefitinib + chemotherapy 0    0  0.47 [0.04;   6.15]      .             .   0.47 [0.04;   6.15]    .              .     .       .
     Erlotinib + chemotherapy:Gefitinib + PARP inhibitor 0    0  0.49 [0.02;  15.07]      .             .   0.49 [0.02;  15.07]    .              .     .       .
                     Erlotinib + chemotherapy:Icotinib 0    0  0.21 [0.01;   5.15]      .             .   0.21 [0.01;   5.15]    .              .     .       .
                   Erlotinib + chemotherapy:Lazertinib 0    0  0.71 [0.16;   3.17]      .             .   0.71 [0.16;   3.17]    .              .     .       .
                  Erlotinib + chemotherapy:Osimertinib 0    0  0.82 [0.22;   3.15]      .             .   0.82 [0.22;   3.15]    .              .     .       .
     Erlotinib + chemotherapy:Osimertinib + chemotherapy 0    0  0.54 [0.11;   2.75]      .             .   0.54 [0.11;   2.75]    .              .     .       .
   Erlotinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.16 [0.02;   1.44]      .             .   0.16 [0.02;   1.44]    .              .     .       .
                      Erlotinib + chemotherapy:Placebo 0    0  1.68 [0.53;   5.32]      .             .   1.68 [0.53;   5.32]    .              .     .       .
                  Erlotinib + chemotherapy:Rociletinib 0    0  0.83 [0.10;   6.79]      .             .   0.83 [0.10;   6.79]    .              .     .       .
               Erlotinib + chemotherapy:antiangiogenesis 0    0  0.25 [0.07;   0.90]      .             .   0.25 [0.07;   0.90]    .              .     .       .
                 Erlotinib + chemotherapy:Zorifertinib 0    0  0.63 [0.08;   4.93]      .             .   0.63 [0.08;   4.93]    .              .     .       .
   Erlotinib + COX2 inhibitor:Erlotinib + HER3 inhibitor 0    0  0.12 [0.00;   4.35]      .             .   0.12 [0.00;   4.35]    .              .     .       .
    Erlotinib + COX2 inhibitor:Erlotinib + IGF-1R inhibitor 0    0  0.25 [0.01;   7.40]      .             .   0.25 [0.01;   7.40]    .              .     .       .
    Erlotinib + COX2 inhibitor:Erlotinib + MET inhibitor 0    0  0.29 [0.01;   7.77]      .             .   0.29 [0.01;   7.77]    .              .     .       .
    Erlotinib + COX2 inhibitor:Erlotinib + MMP inhibitor 0    0  0.03 [0.00;   2.61]      .             .   0.03 [0.00;   2.61]    .              .     .       .
   Erlotinib + COX2 inhibitor:Erlotinib + antiangiogenesis 0    0  0.25 [0.01;   6.53]      .             .   0.25 [0.01;   6.53]    .              .     .       .
              Erlotinib + COX2 inhibitor:Furmonertinib 0    0  0.25 [0.01;   8.44]      .             .   0.25 [0.01;   8.44]    .              .     .       .
                  Erlotinib + COX2 inhibitor:Gefitinib 0    0  0.36 [0.01;   9.84]      .             .   0.36 [0.01;   9.84]    .              .     .       .
        Erlotinib + COX2 inhibitor:Gefitinib/Erlotinib 0    0  0.42 [0.01;  13.07]      .             .   0.42 [0.01;  13.07]    .              .     .       .
     Erlotinib + COX2 inhibitor:Gefitinib + chemotherapy 0    0  0.11 [0.00;   6.33]      .             .   0.11 [0.00;   6.33]    .              .     .       .
   Erlotinib + COX2 inhibitor:Gefitinib + PARP inhibitor 0    0  0.12 [0.00;  11.97]      .             .   0.12 [0.00;  11.97]    .              .     .       .
                   Erlotinib + COX2 inhibitor:Icotinib 0    0  0.05 [0.00;   4.35]      .             .   0.05 [0.00;   4.35]    .              .     .       .
                 Erlotinib + COX2 inhibitor:Lazertinib 0    0  0.18 [0.01;   5.33]      .             .   0.18 [0.01;   5.33]    .              .     .       .
                Erlotinib + COX2 inhibitor:Osimertinib 0    0  0.20 [0.01;   5.77]      .             .   0.20 [0.01;   5.77]    .              .     .       .
   Erlotinib + COX2 inhibitor:Osimertinib + chemotherapy 0    0  0.13 [0.00;   4.29]      .             .   0.13 [0.00;   4.29]    .              .     .       .
 Erlotinib + COX2 inhibitor:Osimertinib + antiangiogenesis 0    0  0.04 [0.00;   1.70]      .             .   0.04 [0.00;   1.70]    .              .     .       .
                    Erlotinib + COX2 inhibitor:Placebo 0    0  0.41 [0.02;  10.91]      .             .   0.41 [0.02;  10.91]    .              .     .       .
                Erlotinib + COX2 inhibitor:Rociletinib 0    0  0.21 [0.01;   8.37]      .             .   0.21 [0.01;   8.37]    .              .     .       .
             Erlotinib + COX2 inhibitor:antiangiogenesis 0    0  0.06 [0.00;   1.70]      .             .   0.06 [0.00;   1.70]    .              .     .       .
               Erlotinib + COX2 inhibitor:Zorifertinib 0    0  0.15 [0.00;   6.21]      .             .   0.15 [0.00;   6.21]    .              .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor 0    0  2.04 [0.31;  13.31]      .             .   2.04 [0.31;  13.31]    .              .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor 0    0  2.40 [0.45;  12.63]      .             .   2.40 [0.45;  12.63]    .              .     .       .
    Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor 0    0  0.27 [0.01;   7.56]      .             .   0.27 [0.01;   7.56]    .              .     .       .
   Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis 0    0  2.05 [0.41;  10.40]      .             .   2.05 [0.41;  10.40]    .              .     .       .
              Erlotinib + HER3 inhibitor:Furmonertinib 0    0  2.09 [0.26;  16.44]      .             .   2.09 [0.26;  16.44]    .              .     .       .
                  Erlotinib + HER3 inhibitor:Gefitinib 0    0  2.97 [0.54;  16.32]      .             .   2.97 [0.54;  16.32]    .              .     .       .
        Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib 0    0  3.41 [0.48;  24.49]      .             .   3.41 [0.48;  24.49]    .              .     .       .
     Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy 0    0  0.94 [0.05;  16.16]      .             .   0.94 [0.05;  16.16]    .              .     .       .
   Erlotinib + HER3 inhibitor:Gefitinib + PARP inhibitor 0    0  0.98 [0.03;  37.22]      .             .   0.98 [0.03;  37.22]    .              .     .       .
                   Erlotinib + HER3 inhibitor:Icotinib 0    0  0.42 [0.01;  12.89]      .             .   0.42 [0.01;  12.89]    .              .     .       .
                 Erlotinib + HER3 inhibitor:Lazertinib 0    0  1.44 [0.21;   9.73]      .             .   1.44 [0.21;   9.73]    .              .     .       .
                Erlotinib + HER3 inhibitor:Osimertinib 0    0  1.66 [0.28;   9.98]      .             .   1.66 [0.28;   9.98]    .              .     .       .
   Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy 0    0  1.10 [0.15;   8.18]      .             .   1.10 [0.15;   8.18]    .              .     .       .
 Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis 0    0  0.32 [0.03;   3.93]      .             .   0.32 [0.03;   3.93]    .              .     .       .
                    Erlotinib + HER3 inhibitor:Placebo 0    0  3.39 [0.65;  17.64]      .             .   3.39 [0.65;  17.64]    .              .     .       .
                Erlotinib + HER3 inhibitor:Rociletinib 0    0  1.68 [0.15;  18.53]      .             .   1.68 [0.15;  18.53]    .              .     .       .
             Erlotinib + HER3 inhibitor:antiangiogenesis 0    0  0.51 [0.09;   2.86]      .             .   0.51 [0.09;   2.86]    .              .     .       .
               Erlotinib + HER3 inhibitor:Zorifertinib 0    0  1.26 [0.12;  13.68]      .             .   1.26 [0.12;  13.68]    .              .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor 0    0  1.18 [0.34;   4.01]      .             .   1.18 [0.34;   4.01]    .              .     .       .
     Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor 0    0  0.13 [0.01;   3.05]      .             .   0.13 [0.01;   3.05]    .              .     .       .
    Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis 0    0  1.01 [0.31;   3.25]      .             .   1.01 [0.31;   3.25]    .              .     .       .
               Erlotinib + IGF-1R inhibitor:Furmonertinib 0    0  1.02 [0.18;   5.79]      .             .   1.02 [0.18;   5.79]    .              .     .       .
                   Erlotinib + IGF-1R inhibitor:Gefitinib 0    0  1.46 [0.41;   5.25]      .             .   1.46 [0.41;   5.25]    .              .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib 0    0  1.67 [0.33;   8.46]      .             .   1.67 [0.33;   8.46]    .              .     .       .
      Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy 0    0  0.46 [0.03;   6.29]      .             .   0.46 [0.03;   6.29]    .              .     .       .
    Erlotinib + IGF-1R inhibitor:Gefitinib + PARP inhibitor 0    0  0.48 [0.02;  15.30]      .             .   0.48 [0.02;  15.30]    .              .     .       .
                    Erlotinib + IGF-1R inhibitor:Icotinib 0    0  0.21 [0.01;   5.24]      .             .   0.21 [0.01;   5.24]    .              .     .       .
                  Erlotinib + IGF-1R inhibitor:Lazertinib 0    0  0.71 [0.15;   3.31]      .             .   0.71 [0.15;   3.31]    .              .     .       .
                 Erlotinib + IGF-1R inhibitor:Osimertinib 0    0  0.82 [0.20;   3.30]      .             .   0.82 [0.20;   3.30]    .              .     .       .
    Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy 0    0  0.54 [0.10;   2.85]      .             .   0.54 [0.10;   2.85]    .              .     .       .
  Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis 0    0  0.16 [0.02;   1.48]      .             .   0.16 [0.02;   1.48]    .              .     .       .
                     Erlotinib + IGF-1R inhibitor:Placebo 0    0  1.66 [0.50;   5.57]      .             .   1.66 [0.50;   5.57]    .              .     .       .
                 Erlotinib + IGF-1R inhibitor:Rociletinib 0    0  0.83 [0.10;   6.88]      .             .   0.83 [0.10;   6.88]    .              .     .       .
              Erlotinib + IGF-1R inhibitor:antiangiogenesis 0    0  0.25 [0.07;   0.93]      .             .   0.25 [0.07;   0.93]    .              .     .       .
                Erlotinib + IGF-1R inhibitor:Zorifertinib 0    0  0.62 [0.08;   5.07]      .             .   0.62 [0.08;   5.07]    .              .     .       .
     Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor 0    0  0.11 [0.01;   2.30]      .             .   0.11 [0.01;   2.30]    .              .     .       .
    Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis 0    0  0.86 [0.39;   1.88]      .             .   0.86 [0.39;   1.88]    .              .     .       .
               Erlotinib + MET inhibitor:Furmonertinib 0    0  0.87 [0.19;   3.90]      .             .   0.87 [0.19;   3.90]    .              .     .       .
                   Erlotinib + MET inhibitor:Gefitinib 0    0  1.24 [0.48;   3.18]      .             .   1.24 [0.48;   3.18]    .              .     .       .
         Erlotinib + MET inhibitor:Gefitinib/Erlotinib 0    0  1.42 [0.36;   5.59]      .             .   1.42 [0.36;   5.59]    .              .     .       .
      Erlotinib + MET inhibitor:Gefitinib + chemotherapy 0    0  0.39 [0.03;   4.61]      .             .   0.39 [0.03;   4.61]    .              .     .       .
    Erlotinib + MET inhibitor:Gefitinib + PARP inhibitor 0    0  0.41 [0.01;  11.64]      .             .   0.41 [0.01;  11.64]    .              .     .       .
                    Erlotinib + MET inhibitor:Icotinib 0    0  0.18 [0.01;   3.95]      .             .   0.18 [0.01;   3.95]    .              .     .       .
                  Erlotinib + MET inhibitor:Lazertinib 0    0  0.60 [0.17;   2.16]      .             .   0.60 [0.17;   2.16]    .              .     .       .
                 Erlotinib + MET inhibitor:Osimertinib 0    0  0.69 [0.23;   2.07]      .             .   0.69 [0.23;   2.07]    .              .     .       .
    Erlotinib + MET inhibitor:Osimertinib + chemotherapy 0    0  0.46 [0.11;   1.90]      .             .   0.46 [0.11;   1.90]    .              .     .       .
  Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis 0    0  0.13 [0.02;   1.06]      .             .   0.13 [0.02;   1.06]    .              .     .       .
                     Erlotinib + MET inhibitor:Placebo 0    0  1.41 [0.61;   3.28]      .             .   1.41 [0.61;   3.28]    .              .     .       .
                 Erlotinib + MET inhibitor:Rociletinib 0    0  0.70 [0.10;   4.86]      .             .   0.70 [0.10;   4.86]    .              .     .       .
              Erlotinib + MET inhibitor:antiangiogenesis 0    0  0.21 [0.08;   0.57]      .             .   0.21 [0.08;   0.57]    .              .     .       .
                Erlotinib + MET inhibitor:Zorifertinib 0    0  0.53 [0.08;   3.57]      .             .   0.53 [0.08;   3.57]    .              .     .       .
    Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis 0    0  7.53 [0.38; 148.30]      .             .   7.53 [0.38; 148.30]    .              .     .       .
               Erlotinib + MMP inhibitor:Furmonertinib 0    0  7.64 [0.30; 195.71]      .             .   7.64 [0.30; 195.71]    .              .     .       .
                   Erlotinib + MMP inhibitor:Gefitinib 0    0 10.89 [0.53; 224.36]      .             .  10.89 [0.53; 224.36]    .              .     .       .
         Erlotinib + MMP inhibitor:Gefitinib/Erlotinib 0    0 12.50 [0.52; 301.86]      .             .  12.50 [0.52; 301.86]    .              .     .       .
      Erlotinib + MMP inhibitor:Gefitinib + chemotherapy 0    0  3.44 [0.08; 151.98]      .             .   3.44 [0.08; 151.98]    .              .     .       .
    Erlotinib + MMP inhibitor:Gefitinib + PARP inhibitor 0    0  3.59 [0.04; 296.50]      .             .   3.59 [0.04; 296.50]    .              .     .       .
                    Erlotinib + MMP inhibitor:Icotinib 0    0  1.54 [0.02; 106.83]      .             .   1.54 [0.02; 106.83]    .              .     .       .
                  Erlotinib + MMP inhibitor:Lazertinib 0    0  5.28 [0.23; 122.71]      .             .   5.28 [0.23; 122.71]    .              .     .       .
                 Erlotinib + MMP inhibitor:Osimertinib 0    0  6.09 [0.28; 132.08]      .             .   6.09 [0.28; 132.08]    .              .     .       .
    Erlotinib + MMP inhibitor:Osimertinib + chemotherapy 0    0  4.01 [0.16;  99.34]      .             .   4.01 [0.16;  99.34]    .              .     .       .
  Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis 0    0  1.16 [0.03;  40.29]      .             .   1.16 [0.03;  40.29]    .              .     .       .
                     Erlotinib + MMP inhibitor:Placebo 0    0 12.41 [0.62; 248.29]      .             .  12.41 [0.62; 248.29]    .              .     .       .
                 Erlotinib + MMP inhibitor:Rociletinib 0    0  6.16 [0.19; 197.15]      .             .   6.16 [0.19; 197.15]    .              .     .       .
              Erlotinib + MMP inhibitor:antiangiogenesis 0    0  1.86 [0.09;  38.86]      .             .   1.86 [0.09;  38.86]    .              .     .       .
                Erlotinib + MMP inhibitor:Zorifertinib 0    0  4.62 [0.15; 146.31]      .             .   4.62 [0.15; 146.31]    .              .     .       .
              Erlotinib + antiangiogenesis:Furmonertinib 0    0  1.02 [0.24;   4.34]      .             .   1.02 [0.24;   4.34]    .              .     .       .
                  Erlotinib + antiangiogenesis:Gefitinib 0    0  1.45 [0.61;   3.44]      .             .   1.45 [0.61;   3.44]    .              .     .       .
        Erlotinib + antiangiogenesis:Gefitinib/Erlotinib 0    0  1.66 [0.44;   6.20]      .             .   1.66 [0.44;   6.20]    .              .     .       .
     Erlotinib + antiangiogenesis:Gefitinib + chemotherapy 0    0  0.46 [0.04;   5.24]      .             .   0.46 [0.04;   5.24]    .              .     .       .
   Erlotinib + antiangiogenesis:Gefitinib + PARP inhibitor 0    0  0.48 [0.02;  13.31]      .             .   0.48 [0.02;  13.31]    .              .     .       .
                   Erlotinib + antiangiogenesis:Icotinib 0    0  0.20 [0.01;   4.51]      .             .   0.20 [0.01;   4.51]    .              .     .       .
                 Erlotinib + antiangiogenesis:Lazertinib 0    0  0.70 [0.21;   2.38]      .             .   0.70 [0.21;   2.38]    .              .     .       .
                Erlotinib + antiangiogenesis:Osimertinib 0    0  0.81 [0.29;   2.27]      .             .   0.81 [0.29;   2.27]    .              .     .       .
   Erlotinib + antiangiogenesis:Osimertinib + chemotherapy 0    0  0.53 [0.13;   2.11]      .             .   0.53 [0.13;   2.11]    .              .     .       .
 Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis 0    0  0.15 [0.02;   1.19]      .             .   0.15 [0.02;   1.19]    .              .     .       .
                    Erlotinib + antiangiogenesis:Placebo 0    0  1.65 [0.77;   3.52]      .             .   1.65 [0.77;   3.52]    .              .     .       .
                Erlotinib + antiangiogenesis:Rociletinib 0    0  0.82 [0.12;   5.47]      .             .   0.82 [0.12;   5.47]    .              .     .       .
             Erlotinib + antiangiogenesis:antiangiogenesis 0    0  0.25 [0.10;   0.62]      .             .   0.25 [0.10;   0.62]    .              .     .       .
               Erlotinib + antiangiogenesis:Zorifertinib 0    0  0.61 [0.09;   4.02]      .             .   0.61 [0.09;   4.02]    .              .     .       .
                             Furmonertinib:Gefitinib 1 1.00  1.42 [0.44;   4.58]   1.42 [0.44;  4.58]      .              .    .              .     .       .
                   Furmonertinib:Gefitinib/Erlotinib 0    0  1.64 [0.29;   9.15]      .             .   1.64 [0.29;   9.15]    .              .     .       .
                Furmonertinib:Gefitinib + chemotherapy 0    0  0.45 [0.03;   5.82]      .             .   0.45 [0.03;   5.82]    .              .     .       .
              Furmonertinib:Gefitinib + PARP inhibitor 0    0  0.47 [0.02;  14.34]      .             .   0.47 [0.02;  14.34]    .              .     .       .
                              Furmonertinib:Icotinib 0    0  0.20 [0.01;   4.90]      .             .   0.20 [0.01;   4.90]    .              .     .       .
                            Furmonertinib:Lazertinib 0    0  0.69 [0.14;   3.47]      .             .   0.69 [0.14;   3.47]    .              .     .       .
                           Furmonertinib:Osimertinib 0    0  0.80 [0.18;   3.62]      .             .   0.80 [0.18;   3.62]    .              .     .       .
              Furmonertinib:Osimertinib + chemotherapy 0    0  0.52 [0.09;   3.07]      .             .   0.52 [0.09;   3.07]    .              .     .       .
            Furmonertinib:Osimertinib + antiangiogenesis 0    0  0.15 [0.01;   1.56]      .             .   0.15 [0.01;   1.56]    .              .     .       .
                               Furmonertinib:Placebo 0    0  1.62 [0.41;   6.45]      .             .   1.62 [0.41;   6.45]    .              .     .       .
                           Furmonertinib:Rociletinib 0    0  0.81 [0.08;   7.95]      .             .   0.81 [0.08;   7.95]    .              .     .       .
                        Furmonertinib:antiangiogenesis 0    0  0.24 [0.05;   1.14]      .             .   0.24 [0.05;   1.14]    .              .     .       .
                          Furmonertinib:Zorifertinib 0    0  0.60 [0.07;   5.36]      .             .   0.60 [0.07;   5.36]    .              .     .       .
                       Gefitinib:Gefitinib/Erlotinib 0    0  1.15 [0.32;   4.07]      .             .   1.15 [0.32;   4.07]    .              .     .       .
                    Gefitinib:Gefitinib + chemotherapy 1 1.00  0.32 [0.03;   3.09]   0.32 [0.03;  3.09]      .              .    .              .     .       .
                  Gefitinib:Gefitinib + PARP inhibitor 1 1.00  0.33 [0.01;   8.20]   0.33 [0.01;  8.20]      .              .    .              .     .       .
                                  Gefitinib:Icotinib 1 1.00  0.14 [0.01;   2.76]   0.14 [0.01;  2.76]      .              .    .              .     .       .
                                Gefitinib:Lazertinib 1 0.38  0.48 [0.16;   1.48]   0.66 [0.11;  3.99]   0.40 [0.10;   1.65] 1.65 [0.17;  16.35]  0.43  0.6684
                               Gefitinib:Osimertinib 0    0  0.56 [0.21;   1.47]      .             .   0.56 [0.21;   1.47]    .              .     .       .
                  Gefitinib:Osimertinib + chemotherapy 0    0  0.37 [0.10;   1.39]      .             .   0.37 [0.10;   1.39]    .              .     .       .
                Gefitinib:Osimertinib + antiangiogenesis 0    0  0.11 [0.01;   0.80]      .             .   0.11 [0.01;   0.80]    .              .     .       .
                                   Gefitinib:Placebo 1 0.34  1.14 [0.55;   2.38]   0.98 [0.28;  3.41]   1.24 [0.50;   3.07] 0.79 [0.17;   3.71] -0.30  0.7637
                               Gefitinib:Rociletinib 0    0  0.57 [0.08;   4.05]      .             .   0.57 [0.08;   4.05]    .              .     .       .
                            Gefitinib:antiangiogenesis 1 0.13  0.17 [0.06;   0.47]   0.03 [0.00;  0.57]   0.22 [0.07;   0.64] 0.15 [0.01;   3.24] -1.20  0.2292
                              Gefitinib:Zorifertinib 0    0  0.42 [0.07;   2.68]      .             .   0.42 [0.07;   2.68]    .              .     .       .
          Gefitinib/Erlotinib:Gefitinib + chemotherapy 0    0  0.28 [0.02;   3.73]      .             .   0.28 [0.02;   3.73]    .              .     .       .
        Gefitinib/Erlotinib:Gefitinib + PARP inhibitor 0    0  0.29 [0.01;   9.08]      .             .   0.29 [0.01;   9.08]    .              .     .       .
                        Gefitinib/Erlotinib:Icotinib 0    0  0.12 [0.00;   3.11]      .             .   0.12 [0.00;   3.11]    .              .     .       .
                      Gefitinib/Erlotinib:Lazertinib 0    0  0.42 [0.13;   1.35]      .             .   0.42 [0.13;   1.35]    .              .     .       .
                     Gefitinib/Erlotinib:Osimertinib 1 1.00  0.49 [0.21;   1.10]   0.49 [0.21;  1.10]      .              .    .              .     .       .
        Gefitinib/Erlotinib:Osimertinib + chemotherapy 0    0  0.32 [0.09;   1.09]      .             .   0.32 [0.09;   1.09]    .              .     .       .
      Gefitinib/Erlotinib:Osimertinib + antiangiogenesis 0    0  0.09 [0.01;   0.65]      .             .   0.09 [0.01;   0.65]    .              .     .       .
                         Gefitinib/Erlotinib:Placebo 0    0  0.99 [0.32;   3.08]      .             .   0.99 [0.32;   3.08]    .              .     .       .
                     Gefitinib/Erlotinib:Rociletinib 0    0  0.49 [0.05;   4.47]      .             .   0.49 [0.05;   4.47]    .              .     .       .
                  Gefitinib/Erlotinib:antiangiogenesis 0    0  0.15 [0.04;   0.62]      .             .   0.15 [0.04;   0.62]    .              .     .       .
                    Gefitinib/Erlotinib:Zorifertinib 1 1.00  0.37 [0.10;   1.41]   0.37 [0.10;  1.41]      .              .    .              .     .       .
     Gefitinib + chemotherapy:Gefitinib + PARP inhibitor 0    0  1.04 [0.02;  53.57]      .             .   1.04 [0.02;  53.57]    .              .     .       .
                     Gefitinib + chemotherapy:Icotinib 0    0  0.45 [0.01;  18.88]      .             .   0.45 [0.01;  18.88]    .              .     .       .
                   Gefitinib + chemotherapy:Lazertinib 0    0  1.53 [0.12;  19.35]      .             .   1.53 [0.12;  19.35]    .              .     .       .
                  Gefitinib + chemotherapy:Osimertinib 0    0  1.77 [0.15;  20.99]      .             .   1.77 [0.15;  20.99]    .              .     .       .
     Gefitinib + chemotherapy:Osimertinib + chemotherapy 0    0  1.17 [0.08;  16.27]      .             .   1.17 [0.08;  16.27]    .              .     .       .
   Gefitinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.34 [0.02;   7.04]      .             .   0.34 [0.02;   7.04]    .              .     .       .
                      Gefitinib + chemotherapy:Placebo 0    0  3.60 [0.33;  39.47]      .             .   3.60 [0.33;  39.47]    .              .     .       .
                  Gefitinib + chemotherapy:Rociletinib 0    0  1.79 [0.09;  36.33]      .             .   1.79 [0.09;  36.33]    .              .     .       .
               Gefitinib + chemotherapy:antiangiogenesis 0    0  0.54 [0.04;   6.54]      .             .   0.54 [0.04;   6.54]    .              .     .       .
                 Gefitinib + chemotherapy:Zorifertinib 0    0  1.34 [0.07;  25.16]      .             .   1.34 [0.07;  25.16]    .              .     .       .
                   Gefitinib + PARP inhibitor:Icotinib 0    0  0.43 [0.01;  34.10]      .             .   0.43 [0.01;  34.10]    .              .     .       .
                 Gefitinib + PARP inhibitor:Lazertinib 0    0  1.47 [0.05;  44.11]      .             .   1.47 [0.05;  44.11]    .              .     .       .
                Gefitinib + PARP inhibitor:Osimertinib 0    0  1.70 [0.06;  48.61]      .             .   1.70 [0.06;  48.61]    .              .     .       .
   Gefitinib + PARP inhibitor:Osimertinib + chemotherapy 0    0  1.12 [0.03;  36.18]      .             .   1.12 [0.03;  36.18]    .              .     .       .
 Gefitinib + PARP inhibitor:Osimertinib + antiangiogenesis 0    0  0.32 [0.01;  14.32]      .             .   0.32 [0.01;  14.32]    .              .     .       .
                    Gefitinib + PARP inhibitor:Placebo 0    0  3.46 [0.13;  93.41]      .             .   3.46 [0.13;  93.41]    .              .     .       .
                Gefitinib + PARP inhibitor:Rociletinib 0    0  1.72 [0.04;  74.37]      .             .   1.72 [0.04;  74.37]    .              .     .       .
             Gefitinib + PARP inhibitor:antiangiogenesis 0    0  0.52 [0.02;  15.06]      .             .   0.52 [0.02;  15.06]    .              .     .       .
               Gefitinib + PARP inhibitor:Zorifertinib 0    0  1.29 [0.03;  52.35]      .             .   1.29 [0.03;  52.35]    .              .     .       .
                                 Icotinib:Lazertinib 0    0  3.43 [0.14;  81.73]      .             .   3.43 [0.14;  81.73]    .              .     .       .
                                Icotinib:Osimertinib 0    0  3.95 [0.17;  89.78]      .             .   3.95 [0.17;  89.78]    .              .     .       .
                   Icotinib:Osimertinib + chemotherapy 0    0  2.61 [0.10;  67.40]      .             .   2.61 [0.10;  67.40]    .              .     .       .
                 Icotinib:Osimertinib + antiangiogenesis 0    0  0.75 [0.02;  27.22]      .             .   0.75 [0.02;  27.22]    .              .     .       .
                                    Icotinib:Placebo 0    0  8.06 [0.38; 171.74]      .             .   8.06 [0.38; 171.74]    .              .     .       .
                                Icotinib:Rociletinib 0    0  4.00 [0.11; 141.11]      .             .   4.00 [0.11; 141.11]    .              .     .       .
                             Icotinib:antiangiogenesis 0    0  1.21 [0.05;  27.85]      .             .   1.21 [0.05;  27.85]    .              .     .       .
                               Icotinib:Zorifertinib 0    0  3.00 [0.09;  98.96]      .             .   3.00 [0.09;  98.96]    .              .     .       .
                              Lazertinib:Osimertinib 1 0.85  1.15 [0.51;   2.63]   1.25 [0.51;  3.05]   0.75 [0.09;   6.23] 1.65 [0.17;  16.35]  0.43  0.6684
                 Lazertinib:Osimertinib + chemotherapy 0    0  0.76 [0.22;   2.60]      .             .   0.76 [0.22;   2.60]    .              .     .       .
               Lazertinib:Osimertinib + antiangiogenesis 0    0  0.22 [0.03;   1.55]      .             .   0.22 [0.03;   1.55]    .              .     .       .
                                  Lazertinib:Placebo 0    0  2.35 [0.83;   6.70]      .             .   2.35 [0.83;   6.70]    .              .     .       .
                              Lazertinib:Rociletinib 0    0  1.17 [0.14;  10.03]      .             .   1.17 [0.14;  10.03]    .              .     .       .
                           Lazertinib:antiangiogenesis 0    0  0.35 [0.09;   1.36]      .             .   0.35 [0.09;   1.36]    .              .     .       .
                             Lazertinib:Zorifertinib 0    0  0.88 [0.15;   5.16]      .             .   0.88 [0.15;   5.16]    .              .     .       .
                Osimertinib:Osimertinib + chemotherapy 1 1.00  0.66 [0.27;   1.64]   0.66 [0.27;  1.64]      .              .    .              .     .       .
              Osimertinib:Osimertinib + antiangiogenesis 2 1.00  0.19 [0.03;   1.12]   0.19 [0.03;  1.12]      .              .    .              .     .       .
                                 Osimertinib:Placebo 2 0.76  2.04 [0.93;   4.47]   1.94 [0.79;  4.78]   2.37 [0.47;  11.88] 0.82 [0.13;   5.18] -0.21  0.8318
                             Osimertinib:Rociletinib 0    0  1.01 [0.13;   7.84]      .             .   1.01 [0.13;   7.84]    .              .     .       .
                          Osimertinib:antiangiogenesis 0    0  0.31 [0.09;   0.99]      .             .   0.31 [0.09;   0.99]    .              .     .       .
                            Osimertinib:Zorifertinib 0    0  0.76 [0.16;   3.65]      .             .   0.76 [0.16;   3.65]    .              .     .       .
 Osimertinib + chemotherapy:Osimertinib + antiangiogenesis 0    0  0.29 [0.04;   2.11]      .             .   0.29 [0.04;   2.11]    .              .     .       .
                    Osimertinib + chemotherapy:Placebo 0    0  3.09 [0.93;  10.29]      .             .   3.09 [0.93;  10.29]    .              .     .       .
                Osimertinib + chemotherapy:Rociletinib 0    0  1.54 [0.16;  14.43]      .             .   1.54 [0.16;  14.43]    .              .     .       .
             Osimertinib + chemotherapy:antiangiogenesis 0    0  0.46 [0.10;   2.06]      .             .   0.46 [0.10;   2.06]    .              .     .       .
               Osimertinib + chemotherapy:Zorifertinib 0    0  1.15 [0.19;   7.08]      .             .   1.15 [0.19;   7.08]    .              .     .       .
                  Osimertinib + antiangiogenesis:Placebo 0    0 10.72 [1.55;  74.36]      .             .  10.72 [1.55;  74.36]    .              .     .       .
              Osimertinib + antiangiogenesis:Rociletinib 0    0  5.33 [0.36;  79.74]      .             .   5.33 [0.36;  79.74]    .              .     .       .
           Osimertinib + antiangiogenesis:antiangiogenesis 0    0  1.61 [0.19;  13.48]      .             .   1.61 [0.19;  13.48]    .              .     .       .
             Osimertinib + antiangiogenesis:Zorifertinib 0    0  3.99 [0.37;  42.58]      .             .   3.99 [0.37;  42.58]    .              .     .       .
                                 Rociletinib:Placebo 0    0  2.01 [0.29;  13.77]      .             .   2.01 [0.29;  13.77]    .              .     .       .
                              antiangiogenesis:Placebo 0    0  6.67 [2.57;  17.30]      .             .   6.67 [2.57;  17.30]    .              .     .       .
                                Zorifertinib:Placebo 0    0  2.68 [0.46;  15.53]      .             .   2.68 [0.46;  15.53]    .              .     .       .
                          Rociletinib:antiangiogenesis 0    0  0.30 [0.04;   2.21]      .             .   0.30 [0.04;   2.21]    .              .     .       .
                            Rociletinib:Zorifertinib 0    0  0.75 [0.06;   9.90]      .             .   0.75 [0.06;   9.90]    .              .     .       .
                         antiangiogenesis:Zorifertinib 0    0  2.49 [0.35;  17.73]      .             .   2.49 [0.35;  17.73]    .              .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

cardiac_total
Random effects model: 

                                                comparison  k prop   nma          95%-CI direct         95%-CI indir.          95%-CI  RoR         95%-CI     z p-value
                           Afatinib:Afatinib + Cetuximab  1 1.00  0.97 [0.40;    2.38]   0.97 [0.40;   2.38]      .               .    .              .     .       .
                         Afatinib:Afatinib + HMGCR inhibitor  1 1.00  0.69 [0.18;    2.71]   0.69 [0.18;   2.71]      .               .    .              .     .       .
                                     Afatinib:Almonertinib  0    0  0.96 [0.39;    2.35]      .              .   0.96 [0.39;    2.35]    .              .     .       .
                         Afatinib:Amivantamab  +  Lazertinib  0    0  0.29 [0.10;    0.79]      .              .   0.29 [0.10;    0.79]    .              .     .       .
                                     Afatinib:Befotertinib  0    0  0.13 [0.01;    2.99]      .              .   0.13 [0.01;    2.99]    .              .     .       .
                                     Afatinib:Chemotherapy  2 0.14  0.86 [0.45;    1.62]   0.35 [0.07;   1.90]   0.99 [0.50;    1.98] 0.36 [0.06;   2.19] -1.12  0.2646
                      Afatinib:Chemotherapy + antiangiogenesis  0    0  5.30 [0.26;  108.11]      .              .   5.30 [0.26;  108.11]    .              .     .       .
                                      Afatinib:Dacomitinib  0    0  1.72 [0.79;    3.72]      .              .   1.72 [0.79;    3.72]    .              .     .       .
                                   Afatinib:DHFR inhibitor  0    0  1.31 [0.26;    6.62]      .              .   1.31 [0.26;    6.62]    .              .     .       .
                                        Afatinib:Erlotinib  1 0.62  1.01 [0.58;    1.77]   1.01 [0.50;   2.05]   1.02 [0.41;    2.52] 0.99 [0.31;   3.13] -0.02  0.9874
                    Afatinib:Erlotinib + Autophagy inhibitor  0    0  0.57 [0.11;    2.86]      .              .   0.57 [0.11;    2.86]    .              .     .       .
                           Afatinib:Erlotinib + chemotherapy  0    0  0.79 [0.29;    2.16]      .              .   0.79 [0.29;    2.16]    .              .     .       .
                         Afatinib:Erlotinib + COX2 inhibitor  0    0  3.15 [0.12;   82.96]      .              .   3.15 [0.12;   82.96]    .              .     .       .
                         Afatinib:Erlotinib + HER3 inhibitor  0    0  0.38 [0.07;    1.99]      .              .   0.38 [0.07;    1.99]    .              .     .       .
                          Afatinib:Erlotinib + HGF inhibitor  0    0  9.10 [0.26;  316.99]      .              .   9.10 [0.26;  316.99]    .              .     .       .
                          Afatinib:Erlotinib + IGF-1R inhibitor  0    0  1.12 [0.49;    2.55]      .              .   1.12 [0.49;    2.55]    .              .     .       .
                          Afatinib:Erlotinib + MET inhibitor  0    0  0.58 [0.26;    1.27]      .              .   0.58 [0.26;    1.27]    .              .     .       .
                          Afatinib:Erlotinib + MMP inhibitor  0    0  0.31 [0.06;    1.76]      .              .   0.31 [0.06;    1.76]    .              .     .       .
                         Afatinib:Erlotinib + antiangiogenesis  0    0  0.89 [0.47;    1.70]      .              .   0.89 [0.47;    1.70]    .              .     .       .
                                    Afatinib:Furmonertinib  0    0  0.93 [0.33;    2.61]      .              .   0.93 [0.33;    2.61]    .              .     .       .
                                        Afatinib:Gefitinib  1 0.40  1.07 [0.51;    2.23]   0.99 [0.31;   3.15]   1.13 [0.44;    2.91] 0.88 [0.20;   3.93] -0.17  0.8685
                              Afatinib:Gefitinib/Erlotinib  0    0  1.10 [0.42;    2.83]      .              .   1.10 [0.42;    2.83]    .              .     .       .
                           Afatinib:Gefitinib + chemotherapy  0    0  0.79 [0.22;    2.84]      .              .   0.79 [0.22;    2.84]    .              .     .       .
                         Afatinib:Gefitinib + PARP inhibitor  0    0  0.35 [0.01;    9.54]      .              .   0.35 [0.01;    9.54]    .              .     .       .
                                         Afatinib:Icotinib  0    0  0.15 [0.01;    3.23]      .              .   0.15 [0.01;    3.23]    .              .     .       .
                                       Afatinib:Lazertinib  0    0  0.42 [0.14;    1.21]      .              .   0.42 [0.14;    1.21]    .              .     .       .
                                      Afatinib:Osimertinib  0    0  0.46 [0.21;    0.99]      .              .   0.46 [0.21;    0.99]    .              .     .       .
                         Afatinib:Osimertinib + chemotherapy  0    0  0.35 [0.14;    0.87]      .              .   0.35 [0.14;    0.87]    .              .     .       .
                      Afatinib:Osimertinib + PD-L1 inhibitor  0    0  1.84 [0.07;   46.00]      .              .   1.84 [0.07;   46.00]    .              .     .       .
                       Afatinib:Osimertinib + antiangiogenesis  0    0  0.15 [0.05;    0.41]      .              .   0.15 [0.05;    0.41]    .              .     .       .
                                          Afatinib:Placebo  1 0.28  1.31 [0.67;    2.56]   2.38 [0.68;   8.39]   1.04 [0.47;    2.28] 2.30 [0.52;  10.14]  1.10  0.2728
                                      Afatinib:Rociletinib  0    0  0.18 [0.06;    0.53]      .              .   0.18 [0.06;    0.53]    .              .     .       .
                                   Afatinib:antiangiogenesis  0    0  0.18 [0.07;    0.44]      .              .   0.18 [0.07;    0.44]    .              .     .       .
                                     Afatinib:Zorifertinib  0    0  0.96 [0.31;    2.96]      .              .   0.96 [0.31;    2.96]    .              .     .       .
           Afatinib + Cetuximab:Afatinib + HMGCR inhibitor  0    0  0.71 [0.14;    3.64]      .              .   0.71 [0.14;    3.64]    .              .     .       .
                       Afatinib + Cetuximab:Almonertinib  0    0  0.99 [0.28;    3.51]      .              .   0.99 [0.28;    3.51]    .              .     .       .
           Afatinib + Cetuximab:Amivantamab  +  Lazertinib  0    0  0.29 [0.08;    1.14]      .              .   0.29 [0.08;    1.14]    .              .     .       .
                       Afatinib + Cetuximab:Befotertinib  0    0  0.14 [0.01;    3.49]      .              .   0.14 [0.01;    3.49]    .              .     .       .
                       Afatinib + Cetuximab:Chemotherapy  0    0  0.88 [0.29;    2.64]      .              .   0.88 [0.29;    2.64]    .              .     .       .
        Afatinib + Cetuximab:Chemotherapy + antiangiogenesis  0    0  5.45 [0.23;  126.59]      .              .   5.45 [0.23;  126.59]    .              .     .       .
                        Afatinib + Cetuximab:Dacomitinib  0    0  1.77 [0.54;    5.77]      .              .   1.77 [0.54;    5.77]    .              .     .       .
                     Afatinib + Cetuximab:DHFR inhibitor  0    0  1.34 [0.21;    8.57]      .              .   1.34 [0.21;    8.57]    .              .     .       .
                          Afatinib + Cetuximab:Erlotinib  0    0  1.04 [0.36;    2.99]      .              .   1.04 [0.36;    2.99]    .              .     .       .
      Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor  0    0  0.59 [0.09;    3.71]      .              .   0.59 [0.09;    3.71]    .              .     .       .
             Afatinib + Cetuximab:Erlotinib + chemotherapy  0    0  0.81 [0.21;    3.12]      .              .   0.81 [0.21;    3.12]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + COX2 inhibitor  0    0  3.24 [0.11;   96.20]      .              .   3.24 [0.11;   96.20]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + HER3 inhibitor  0    0  0.39 [0.06;    2.57]      .              .   0.39 [0.06;    2.57]    .              .     .       .
            Afatinib + Cetuximab:Erlotinib + HGF inhibitor  0    0  9.36 [0.24;  364.20]      .              .   9.36 [0.24;  364.20]    .              .     .       .
            Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor  0    0  1.15 [0.34;    3.89]      .              .   1.15 [0.34;    3.89]    .              .     .       .
            Afatinib + Cetuximab:Erlotinib + MET inhibitor  0    0  0.59 [0.18;    1.96]      .              .   0.59 [0.18;    1.96]    .              .     .       .
            Afatinib + Cetuximab:Erlotinib + MMP inhibitor  0    0  0.32 [0.05;    2.26]      .              .   0.32 [0.05;    2.26]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + antiangiogenesis  0    0  0.92 [0.31;    2.77]      .              .   0.92 [0.31;    2.77]    .              .     .       .
                      Afatinib + Cetuximab:Furmonertinib  0    0  0.95 [0.24;    3.74]      .              .   0.95 [0.24;    3.74]    .              .     .       .
                          Afatinib + Cetuximab:Gefitinib  0    0  1.10 [0.35;    3.51]      .              .   1.10 [0.35;    3.51]    .              .     .       .
                Afatinib + Cetuximab:Gefitinib/Erlotinib  0    0  1.13 [0.31;    4.15]      .              .   1.13 [0.31;    4.15]    .              .     .       .
             Afatinib + Cetuximab:Gefitinib + chemotherapy  0    0  0.82 [0.17;    3.87]      .              .   0.82 [0.17;    3.87]    .              .     .       .
           Afatinib + Cetuximab:Gefitinib + PARP inhibitor  0    0  0.36 [0.01;   11.05]      .              .   0.36 [0.01;   11.05]    .              .     .       .
                           Afatinib + Cetuximab:Icotinib  0    0  0.16 [0.01;    3.77]      .              .   0.16 [0.01;    3.77]    .              .     .       .
                         Afatinib + Cetuximab:Lazertinib  0    0  0.43 [0.11;    1.72]      .              .   0.43 [0.11;    1.72]    .              .     .       .
                        Afatinib + Cetuximab:Osimertinib  0    0  0.47 [0.14;    1.53]      .              .   0.47 [0.14;    1.53]    .              .     .       .
           Afatinib + Cetuximab:Osimertinib + chemotherapy  0    0  0.36 [0.10;    1.29]      .              .   0.36 [0.10;    1.29]    .              .     .       .
        Afatinib + Cetuximab:Osimertinib + PD-L1 inhibitor  0    0  1.89 [0.07;   53.44]      .              .   1.89 [0.07;   53.44]    .              .     .       .
         Afatinib + Cetuximab:Osimertinib + antiangiogenesis  0    0  0.15 [0.04;    0.60]      .              .   0.15 [0.04;    0.60]    .              .     .       .
                            Afatinib + Cetuximab:Placebo  0    0  1.35 [0.44;    4.12]      .              .   1.35 [0.44;    4.12]    .              .     .       .
                        Afatinib + Cetuximab:Rociletinib  0    0  0.19 [0.05;    0.75]      .              .   0.19 [0.05;    0.75]    .              .     .       .
                     Afatinib + Cetuximab:antiangiogenesis  0    0  0.19 [0.05;    0.66]      .              .   0.19 [0.05;    0.66]    .              .     .       .
                       Afatinib + Cetuximab:Zorifertinib  0    0  0.99 [0.24;    4.16]      .              .   0.99 [0.24;    4.16]    .              .     .       .
                     Afatinib + HMGCR inhibitor:Almonertinib  0    0  1.39 [0.27;    7.13]      .              .   1.39 [0.27;    7.13]    .              .     .       .
         Afatinib + HMGCR inhibitor:Amivantamab  +  Lazertinib  0    0  0.41 [0.08;    2.27]      .              .   0.41 [0.08;    2.27]    .              .     .       .
                     Afatinib + HMGCR inhibitor:Befotertinib  0    0  0.20 [0.01;    5.78]      .              .   0.20 [0.01;    5.78]    .              .     .       .
                     Afatinib + HMGCR inhibitor:Chemotherapy  0    0  1.24 [0.27;    5.60]      .              .   1.24 [0.27;    5.60]    .              .     .       .
      Afatinib + HMGCR inhibitor:Chemotherapy + antiangiogenesis  0    0  7.68 [0.28;  210.42]      .              .   7.68 [0.28;  210.42]    .              .     .       .
                      Afatinib + HMGCR inhibitor:Dacomitinib  0    0  2.49 [0.52;   11.97]      .              .   2.49 [0.52;   11.97]    .              .     .       .
                   Afatinib + HMGCR inhibitor:DHFR inhibitor  0    0  1.89 [0.23;   15.80]      .              .   1.89 [0.23;   15.80]    .              .     .       .
                        Afatinib + HMGCR inhibitor:Erlotinib  0    0  1.46 [0.33;    6.42]      .              .   1.46 [0.33;    6.42]    .              .     .       .
    Afatinib + HMGCR inhibitor:Erlotinib + Autophagy inhibitor  0    0  0.83 [0.10;    6.84]      .              .   0.83 [0.10;    6.84]    .              .     .       .
           Afatinib + HMGCR inhibitor:Erlotinib + chemotherapy  0    0  1.15 [0.21;    6.25]      .              .   1.15 [0.21;    6.25]    .              .     .       .
         Afatinib + HMGCR inhibitor:Erlotinib + COX2 inhibitor  0    0  4.56 [0.13;  158.08]      .              .   4.56 [0.13;  158.08]    .              .     .       .
         Afatinib + HMGCR inhibitor:Erlotinib + HER3 inhibitor  0    0  0.56 [0.07;    4.72]      .              .   0.56 [0.07;    4.72]    .              .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + HGF inhibitor  0    0 13.18 [0.29;  592.02]      .              .  13.18 [0.29;  592.02]    .              .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + IGF-1R inhibitor  0    0  1.62 [0.33;    8.01]      .              .   1.62 [0.33;    8.01]    .              .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + MET inhibitor  0    0  0.83 [0.17;    4.05]      .              .   0.83 [0.17;    4.05]    .              .     .       .
          Afatinib + HMGCR inhibitor:Erlotinib + MMP inhibitor  0    0  0.45 [0.05;    4.11]      .              .   0.45 [0.05;    4.11]    .              .     .       .
         Afatinib + HMGCR inhibitor:Erlotinib + antiangiogenesis  0    0  1.30 [0.29;    5.86]      .              .   1.30 [0.29;    5.86]    .              .     .       .
                    Afatinib + HMGCR inhibitor:Furmonertinib  0    0  1.34 [0.24;    7.46]      .              .   1.34 [0.24;    7.46]    .              .     .       .
                        Afatinib + HMGCR inhibitor:Gefitinib  0    0  1.55 [0.33;    7.32]      .              .   1.55 [0.33;    7.32]    .              .     .       .
              Afatinib + HMGCR inhibitor:Gefitinib/Erlotinib  0    0  1.59 [0.30;    8.38]      .              .   1.59 [0.30;    8.38]    .              .     .       .
           Afatinib + HMGCR inhibitor:Gefitinib + chemotherapy  0    0  1.15 [0.18;    7.45]      .              .   1.15 [0.18;    7.45]    .              .     .       .
         Afatinib + HMGCR inhibitor:Gefitinib + PARP inhibitor  0    0  0.51 [0.01;   18.14]      .              .   0.51 [0.01;   18.14]    .              .     .       .
                         Afatinib + HMGCR inhibitor:Icotinib  0    0  0.22 [0.01;    6.26]      .              .   0.22 [0.01;    6.26]    .              .     .       .
                       Afatinib + HMGCR inhibitor:Lazertinib  0    0  0.60 [0.11;    3.41]      .              .   0.60 [0.11;    3.41]    .              .     .       .
                      Afatinib + HMGCR inhibitor:Osimertinib  0    0  0.66 [0.14;    3.18]      .              .   0.66 [0.14;    3.18]    .              .     .       .
         Afatinib + HMGCR inhibitor:Osimertinib + chemotherapy  0    0  0.51 [0.10;    2.63]      .              .   0.51 [0.10;    2.63]    .              .     .       .
      Afatinib + HMGCR inhibitor:Osimertinib + PD-L1 inhibitor  0    0  2.66 [0.08;   88.00]      .              .   2.66 [0.08;   88.00]    .              .     .       .
       Afatinib + HMGCR inhibitor:Osimertinib + antiangiogenesis  0    0  0.22 [0.04;    1.19]      .              .   0.22 [0.04;    1.19]    .              .     .       .
                          Afatinib + HMGCR inhibitor:Placebo  0    0  1.90 [0.41;    8.70]      .              .   1.90 [0.41;    8.70]    .              .     .       .
                      Afatinib + HMGCR inhibitor:Rociletinib  0    0  0.26 [0.05;    1.49]      .              .   0.26 [0.05;    1.49]    .              .     .       .
                   Afatinib + HMGCR inhibitor:antiangiogenesis  0    0  0.26 [0.05;    1.34]      .              .   0.26 [0.05;    1.34]    .              .     .       .
                     Afatinib + HMGCR inhibitor:Zorifertinib  0    0  1.40 [0.24;    8.18]      .              .   1.40 [0.24;    8.18]    .              .     .       .
                     Almonertinib:Amivantamab  +  Lazertinib  0    0  0.30 [0.10;    0.92]      .              .   0.30 [0.10;    0.92]    .              .     .       .
                                 Almonertinib:Befotertinib  0    0  0.14 [0.01;    2.98]      .              .   0.14 [0.01;    2.98]    .              .     .       .
                                 Almonertinib:Chemotherapy  0    0  0.89 [0.37;    2.13]      .              .   0.89 [0.37;    2.13]    .              .     .       .
                  Almonertinib:Chemotherapy + antiangiogenesis  0    0  5.52 [0.26;  118.28]      .              .   5.52 [0.26;  118.28]    .              .     .       .
                                  Almonertinib:Dacomitinib  0    0  1.79 [0.66;    4.83]      .              .   1.79 [0.66;    4.83]    .              .     .       .
                               Almonertinib:DHFR inhibitor  0    0  1.36 [0.24;    7.85]      .              .   1.36 [0.24;    7.85]    .              .     .       .
                                    Almonertinib:Erlotinib  0    0  1.05 [0.44;    2.50]      .              .   1.05 [0.44;    2.50]    .              .     .       .
                Almonertinib:Erlotinib + Autophagy inhibitor  0    0  0.60 [0.10;    3.39]      .              .   0.60 [0.10;    3.39]    .              .     .       .
                       Almonertinib:Erlotinib + chemotherapy  0    0  0.82 [0.25;    2.72]      .              .   0.82 [0.25;    2.72]    .              .     .       .
                     Almonertinib:Erlotinib + COX2 inhibitor  0    0  3.28 [0.12;   92.28]      .              .   3.28 [0.12;   92.28]    .              .     .       .
                     Almonertinib:Erlotinib + HER3 inhibitor  0    0  0.40 [0.07;    2.35]      .              .   0.40 [0.07;    2.35]    .              .     .       .
                      Almonertinib:Erlotinib + HGF inhibitor  0    0  9.48 [0.26;  350.82]      .              .   9.48 [0.26;  350.82]    .              .     .       .
                      Almonertinib:Erlotinib + IGF-1R inhibitor  0    0  1.17 [0.41;    3.35]      .              .   1.17 [0.41;    3.35]    .              .     .       .
                      Almonertinib:Erlotinib + MET inhibitor  0    0  0.60 [0.21;    1.68]      .              .   0.60 [0.21;    1.68]    .              .     .       .
                      Almonertinib:Erlotinib + MMP inhibitor  0    0  0.33 [0.05;    2.08]      .              .   0.33 [0.05;    2.08]    .              .     .       .
                     Almonertinib:Erlotinib + antiangiogenesis  0    0  0.93 [0.37;    2.33]      .              .   0.93 [0.37;    2.33]    .              .     .       .
                                Almonertinib:Furmonertinib  0    0  0.97 [0.40;    2.36]      .              .   0.97 [0.40;    2.36]    .              .     .       .
                                    Almonertinib:Gefitinib  1 1.00  1.12 [0.67;    1.87]   1.12 [0.67;   1.87]      .               .    .              .     .       .
                          Almonertinib:Gefitinib/Erlotinib  0    0  1.14 [0.38;    3.41]      .              .   1.14 [0.38;    3.41]    .              .     .       .
                       Almonertinib:Gefitinib + chemotherapy  0    0  0.83 [0.26;    2.64]      .              .   0.83 [0.26;    2.64]    .              .     .       .
                     Almonertinib:Gefitinib + PARP inhibitor  0    0  0.37 [0.01;    9.53]      .              .   0.37 [0.01;    9.53]    .              .     .       .
                                     Almonertinib:Icotinib  0    0  0.16 [0.01;    3.21]      .              .   0.16 [0.01;    3.21]    .              .     .       .
                                   Almonertinib:Lazertinib  0    0  0.43 [0.14;    1.37]      .              .   0.43 [0.14;    1.37]    .              .     .       .
                                  Almonertinib:Osimertinib  0    0  0.47 [0.18;    1.23]      .              .   0.47 [0.18;    1.23]    .              .     .       .
                     Almonertinib:Osimertinib + chemotherapy  0    0  0.37 [0.13;    1.05]      .              .   0.37 [0.13;    1.05]    .              .     .       .
                  Almonertinib:Osimertinib + PD-L1 inhibitor  0    0  1.91 [0.07;   50.17]      .              .   1.91 [0.07;   50.17]    .              .     .       .
                   Almonertinib:Osimertinib + antiangiogenesis  0    0  0.16 [0.05;    0.50]      .              .   0.16 [0.05;    0.50]    .              .     .       .
                                      Almonertinib:Placebo  0    0  1.37 [0.57;    3.30]      .              .   1.37 [0.57;    3.30]    .              .     .       .
                                  Almonertinib:Rociletinib  0    0  0.19 [0.05;    0.66]      .              .   0.19 [0.05;    0.66]    .              .     .       .
                               Almonertinib:antiangiogenesis  0    0  0.19 [0.06;    0.56]      .              .   0.19 [0.06;    0.56]    .              .     .       .
                                 Almonertinib:Zorifertinib  0    0  1.00 [0.29;    3.49]      .              .   1.00 [0.29;    3.49]    .              .     .       .
                     Amivantamab  +  Lazertinib:Befotertinib  0    0  0.47 [0.02;   11.31]      .              .   0.47 [0.02;   11.31]    .              .     .       .
                     Amivantamab  +  Lazertinib:Chemotherapy  0    0  3.00 [1.15;    7.82]      .              .   3.00 [1.15;    7.82]    .              .     .       .
      Amivantamab  +  Lazertinib:Chemotherapy + antiangiogenesis  0    0 18.57 [0.93;  370.95]      .              .  18.57 [0.93;  370.95]    .              .     .       .
                      Amivantamab  +  Lazertinib:Dacomitinib  0    0  6.02 [2.11;   17.22]      .              .   6.02 [2.11;   17.22]    .              .     .       .
                   Amivantamab  +  Lazertinib:DHFR inhibitor  0    0  4.58 [0.76;   27.41]      .              .   4.58 [0.76;   27.41]    .              .     .       .
                        Amivantamab  +  Lazertinib:Erlotinib  0    0  3.54 [1.39;    9.06]      .              .   3.54 [1.39;    9.06]    .              .     .       .
    Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor  0    0  2.00 [0.34;   11.84]      .              .   2.00 [0.34;   11.84]    .              .     .       .
           Amivantamab  +  Lazertinib:Erlotinib + chemotherapy  0    0  2.77 [0.79;    9.68]      .              .   2.77 [0.79;    9.68]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + COX2 inhibitor  0    0 11.03 [0.38;  316.67]      .              .  11.03 [0.38;  316.67]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor  0    0  1.35 [0.22;    8.21]      .              .   1.35 [0.22;    8.21]    .              .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + HGF inhibitor  0    0 31.89 [0.85; 1202.04]      .              .  31.89 [0.85; 1202.04]    .              .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor  0    0  3.93 [1.29;   11.99]      .              .   3.93 [1.29;   11.99]    .              .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor  0    0  2.02 [0.68;    6.03]      .              .   2.02 [0.68;    6.03]    .              .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor  0    0  1.10 [0.17;    7.24]      .              .   1.10 [0.17;    7.24]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis  0    0  3.13 [1.16;    8.43]      .              .   3.13 [1.16;    8.43]    .              .     .       .
                    Amivantamab  +  Lazertinib:Furmonertinib  0    0  3.25 [0.94;   11.28]      .              .   3.25 [0.94;   11.28]    .              .     .       .
                        Amivantamab  +  Lazertinib:Gefitinib  0    0  3.75 [1.37;   10.29]      .              .   3.75 [1.37;   10.29]    .              .     .       .
              Amivantamab  +  Lazertinib:Gefitinib/Erlotinib  0    0  3.84 [1.59;    9.26]      .              .   3.84 [1.59;    9.26]    .              .     .       .
           Amivantamab  +  Lazertinib:Gefitinib + chemotherapy  0    0  2.78 [0.65;   11.85]      .              .   2.78 [0.65;   11.85]    .              .     .       .
         Amivantamab  +  Lazertinib:Gefitinib + PARP inhibitor  0    0  1.24 [0.04;   35.91]      .              .   1.24 [0.04;   35.91]    .              .     .       .
                         Amivantamab  +  Lazertinib:Icotinib  0    0  0.53 [0.02;   12.22]      .              .   0.53 [0.02;   12.22]    .              .     .       .
                       Amivantamab  +  Lazertinib:Lazertinib  1 0.92  1.46 [0.66;    3.25]   1.35 [0.59;   3.09]   3.98 [0.21;   73.81] 0.34 [0.02;   7.04] -0.70  0.4838
                      Amivantamab  +  Lazertinib:Osimertinib  1 0.96  1.59 [0.80;    3.18]   1.68 [0.83;   3.39]   0.47 [0.01;   15.55] 3.59 [0.10; 127.99]  0.70  0.4838
         Amivantamab  +  Lazertinib:Osimertinib + chemotherapy  0    0  1.24 [0.54;    2.83]      .              .   1.24 [0.54;    2.83]    .              .     .       .
      Amivantamab  +  Lazertinib:Osimertinib + PD-L1 inhibitor  0    0  6.43 [0.26;  158.06]      .              .   6.43 [0.26;  158.06]    .              .     .       .
       Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis  0    0  0.52 [0.20;    1.36]      .              .   0.52 [0.20;    1.36]    .              .     .       .
                          Amivantamab  +  Lazertinib:Placebo  0    0  4.59 [2.00;   10.55]      .              .   4.59 [2.00;   10.55]    .              .     .       .
                      Amivantamab  +  Lazertinib:Rociletinib  0    0  0.63 [0.17;    2.35]      .              .   0.63 [0.17;    2.35]    .              .     .       .
                   Amivantamab  +  Lazertinib:antiangiogenesis  0    0  0.63 [0.20;    2.04]      .              .   0.63 [0.20;    2.04]    .              .     .       .
                     Amivantamab  +  Lazertinib:Zorifertinib  0    0  3.38 [1.17;    9.78]      .              .   3.38 [1.17;    9.78]    .              .     .       .
                                 Befotertinib:Chemotherapy  0    0  6.35 [0.29;  139.84]      .              .   6.35 [0.29;  139.84]    .              .     .       .
                  Befotertinib:Chemotherapy + antiangiogenesis  0    0 39.32 [0.55; 2800.75]      .              .  39.32 [0.55; 2800.75]    .              .     .       .
                                  Befotertinib:Dacomitinib  0    0 12.75 [0.56;  291.34]      .              .  12.75 [0.56;  291.34]    .              .     .       .
                               Befotertinib:DHFR inhibitor  0    0  9.70 [0.31;  304.15]      .              .   9.70 [0.31;  304.15]    .              .     .       .
                                    Befotertinib:Erlotinib  0    0  7.50 [0.34;  165.03]      .              .   7.50 [0.34;  165.03]    .              .     .       .
                Befotertinib:Erlotinib + Autophagy inhibitor  0    0  4.25 [0.14;  132.27]      .              .   4.25 [0.14;  132.27]    .              .     .       .
                       Befotertinib:Erlotinib + chemotherapy  0    0  5.87 [0.24;  143.75]      .              .   5.87 [0.24;  143.75]    .              .     .       .
                     Befotertinib:Erlotinib + COX2 inhibitor  0    0 23.37 [0.27; 2032.17]      .              .  23.37 [0.27; 2032.17]    .              .     .       .
                     Befotertinib:Erlotinib + HER3 inhibitor  0    0  2.85 [0.09;   90.27]      .              .   2.85 [0.09;   90.27]    .              .     .       .
                      Befotertinib:Erlotinib + HGF inhibitor  0    0 67.54 [0.63; 7233.93]      .              .  67.54 [0.63; 7233.93]    .              .     .       .
                      Befotertinib:Erlotinib + IGF-1R inhibitor  0    0  8.32 [0.36;  194.04]      .              .   8.32 [0.36;  194.04]    .              .     .       .
                      Befotertinib:Erlotinib + MET inhibitor  0    0  4.28 [0.18;   98.91]      .              .   4.28 [0.18;   98.91]    .              .     .       .
                      Befotertinib:Erlotinib + MMP inhibitor  0    0  2.33 [0.07;   76.80]      .              .   2.33 [0.07;   76.80]    .              .     .       .
                     Befotertinib:Erlotinib + antiangiogenesis  0    0  6.64 [0.30;  148.24]      .              .   6.64 [0.30;  148.24]    .              .     .       .
                                Befotertinib:Furmonertinib  0    0  6.88 [0.31;  152.55]      .              .   6.88 [0.31;  152.55]    .              .     .       .
                                    Befotertinib:Gefitinib  0    0  7.95 [0.39;  161.50]      .              .   7.95 [0.39;  161.50]    .              .     .       .
                          Befotertinib:Gefitinib/Erlotinib  0    0  8.13 [0.34;  192.19]      .              .   8.13 [0.34;  192.19]    .              .     .       .
                       Befotertinib:Gefitinib + chemotherapy  0    0  5.89 [0.24;  142.59]      .              .   5.89 [0.24;  142.59]    .              .     .       .
                     Befotertinib:Gefitinib + PARP inhibitor  0    0  2.62 [0.03;  214.34]      .              .   2.62 [0.03;  214.34]    .              .     .       .
                                     Befotertinib:Icotinib  1 1.00  1.12 [0.68;    1.86]   1.12 [0.68;   1.86]      .               .    .              .     .       .
                                   Befotertinib:Lazertinib  0    0  3.09 [0.13;   74.45]      .              .   3.09 [0.13;   74.45]    .              .     .       .
                                  Befotertinib:Osimertinib  0    0  3.38 [0.15;   76.15]      .              .   3.38 [0.15;   76.15]    .              .     .       .
                     Befotertinib:Osimertinib + chemotherapy  0    0  2.62 [0.11;   61.03]      .              .   2.62 [0.11;   61.03]    .              .     .       .
                  Befotertinib:Osimertinib + PD-L1 inhibitor  0    0 13.62 [0.16; 1124.71]      .              .  13.62 [0.16; 1124.71]    .              .     .       .
                   Befotertinib:Osimertinib + antiangiogenesis  0    0  1.11 [0.05;   26.81]      .              .   1.11 [0.05;   26.81]    .              .     .       .
                                      Befotertinib:Placebo  0    0  9.73 [0.44;  215.02]      .              .   9.73 [0.44;  215.02]    .              .     .       .
                                  Befotertinib:Rociletinib  0    0  1.34 [0.05;   33.70]      .              .   1.34 [0.05;   33.70]    .              .     .       .
                               Befotertinib:antiangiogenesis  0    0  1.34 [0.06;   31.64]      .              .   1.34 [0.06;   31.64]    .              .     .       .
                                 Befotertinib:Zorifertinib  0    0  7.15 [0.29;  178.79]      .              .   7.15 [0.29;  178.79]    .              .     .       .
                  Chemotherapy:Chemotherapy + antiangiogenesis  0    0  6.20 [0.31;  124.09]      .              .   6.20 [0.31;  124.09]    .              .     .       .
                                  Chemotherapy:Dacomitinib  0    0  2.01 [1.00;    4.02]      .              .   2.01 [1.00;    4.02]    .              .     .       .
                               Chemotherapy:DHFR inhibitor  0    0  1.53 [0.31;    7.43]      .              .   1.53 [0.31;    7.43]    .              .     .       .
                                    Chemotherapy:Erlotinib  7 0.77  1.18 [0.77;    1.81]   1.22 [0.75;   1.97]   1.08 [0.44;    2.62] 1.13 [0.41;   3.09]  0.23  0.8193
                Chemotherapy:Erlotinib + Autophagy inhibitor  0    0  0.67 [0.14;    3.21]      .              .   0.67 [0.14;    3.21]    .              .     .       .
                       Chemotherapy:Erlotinib + chemotherapy  1 0.26  0.92 [0.37;    2.29]   0.97 [0.16;   5.79]   0.91 [0.32;    2.60] 1.07 [0.14;   8.50]  0.07  0.9465
                     Chemotherapy:Erlotinib + COX2 inhibitor  0    0  3.68 [0.14;   95.07]      .              .   3.68 [0.14;   95.07]    .              .     .       .
                     Chemotherapy:Erlotinib + HER3 inhibitor  0    0  0.45 [0.09;    2.23]      .              .   0.45 [0.09;    2.23]    .              .     .       .
                      Chemotherapy:Erlotinib + HGF inhibitor  0    0 10.64 [0.31;  363.85]      .              .  10.64 [0.31;  363.85]    .              .     .       .
                      Chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  1.31 [0.63;    2.74]      .              .   1.31 [0.63;    2.74]    .              .     .       .
                      Chemotherapy:Erlotinib + MET inhibitor  0    0  0.67 [0.33;    1.36]      .              .   0.67 [0.33;    1.36]    .              .     .       .
                      Chemotherapy:Erlotinib + MMP inhibitor  0    0  0.37 [0.07;    1.99]      .              .   0.37 [0.07;    1.99]    .              .     .       .
                     Chemotherapy:Erlotinib + antiangiogenesis  0    0  1.05 [0.62;    1.77]      .              .   1.05 [0.62;    1.77]    .              .     .       .
                                Chemotherapy:Furmonertinib  0    0  1.08 [0.39;    2.98]      .              .   1.08 [0.39;    2.98]    .              .     .       .
                                    Chemotherapy:Gefitinib  2 0.40  1.25 [0.62;    2.53]   0.99 [0.32;   3.04]   1.46 [0.59;    3.60] 0.68 [0.16;   2.87] -0.52  0.6027
                          Chemotherapy:Gefitinib/Erlotinib  0    0  1.28 [0.53;    3.11]      .              .   1.28 [0.53;    3.11]    .              .     .       .
                       Chemotherapy:Gefitinib + chemotherapy  0    0  0.93 [0.26;    3.26]      .              .   0.93 [0.26;    3.26]    .              .     .       .
                     Chemotherapy:Gefitinib + PARP inhibitor  0    0  0.41 [0.02;   11.08]      .              .   0.41 [0.02;   11.08]    .              .     .       .
                                     Chemotherapy:Icotinib  0    0  0.18 [0.01;    3.75]      .              .   0.18 [0.01;    3.75]    .              .     .       .
                                   Chemotherapy:Lazertinib  0    0  0.49 [0.18;    1.35]      .              .   0.49 [0.18;    1.35]    .              .     .       .
                                  Chemotherapy:Osimertinib  1 0.31  0.53 [0.26;    1.07]   0.40 [0.11;   1.40]   0.61 [0.26;    1.41] 0.65 [0.14;   2.97] -0.55  0.5817
                     Chemotherapy:Osimertinib + chemotherapy  0    0  0.41 [0.18;    0.95]      .              .   0.41 [0.18;    0.95]    .              .     .       .
                  Chemotherapy:Osimertinib + PD-L1 inhibitor  0    0  2.15 [0.09;   52.87]      .              .   2.15 [0.09;   52.87]    .              .     .       .
                   Chemotherapy:Osimertinib + antiangiogenesis  0    0  0.17 [0.07;    0.46]      .              .   0.17 [0.07;    0.46]    .              .     .       .
                                      Chemotherapy:Placebo  0    0  1.53 [0.82;    2.85]      .              .   1.53 [0.82;    2.85]    .              .     .       .
                                  Chemotherapy:Rociletinib  0    0  0.21 [0.08;    0.58]      .              .   0.21 [0.08;    0.58]    .              .     .       .
                               Chemotherapy:antiangiogenesis  0    0  0.21 [0.09;    0.48]      .              .   0.21 [0.09;    0.48]    .              .     .       .
                                 Chemotherapy:Zorifertinib  0    0  1.13 [0.39;    3.28]      .              .   1.13 [0.39;    3.28]    .              .     .       .
                   Chemotherapy + antiangiogenesis:Dacomitinib  0    0  0.32 [0.02;    6.69]      .              .   0.32 [0.02;    6.69]    .              .     .       .
                Chemotherapy + antiangiogenesis:DHFR inhibitor  0    0  0.25 [0.01;    7.07]      .              .   0.25 [0.01;    7.07]    .              .     .       .
                     Chemotherapy + antiangiogenesis:Erlotinib  0    0  0.19 [0.01;    3.79]      .              .   0.19 [0.01;    3.79]    .              .     .       .
 Chemotherapy + antiangiogenesis:Erlotinib + Autophagy inhibitor  0    0  0.11 [0.00;    3.07]      .              .   0.11 [0.00;    3.07]    .              .     .       .
        Chemotherapy + antiangiogenesis:Erlotinib + chemotherapy  0    0  0.15 [0.01;    3.32]      .              .   0.15 [0.01;    3.32]    .              .     .       .
      Chemotherapy + antiangiogenesis:Erlotinib + COX2 inhibitor  0    0  0.59 [0.01;   48.22]      .              .   0.59 [0.01;   48.22]    .              .     .       .
      Chemotherapy + antiangiogenesis:Erlotinib + HER3 inhibitor  0    0  0.07 [0.00;    2.10]      .              .   0.07 [0.00;    2.10]    .              .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + HGF inhibitor  0    0  1.72 [0.02;  172.20]      .              .   1.72 [0.02;  172.20]    .              .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + IGF-1R inhibitor  0    0  0.21 [0.01;    4.47]      .              .   0.21 [0.01;    4.47]    .              .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + MET inhibitor  0    0  0.11 [0.01;    2.28]      .              .   0.11 [0.01;    2.28]    .              .     .       .
       Chemotherapy + antiangiogenesis:Erlotinib + MMP inhibitor  0    0  0.06 [0.00;    1.79]      .              .   0.06 [0.00;    1.79]    .              .     .       .
      Chemotherapy + antiangiogenesis:Erlotinib + antiangiogenesis  0    0  0.17 [0.01;    3.41]      .              .   0.17 [0.01;    3.41]    .              .     .       .
                 Chemotherapy + antiangiogenesis:Furmonertinib  0    0  0.18 [0.01;    3.91]      .              .   0.18 [0.01;    3.91]    .              .     .       .
                     Chemotherapy + antiangiogenesis:Gefitinib  0    0  0.20 [0.01;    4.15]      .              .   0.20 [0.01;    4.15]    .              .     .       .
           Chemotherapy + antiangiogenesis:Gefitinib/Erlotinib  0    0  0.21 [0.01;    4.01]      .              .   0.21 [0.01;    4.01]    .              .     .       .
        Chemotherapy + antiangiogenesis:Gefitinib + chemotherapy  0    0  0.15 [0.01;    3.66]      .              .   0.15 [0.01;    3.66]    .              .     .       .
      Chemotherapy + antiangiogenesis:Gefitinib + PARP inhibitor  0    0  0.07 [0.00;    5.49]      .              .   0.07 [0.00;    5.49]    .              .     .       .
                      Chemotherapy + antiangiogenesis:Icotinib  0    0  0.03 [0.00;    1.98]      .              .   0.03 [0.00;    1.98]    .              .     .       .
                    Chemotherapy + antiangiogenesis:Lazertinib  0    0  0.08 [0.00;    1.62]      .              .   0.08 [0.00;    1.62]    .              .     .       .
                   Chemotherapy + antiangiogenesis:Osimertinib  1 1.00  0.09 [0.00;    1.58]   0.09 [0.00;   1.58]      .               .    .              .     .       .
      Chemotherapy + antiangiogenesis:Osimertinib + chemotherapy  0    0  0.07 [0.00;    1.27]      .              .   0.07 [0.00;    1.27]    .              .     .       .
   Chemotherapy + antiangiogenesis:Osimertinib + PD-L1 inhibitor  0    0  0.35 [0.00;   24.86]      .              .   0.35 [0.00;   24.86]    .              .     .       .
    Chemotherapy + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  0.03 [0.00;    0.56]      .              .   0.03 [0.00;    0.56]    .              .     .       .
                       Chemotherapy + antiangiogenesis:Placebo  0    0  0.25 [0.01;    4.75]      .              .   0.25 [0.01;    4.75]    .              .     .       .
                   Chemotherapy + antiangiogenesis:Rociletinib  0    0  0.03 [0.00;    0.78]      .              .   0.03 [0.00;    0.78]    .              .     .       .
                Chemotherapy + antiangiogenesis:antiangiogenesis  0    0  0.03 [0.00;    0.73]      .              .   0.03 [0.00;    0.73]    .              .     .       .
                  Chemotherapy + antiangiogenesis:Zorifertinib  0    0  0.18 [0.01;    3.74]      .              .   0.18 [0.01;    3.74]    .              .     .       .
                                Dacomitinib:DHFR inhibitor  0    0  0.76 [0.15;    3.87]      .              .   0.76 [0.15;    3.87]    .              .     .       .
                                     Dacomitinib:Erlotinib  1 0.81  0.59 [0.33;    1.04]   0.67 [0.35;   1.25]   0.34 [0.09;    1.27] 1.95 [0.45;   8.38]  0.90  0.3685
                 Dacomitinib:Erlotinib + Autophagy inhibitor  0    0  0.33 [0.07;    1.67]      .              .   0.33 [0.07;    1.67]    .              .     .       .
                        Dacomitinib:Erlotinib + chemotherapy  0    0  0.46 [0.17;    1.27]      .              .   0.46 [0.17;    1.27]    .              .     .       .
                      Dacomitinib:Erlotinib + COX2 inhibitor  0    0  1.83 [0.07;   48.35]      .              .   1.83 [0.07;   48.35]    .              .     .       .
                      Dacomitinib:Erlotinib + HER3 inhibitor  0    0  0.22 [0.04;    1.16]      .              .   0.22 [0.04;    1.16]    .              .     .       .
                       Dacomitinib:Erlotinib + HGF inhibitor  0    0  5.30 [0.15;  184.72]      .              .   5.30 [0.15;  184.72]    .              .     .       .
                       Dacomitinib:Erlotinib + IGF-1R inhibitor  0    0  0.65 [0.28;    1.50]      .              .   0.65 [0.28;    1.50]    .              .     .       .
                       Dacomitinib:Erlotinib + MET inhibitor  0    0  0.34 [0.15;    0.75]      .              .   0.34 [0.15;    0.75]    .              .     .       .
                       Dacomitinib:Erlotinib + MMP inhibitor  0    0  0.18 [0.03;    1.03]      .              .   0.18 [0.03;    1.03]    .              .     .       .
                      Dacomitinib:Erlotinib + antiangiogenesis  0    0  0.52 [0.27;    1.00]      .              .   0.52 [0.27;    1.00]    .              .     .       .
                                 Dacomitinib:Furmonertinib  0    0  0.54 [0.18;    1.65]      .              .   0.54 [0.18;    1.65]    .              .     .       .
                                     Dacomitinib:Gefitinib  1 0.09  0.62 [0.27;    1.45]   0.99 [0.06;  15.87]   0.59 [0.24;    1.45] 1.66 [0.09;  30.69]  0.34  0.7334
                           Dacomitinib:Gefitinib/Erlotinib  0    0  0.64 [0.24;    1.70]      .              .   0.64 [0.24;    1.70]    .              .     .       .
                        Dacomitinib:Gefitinib + chemotherapy  0    0  0.46 [0.12;    1.77]      .              .   0.46 [0.12;    1.77]    .              .     .       .
                      Dacomitinib:Gefitinib + PARP inhibitor  0    0  0.21 [0.01;    5.70]      .              .   0.21 [0.01;    5.70]    .              .     .       .
                                      Dacomitinib:Icotinib  0    0  0.09 [0.00;    1.93]      .              .   0.09 [0.00;    1.93]    .              .     .       .
                                    Dacomitinib:Lazertinib  0    0  0.24 [0.08;    0.73]      .              .   0.24 [0.08;    0.73]    .              .     .       .
                                   Dacomitinib:Osimertinib  0    0  0.26 [0.12;    0.60]      .              .   0.26 [0.12;    0.60]    .              .     .       .
                      Dacomitinib:Osimertinib + chemotherapy  0    0  0.21 [0.08;    0.52]      .              .   0.21 [0.08;    0.52]    .              .     .       .
                   Dacomitinib:Osimertinib + PD-L1 inhibitor  0    0  1.07 [0.04;   27.05]      .              .   1.07 [0.04;   27.05]    .              .     .       .
                    Dacomitinib:Osimertinib + antiangiogenesis  0    0  0.09 [0.03;    0.25]      .              .   0.09 [0.03;    0.25]    .              .     .       .
                                       Dacomitinib:Placebo  1 0.29  0.76 [0.37;    1.55]   0.40 [0.11;   1.49]   1.00 [0.43;    2.31] 0.40 [0.08;   1.91] -1.15  0.2494
                                   Dacomitinib:Rociletinib  0    0  0.11 [0.04;    0.31]      .              .   0.11 [0.04;    0.31]    .              .     .       .
                                Dacomitinib:antiangiogenesis  0    0  0.10 [0.04;    0.26]      .              .   0.10 [0.04;    0.26]    .              .     .       .
                                  Dacomitinib:Zorifertinib  0    0  0.56 [0.18;    1.77]      .              .   0.56 [0.18;    1.77]    .              .     .       .
                                  DHFR inhibitor:Erlotinib  1 1.00  0.77 [0.17;    3.55]   0.77 [0.17;   3.55]      .               .    .              .     .       .
              DHFR inhibitor:Erlotinib + Autophagy inhibitor  0    0  0.44 [0.05;    3.74]      .              .   0.44 [0.05;    3.74]    .              .     .       .
                     DHFR inhibitor:Erlotinib + chemotherapy  0    0  0.61 [0.11;    3.45]      .              .   0.61 [0.11;    3.45]    .              .     .       .
                   DHFR inhibitor:Erlotinib + COX2 inhibitor  0    0  2.41 [0.07;   85.17]      .              .   2.41 [0.07;   85.17]    .              .     .       .
                   DHFR inhibitor:Erlotinib + HER3 inhibitor  0    0  0.29 [0.03;    2.58]      .              .   0.29 [0.03;    2.58]    .              .     .       .
                    DHFR inhibitor:Erlotinib + HGF inhibitor  0    0  6.97 [0.15;  318.55]      .              .   6.97 [0.15;  318.55]    .              .     .       .
                    DHFR inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.86 [0.17;    4.42]      .              .   0.86 [0.17;    4.42]    .              .     .       .
                    DHFR inhibitor:Erlotinib + MET inhibitor  0    0  0.44 [0.09;    2.24]      .              .   0.44 [0.09;    2.24]    .              .     .       .
                    DHFR inhibitor:Erlotinib + MMP inhibitor  0    0  0.24 [0.03;    2.24]      .              .   0.24 [0.03;    2.24]    .              .     .       .
                   DHFR inhibitor:Erlotinib + antiangiogenesis  0    0  0.68 [0.14;    3.24]      .              .   0.68 [0.14;    3.24]    .              .     .       .
                              DHFR inhibitor:Furmonertinib  0    0  0.71 [0.11;    4.40]      .              .   0.71 [0.11;    4.40]    .              .     .       .
                                  DHFR inhibitor:Gefitinib  0    0  0.82 [0.15;    4.37]      .              .   0.82 [0.15;    4.37]    .              .     .       .
                        DHFR inhibitor:Gefitinib/Erlotinib  0    0  0.84 [0.15;    4.83]      .              .   0.84 [0.15;    4.83]    .              .     .       .
                     DHFR inhibitor:Gefitinib + chemotherapy  0    0  0.61 [0.08;    4.36]      .              .   0.61 [0.08;    4.36]    .              .     .       .
                   DHFR inhibitor:Gefitinib + PARP inhibitor  0    0  0.27 [0.01;   10.13]      .              .   0.27 [0.01;   10.13]    .              .     .       .
                                   DHFR inhibitor:Icotinib  0    0  0.12 [0.00;    3.50]      .              .   0.12 [0.00;    3.50]    .              .     .       .
                                 DHFR inhibitor:Lazertinib  0    0  0.32 [0.05;    1.97]      .              .   0.32 [0.05;    1.97]    .              .     .       .
                                DHFR inhibitor:Osimertinib  0    0  0.35 [0.07;    1.84]      .              .   0.35 [0.07;    1.84]    .              .     .       .
                   DHFR inhibitor:Osimertinib + chemotherapy  0    0  0.27 [0.05;    1.52]      .              .   0.27 [0.05;    1.52]    .              .     .       .
                DHFR inhibitor:Osimertinib + PD-L1 inhibitor  0    0  1.40 [0.04;   48.50]      .              .   1.40 [0.04;   48.50]    .              .     .       .
                 DHFR inhibitor:Osimertinib + antiangiogenesis  0    0  0.11 [0.02;    0.69]      .              .   0.11 [0.02;    0.69]    .              .     .       .
                                    DHFR inhibitor:Placebo  0    0  1.00 [0.20;    5.06]      .              .   1.00 [0.20;    5.06]    .              .     .       .
                                DHFR inhibitor:Rociletinib  0    0  0.14 [0.02;    0.82]      .              .   0.14 [0.02;    0.82]    .              .     .       .
                             DHFR inhibitor:antiangiogenesis  0    0  0.14 [0.03;    0.74]      .              .   0.14 [0.03;    0.74]    .              .     .       .
                               DHFR inhibitor:Zorifertinib  0    0  0.74 [0.12;    4.69]      .              .   0.74 [0.12;    4.69]    .              .     .       .
                   Erlotinib:Erlotinib + Autophagy inhibitor  1 1.00  0.57 [0.13;    2.56]   0.57 [0.13;   2.56]      .               .    .              .     .       .
                          Erlotinib:Erlotinib + chemotherapy  3 0.84  0.78 [0.34;    1.82]   0.73 [0.29;   1.83]   1.15 [0.14;    9.57] 0.63 [0.06;   6.38] -0.39  0.6980
                        Erlotinib:Erlotinib + COX2 inhibitor  1 1.00  3.11 [0.12;   78.18]   3.11 [0.12;  78.18]      .               .    .              .     .       .
                        Erlotinib:Erlotinib + HER3 inhibitor  1 1.00  0.38 [0.08;    1.78]   0.38 [0.08;   1.78]      .               .    .              .     .       .
                         Erlotinib:Erlotinib + HGF inhibitor  1 1.00  9.00 [0.27;  299.86]   9.00 [0.27; 299.86]      .               .    .              .     .       .
                         Erlotinib:Erlotinib + IGF-1R inhibitor  2 1.00  1.11 [0.61;    2.03]   1.11 [0.61;   2.03]      .               .    .              .     .       .
                         Erlotinib:Erlotinib + MET inhibitor  3 1.00  0.57 [0.32;    1.00]   0.57 [0.32;   1.00]      .               .    .              .     .       .
                         Erlotinib:Erlotinib + MMP inhibitor  1 1.00  0.31 [0.06;    1.59]   0.31 [0.06;   1.59]      .               .    .              .     .       .
                        Erlotinib:Erlotinib + antiangiogenesis 10 0.98  0.88 [0.65;    1.21]   0.87 [0.64;   1.20]   1.75 [0.16;   19.66] 0.50 [0.04;   5.73] -0.56  0.5769
                                   Erlotinib:Furmonertinib  0    0  0.92 [0.34;    2.51]      .              .   0.92 [0.34;    2.51]    .              .     .       .
                                       Erlotinib:Gefitinib  0    0  1.06 [0.53;    2.12]      .              .   1.06 [0.53;    2.12]    .              .     .       .
                             Erlotinib:Gefitinib/Erlotinib  0    0  1.08 [0.46;    2.57]      .              .   1.08 [0.46;    2.57]    .              .     .       .
                          Erlotinib:Gefitinib + chemotherapy  0    0  0.79 [0.22;    2.74]      .              .   0.79 [0.22;    2.74]    .              .     .       .
                        Erlotinib:Gefitinib + PARP inhibitor  0    0  0.35 [0.01;    9.35]      .              .   0.35 [0.01;    9.35]    .              .     .       .
                                        Erlotinib:Icotinib  0    0  0.15 [0.01;    3.16]      .              .   0.15 [0.01;    3.16]    .              .     .       .
                                      Erlotinib:Lazertinib  0    0  0.41 [0.15;    1.12]      .              .   0.41 [0.15;    1.12]    .              .     .       .
                                     Erlotinib:Osimertinib  0    0  0.45 [0.23;    0.88]      .              .   0.45 [0.23;    0.88]    .              .     .       .
                        Erlotinib:Osimertinib + chemotherapy  0    0  0.35 [0.16;    0.78]      .              .   0.35 [0.16;    0.78]    .              .     .       .
                     Erlotinib:Osimertinib + PD-L1 inhibitor  0    0  1.81 [0.07;   44.41]      .              .   1.81 [0.07;   44.41]    .              .     .       .
                      Erlotinib:Osimertinib + antiangiogenesis  0    0  0.15 [0.06;    0.38]      .              .   0.15 [0.06;    0.38]    .              .     .       .
                                         Erlotinib:Placebo  3 0.46  1.30 [0.75;    2.24]   1.44 [0.65;   3.23]   1.18 [0.56;    2.49] 1.22 [0.41;   3.65]  0.36  0.7226
                                     Erlotinib:Rociletinib  1 1.00  0.18 [0.07;    0.45]   0.18 [0.07;   0.45]      .               .    .              .     .       .
                                  Erlotinib:antiangiogenesis  2 0.81  0.18 [0.09;    0.37]   0.20 [0.09;   0.45]   0.10 [0.02;    0.51] 2.05 [0.33;  12.71]  0.77  0.4387
                                    Erlotinib:Zorifertinib  0    0  0.95 [0.33;    2.72]      .              .   0.95 [0.33;    2.72]    .              .     .       .
      Erlotinib + Autophagy inhibitor:Erlotinib + chemotherapy  0    0  1.38 [0.25;    7.79]      .              .   1.38 [0.25;    7.79]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + COX2 inhibitor  0    0  5.51 [0.16;  193.27]      .              .   5.51 [0.16;  193.27]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + HER3 inhibitor  0    0  0.67 [0.08;    5.82]      .              .   0.67 [0.08;    5.82]    .              .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + HGF inhibitor  0    0 15.91 [0.35;  723.17]      .              .  15.91 [0.35;  723.17]    .              .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor  0    0  1.96 [0.39;    9.95]      .              .   1.96 [0.39;    9.95]    .              .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor  0    0  1.01 [0.20;    5.04]      .              .   1.01 [0.20;    5.04]    .              .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + MMP inhibitor  0    0  0.55 [0.06;    5.07]      .              .   0.55 [0.06;    5.07]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis  0    0  1.56 [0.33;    7.30]      .              .   1.56 [0.33;    7.30]    .              .     .       .
               Erlotinib + Autophagy inhibitor:Furmonertinib  0    0  1.62 [0.26;    9.93]      .              .   1.62 [0.26;    9.93]    .              .     .       .
                   Erlotinib + Autophagy inhibitor:Gefitinib  0    0  1.87 [0.36;    9.85]      .              .   1.87 [0.36;    9.85]    .              .     .       .
         Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib  0    0  1.91 [0.34;   10.89]      .              .   1.91 [0.34;   10.89]    .              .     .       .
      Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy  0    0  1.39 [0.20;    9.85]      .              .   1.39 [0.20;    9.85]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Gefitinib + PARP inhibitor  0    0  0.62 [0.02;   22.98]      .              .   0.62 [0.02;   22.98]    .              .     .       .
                    Erlotinib + Autophagy inhibitor:Icotinib  0    0  0.26 [0.01;    7.95]      .              .   0.26 [0.01;    7.95]    .              .     .       .
                  Erlotinib + Autophagy inhibitor:Lazertinib  0    0  0.73 [0.12;    4.44]      .              .   0.73 [0.12;    4.44]    .              .     .       .
                 Erlotinib + Autophagy inhibitor:Osimertinib  0    0  0.80 [0.15;    4.14]      .              .   0.80 [0.15;    4.14]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy  0    0  0.62 [0.11;    3.42]      .              .   0.62 [0.11;    3.42]    .              .     .       .
 Erlotinib + Autophagy inhibitor:Osimertinib + PD-L1 inhibitor  0    0  3.21 [0.09;  110.05]      .              .   3.21 [0.09;  110.05]    .              .     .       .
  Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis  0    0  0.26 [0.04;    1.55]      .              .   0.26 [0.04;    1.55]    .              .     .       .
                     Erlotinib + Autophagy inhibitor:Placebo  0    0  2.29 [0.46;   11.40]      .              .   2.29 [0.46;   11.40]    .              .     .       .
                 Erlotinib + Autophagy inhibitor:Rociletinib  0    0  0.32 [0.05;    1.85]      .              .   0.32 [0.05;    1.85]    .              .     .       .
              Erlotinib + Autophagy inhibitor:antiangiogenesis  0    0  0.32 [0.06;    1.67]      .              .   0.32 [0.06;    1.67]    .              .     .       .
                Erlotinib + Autophagy inhibitor:Zorifertinib  0    0  1.69 [0.27;   10.58]      .              .   1.69 [0.27;   10.58]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + COX2 inhibitor  0    0  3.98 [0.14;  111.47]      .              .   3.98 [0.14;  111.47]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor  0    0  0.49 [0.08;    2.83]      .              .   0.49 [0.08;    2.83]    .              .     .       .
            Erlotinib + chemotherapy:Erlotinib + HGF inhibitor  0    0 11.51 [0.31;  423.94]      .              .  11.51 [0.31;  423.94]    .              .     .       .
            Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  1.42 [0.50;    4.00]      .              .   1.42 [0.50;    4.00]    .              .     .       .
            Erlotinib + chemotherapy:Erlotinib + MET inhibitor  0    0  0.73 [0.26;    2.01]      .              .   0.73 [0.26;    2.01]    .              .     .       .
            Erlotinib + chemotherapy:Erlotinib + MMP inhibitor  0    0  0.40 [0.06;    2.50]      .              .   0.40 [0.06;    2.50]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + antiangiogenesis  0    0  1.13 [0.46;    2.78]      .              .   1.13 [0.46;    2.78]    .              .     .       .
                      Erlotinib + chemotherapy:Furmonertinib  0    0  1.17 [0.32;    4.30]      .              .   1.17 [0.32;    4.30]    .              .     .       .
                          Erlotinib + chemotherapy:Gefitinib  0    0  1.35 [0.46;    3.98]      .              .   1.35 [0.46;    3.98]    .              .     .       .
                Erlotinib + chemotherapy:Gefitinib/Erlotinib  0    0  1.39 [0.42;    4.58]      .              .   1.39 [0.42;    4.58]    .              .     .       .
             Erlotinib + chemotherapy:Gefitinib + chemotherapy  0    0  1.00 [0.22;    4.49]      .              .   1.00 [0.22;    4.49]    .              .     .       .
           Erlotinib + chemotherapy:Gefitinib + PARP inhibitor  0    0  0.45 [0.02;   13.24]      .              .   0.45 [0.02;   13.24]    .              .     .       .
                           Erlotinib + chemotherapy:Icotinib  0    0  0.19 [0.01;    4.51]      .              .   0.19 [0.01;    4.51]    .              .     .       .
                         Erlotinib + chemotherapy:Lazertinib  0    0  0.53 [0.14;    1.93]      .              .   0.53 [0.14;    1.93]    .              .     .       .
                        Erlotinib + chemotherapy:Osimertinib  0    0  0.58 [0.20;    1.67]      .              .   0.58 [0.20;    1.67]    .              .     .       .
           Erlotinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.45 [0.14;    1.42]      .              .   0.45 [0.14;    1.42]    .              .     .       .
        Erlotinib + chemotherapy:Osimertinib + PD-L1 inhibitor  0    0  2.32 [0.09;   63.10]      .              .   2.32 [0.09;   63.10]    .              .     .       .
         Erlotinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.19 [0.05;    0.66]      .              .   0.19 [0.05;    0.66]    .              .     .       .
                            Erlotinib + chemotherapy:Placebo  0    0  1.66 [0.61;    4.49]      .              .   1.66 [0.61;    4.49]    .              .     .       .
                        Erlotinib + chemotherapy:Rociletinib  0    0  0.23 [0.07;    0.79]      .              .   0.23 [0.07;    0.79]    .              .     .       .
                     Erlotinib + chemotherapy:antiangiogenesis  0    0  0.23 [0.08;    0.69]      .              .   0.23 [0.08;    0.69]    .              .     .       .
                       Erlotinib + chemotherapy:Zorifertinib  0    0  1.22 [0.32;    4.64]      .              .   1.22 [0.32;    4.64]    .              .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + HER3 inhibitor  0    0  0.12 [0.00;    4.35]      .              .   0.12 [0.00;    4.35]    .              .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + HGF inhibitor  0    0  2.89 [0.02;  338.19]      .              .   2.89 [0.02;  338.19]    .              .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.36 [0.01;    9.45]      .              .   0.36 [0.01;    9.45]    .              .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + MET inhibitor  0    0  0.18 [0.01;    4.82]      .              .   0.18 [0.01;    4.82]    .              .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + MMP inhibitor  0    0  0.10 [0.00;    3.70]      .              .   0.10 [0.00;    3.70]    .              .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + antiangiogenesis  0    0  0.28 [0.01;    7.24]      .              .   0.28 [0.01;    7.24]    .              .     .       .
                    Erlotinib + COX2 inhibitor:Furmonertinib  0    0  0.29 [0.01;    8.62]      .              .   0.29 [0.01;    8.62]    .              .     .       .
                        Erlotinib + COX2 inhibitor:Gefitinib  0    0  0.34 [0.01;    9.19]      .              .   0.34 [0.01;    9.19]    .              .     .       .
              Erlotinib + COX2 inhibitor:Gefitinib/Erlotinib  0    0  0.35 [0.01;    9.78]      .              .   0.35 [0.01;    9.78]    .              .     .       .
           Erlotinib + COX2 inhibitor:Gefitinib + chemotherapy  0    0  0.25 [0.01;    8.00]      .              .   0.25 [0.01;    8.00]    .              .     .       .
         Erlotinib + COX2 inhibitor:Gefitinib + PARP inhibitor  0    0  0.11 [0.00;   11.20]      .              .   0.11 [0.00;   11.20]    .              .     .       .
                         Erlotinib + COX2 inhibitor:Icotinib  0    0  0.05 [0.00;    4.06]      .              .   0.05 [0.00;    4.06]    .              .     .       .
                       Erlotinib + COX2 inhibitor:Lazertinib  0    0  0.13 [0.00;    3.86]      .              .   0.13 [0.00;    3.86]    .              .     .       .
                      Erlotinib + COX2 inhibitor:Osimertinib  0    0  0.14 [0.01;    3.89]      .              .   0.14 [0.01;    3.89]    .              .     .       .
         Erlotinib + COX2 inhibitor:Osimertinib + chemotherapy  0    0  0.11 [0.00;    3.11]      .              .   0.11 [0.00;    3.11]    .              .     .       .
      Erlotinib + COX2 inhibitor:Osimertinib + PD-L1 inhibitor  0    0  0.58 [0.01;   54.59]      .              .   0.58 [0.01;   54.59]    .              .     .       .
       Erlotinib + COX2 inhibitor:Osimertinib + antiangiogenesis  0    0  0.05 [0.00;    1.36]      .              .   0.05 [0.00;    1.36]    .              .     .       .
                          Erlotinib + COX2 inhibitor:Placebo  0    0  0.42 [0.02;   10.94]      .              .   0.42 [0.02;   10.94]    .              .     .       .
                      Erlotinib + COX2 inhibitor:Rociletinib  0    0  0.06 [0.00;    1.64]      .              .   0.06 [0.00;    1.64]    .              .     .       .
                   Erlotinib + COX2 inhibitor:antiangiogenesis  0    0  0.06 [0.00;    1.56]      .              .   0.06 [0.00;    1.56]    .              .     .       .
                     Erlotinib + COX2 inhibitor:Zorifertinib  0    0  0.31 [0.01;    9.08]      .              .   0.31 [0.01;    9.08]    .              .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + HGF inhibitor  0    0 23.70 [0.51; 1093.73]      .              .  23.70 [0.51; 1093.73]    .              .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor  0    0  2.92 [0.56;   15.36]      .              .   2.92 [0.56;   15.36]    .              .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor  0    0  1.50 [0.29;    7.77]      .              .   1.50 [0.29;    7.77]    .              .     .       .
          Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor  0    0  0.82 [0.09;    7.75]      .              .   0.82 [0.09;    7.75]    .              .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis  0    0  2.33 [0.48;   11.28]      .              .   2.33 [0.48;   11.28]    .              .     .       .
                    Erlotinib + HER3 inhibitor:Furmonertinib  0    0  2.42 [0.38;   15.27]      .              .   2.42 [0.38;   15.27]    .              .     .       .
                        Erlotinib + HER3 inhibitor:Gefitinib  0    0  2.79 [0.51;   15.18]      .              .   2.79 [0.51;   15.18]    .              .     .       .
              Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib  0    0  2.85 [0.49;   16.76]      .              .   2.85 [0.49;   16.76]    .              .     .       .
           Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy  0    0  2.07 [0.28;   15.10]      .              .   2.07 [0.28;   15.10]    .              .     .       .
         Erlotinib + HER3 inhibitor:Gefitinib + PARP inhibitor  0    0  0.92 [0.02;   34.78]      .              .   0.92 [0.02;   34.78]    .              .     .       .
                         Erlotinib + HER3 inhibitor:Icotinib  0    0  0.39 [0.01;   12.05]      .              .   0.39 [0.01;   12.05]    .              .     .       .
                       Erlotinib + HER3 inhibitor:Lazertinib  0    0  1.08 [0.17;    6.83]      .              .   1.08 [0.17;    6.83]    .              .     .       .
                      Erlotinib + HER3 inhibitor:Osimertinib  0    0  1.19 [0.22;    6.39]      .              .   1.19 [0.22;    6.39]    .              .     .       .
         Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy  0    0  0.92 [0.16;    5.26]      .              .   0.92 [0.16;    5.26]    .              .     .       .
      Erlotinib + HER3 inhibitor:Osimertinib + PD-L1 inhibitor  0    0  4.78 [0.14;  166.64]      .              .   4.78 [0.14;  166.64]    .              .     .       .
       Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis  0    0  0.39 [0.06;    2.38]      .              .   0.39 [0.06;    2.38]    .              .     .       .
                          Erlotinib + HER3 inhibitor:Placebo  0    0  3.41 [0.66;   17.60]      .              .   3.41 [0.66;   17.60]    .              .     .       .
                      Erlotinib + HER3 inhibitor:Rociletinib  0    0  0.47 [0.08;    2.84]      .              .   0.47 [0.08;    2.84]    .              .     .       .
                   Erlotinib + HER3 inhibitor:antiangiogenesis  0    0  0.47 [0.09;    2.58]      .              .   0.47 [0.09;    2.58]    .              .     .       .
                     Erlotinib + HER3 inhibitor:Zorifertinib  0    0  2.51 [0.39;   16.26]      .              .   2.51 [0.39;   16.26]    .              .     .       .
           Erlotinib + HGF inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.12 [0.00;    4.32]      .              .   0.12 [0.00;    4.32]    .              .     .       .
           Erlotinib + HGF inhibitor:Erlotinib + MET inhibitor  0    0  0.06 [0.00;    2.21]      .              .   0.06 [0.00;    2.21]    .              .     .       .
           Erlotinib + HGF inhibitor:Erlotinib + MMP inhibitor  0    0  0.03 [0.00;    1.65]      .              .   0.03 [0.00;    1.65]    .              .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + antiangiogenesis  0    0  0.10 [0.00;    3.32]      .              .   0.10 [0.00;    3.32]    .              .     .       .
                     Erlotinib + HGF inhibitor:Furmonertinib  0    0  0.10 [0.00;    3.91]      .              .   0.10 [0.00;    3.91]    .              .     .       .
                         Erlotinib + HGF inhibitor:Gefitinib  0    0  0.12 [0.00;    4.20]      .              .   0.12 [0.00;    4.20]    .              .     .       .
               Erlotinib + HGF inhibitor:Gefitinib/Erlotinib  0    0  0.12 [0.00;    4.45]      .              .   0.12 [0.00;    4.45]    .              .     .       .
            Erlotinib + HGF inhibitor:Gefitinib + chemotherapy  0    0  0.09 [0.00;    3.61]      .              .   0.09 [0.00;    3.61]    .              .     .       .
          Erlotinib + HGF inhibitor:Gefitinib + PARP inhibitor  0    0  0.04 [0.00;    4.74]      .              .   0.04 [0.00;    4.74]    .              .     .       .
                          Erlotinib + HGF inhibitor:Icotinib  0    0  0.02 [0.00;    1.73]      .              .   0.02 [0.00;    1.73]    .              .     .       .
                        Erlotinib + HGF inhibitor:Lazertinib  0    0  0.05 [0.00;    1.75]      .              .   0.05 [0.00;    1.75]    .              .     .       .
                       Erlotinib + HGF inhibitor:Osimertinib  0    0  0.05 [0.00;    1.78]      .              .   0.05 [0.00;    1.78]    .              .     .       .
          Erlotinib + HGF inhibitor:Osimertinib + chemotherapy  0    0  0.04 [0.00;    1.42]      .              .   0.04 [0.00;    1.42]    .              .     .       .
       Erlotinib + HGF inhibitor:Osimertinib + PD-L1 inhibitor  0    0  0.20 [0.00;   23.19]      .              .   0.20 [0.00;   23.19]    .              .     .       .
        Erlotinib + HGF inhibitor:Osimertinib + antiangiogenesis  0    0  0.02 [0.00;    0.62]      .              .   0.02 [0.00;    0.62]    .              .     .       .
                           Erlotinib + HGF inhibitor:Placebo  0    0  0.14 [0.00;    5.01]      .              .   0.14 [0.00;    5.01]    .              .     .       .
                       Erlotinib + HGF inhibitor:Rociletinib  0    0  0.02 [0.00;    0.74]      .              .   0.02 [0.00;    0.74]    .              .     .       .
                    Erlotinib + HGF inhibitor:antiangiogenesis  0    0  0.02 [0.00;    0.71]      .              .   0.02 [0.00;    0.71]    .              .     .       .
                      Erlotinib + HGF inhibitor:Zorifertinib  0    0  0.11 [0.00;    4.12]      .              .   0.11 [0.00;    4.12]    .              .     .       .
           Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor  0    0  0.51 [0.23;    1.17]      .              .   0.51 [0.23;    1.17]    .              .     .       .
           Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor  0    0  0.28 [0.05;    1.60]      .              .   0.28 [0.05;    1.60]    .              .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis  0    0  0.80 [0.40;    1.57]      .              .   0.80 [0.40;    1.57]    .              .     .       .
                     Erlotinib + IGF-1R inhibitor:Furmonertinib  0    0  0.83 [0.26;    2.67]      .              .   0.83 [0.26;    2.67]    .              .     .       .
                         Erlotinib + IGF-1R inhibitor:Gefitinib  0    0  0.95 [0.38;    2.39]      .              .   0.95 [0.38;    2.39]    .              .     .       .
               Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib  0    0  0.98 [0.34;    2.80]      .              .   0.98 [0.34;    2.80]    .              .     .       .
            Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy  0    0  0.71 [0.18;    2.84]      .              .   0.71 [0.18;    2.84]    .              .     .       .
          Erlotinib + IGF-1R inhibitor:Gefitinib + PARP inhibitor  0    0  0.31 [0.01;    8.91]      .              .   0.31 [0.01;    8.91]    .              .     .       .
                          Erlotinib + IGF-1R inhibitor:Icotinib  0    0  0.14 [0.01;    3.02]      .              .   0.14 [0.01;    3.02]    .              .     .       .
                        Erlotinib + IGF-1R inhibitor:Lazertinib  0    0  0.37 [0.12;    1.19]      .              .   0.37 [0.12;    1.19]    .              .     .       .
                       Erlotinib + IGF-1R inhibitor:Osimertinib  0    0  0.41 [0.16;    1.00]      .              .   0.41 [0.16;    1.00]    .              .     .       .
          Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy  0    0  0.31 [0.11;    0.86]      .              .   0.31 [0.11;    0.86]    .              .     .       .
       Erlotinib + IGF-1R inhibitor:Osimertinib + PD-L1 inhibitor  0    0  1.64 [0.06;   42.36]      .              .   1.64 [0.06;   42.36]    .              .     .       .
        Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis  0    0  0.13 [0.04;    0.41]      .              .   0.13 [0.04;    0.41]    .              .     .       .
                           Erlotinib + IGF-1R inhibitor:Placebo  0    0  1.17 [0.52;    2.64]      .              .   1.17 [0.52;    2.64]    .              .     .       .
                       Erlotinib + IGF-1R inhibitor:Rociletinib  0    0  0.16 [0.05;    0.48]      .              .   0.16 [0.05;    0.48]    .              .     .       .
                    Erlotinib + IGF-1R inhibitor:antiangiogenesis  0    0  0.16 [0.06;    0.41]      .              .   0.16 [0.06;    0.41]    .              .     .       .
                      Erlotinib + IGF-1R inhibitor:Zorifertinib  0    0  0.86 [0.26;    2.88]      .              .   0.86 [0.26;    2.88]    .              .     .       .
           Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor  0    0  0.54 [0.10;    3.07]      .              .   0.54 [0.10;    3.07]    .              .     .       .
          Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis  0    0  1.55 [0.82;    2.96]      .              .   1.55 [0.82;    2.96]    .              .     .       .
                     Erlotinib + MET inhibitor:Furmonertinib  0    0  1.61 [0.51;    5.09]      .              .   1.61 [0.51;    5.09]    .              .     .       .
                         Erlotinib + MET inhibitor:Gefitinib  0    0  1.86 [0.76;    4.54]      .              .   1.86 [0.76;    4.54]    .              .     .       .
               Erlotinib + MET inhibitor:Gefitinib/Erlotinib  0    0  1.90 [0.68;    5.33]      .              .   1.90 [0.68;    5.33]    .              .     .       .
            Erlotinib + MET inhibitor:Gefitinib + chemotherapy  0    0  1.38 [0.35;    5.43]      .              .   1.38 [0.35;    5.43]    .              .     .       .
          Erlotinib + MET inhibitor:Gefitinib + PARP inhibitor  0    0  0.61 [0.02;   17.22]      .              .   0.61 [0.02;   17.22]    .              .     .       .
                          Erlotinib + MET inhibitor:Icotinib  0    0  0.26 [0.01;    5.84]      .              .   0.26 [0.01;    5.84]    .              .     .       .
                        Erlotinib + MET inhibitor:Lazertinib  0    0  0.72 [0.23;    2.27]      .              .   0.72 [0.23;    2.27]    .              .     .       .
                       Erlotinib + MET inhibitor:Osimertinib  0    0  0.79 [0.33;    1.89]      .              .   0.79 [0.33;    1.89]    .              .     .       .
          Erlotinib + MET inhibitor:Osimertinib + chemotherapy  0    0  0.61 [0.23;    1.64]      .              .   0.61 [0.23;    1.64]    .              .     .       .
       Erlotinib + MET inhibitor:Osimertinib + PD-L1 inhibitor  0    0  3.19 [0.12;   81.86]      .              .   3.19 [0.12;   81.86]    .              .     .       .
        Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis  0    0  0.26 [0.09;    0.78]      .              .   0.26 [0.09;    0.78]    .              .     .       .
                           Erlotinib + MET inhibitor:Placebo  0    0  2.28 [1.04;    4.99]      .              .   2.28 [1.04;    4.99]    .              .     .       .
                       Erlotinib + MET inhibitor:Rociletinib  0    0  0.31 [0.11;    0.92]      .              .   0.31 [0.11;    0.92]    .              .     .       .
                    Erlotinib + MET inhibitor:antiangiogenesis  0    0  0.31 [0.13;    0.78]      .              .   0.31 [0.13;    0.78]    .              .     .       .
                      Erlotinib + MET inhibitor:Zorifertinib  0    0  1.67 [0.51;    5.50]      .              .   1.67 [0.51;    5.50]    .              .     .       .
          Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis  0    0  2.85 [0.54;   15.06]      .              .   2.85 [0.54;   15.06]    .              .     .       .
                     Erlotinib + MMP inhibitor:Furmonertinib  0    0  2.96 [0.43;   20.15]      .              .   2.96 [0.43;   20.15]    .              .     .       .
                         Erlotinib + MMP inhibitor:Gefitinib  0    0  3.41 [0.58;   20.16]      .              .   3.41 [0.58;   20.16]    .              .     .       .
               Erlotinib + MMP inhibitor:Gefitinib/Erlotinib  0    0  3.49 [0.55;   22.18]      .              .   3.49 [0.55;   22.18]    .              .     .       .
            Erlotinib + MMP inhibitor:Gefitinib + chemotherapy  0    0  2.53 [0.32;   19.82]      .              .   2.53 [0.32;   19.82]    .              .     .       .
          Erlotinib + MMP inhibitor:Gefitinib + PARP inhibitor  0    0  1.13 [0.03;   44.25]      .              .   1.13 [0.03;   44.25]    .              .     .       .
                          Erlotinib + MMP inhibitor:Icotinib  0    0  0.48 [0.02;   15.36]      .              .   0.48 [0.02;   15.36]    .              .     .       .
                        Erlotinib + MMP inhibitor:Lazertinib  0    0  1.33 [0.20;    9.02]      .              .   1.33 [0.20;    9.02]    .              .     .       .
                       Erlotinib + MMP inhibitor:Osimertinib  0    0  1.45 [0.25;    8.49]      .              .   1.45 [0.25;    8.49]    .              .     .       .
          Erlotinib + MMP inhibitor:Osimertinib + chemotherapy  0    0  1.13 [0.18;    6.97]      .              .   1.13 [0.18;    6.97]    .              .     .       .
       Erlotinib + MMP inhibitor:Osimertinib + PD-L1 inhibitor  0    0  5.85 [0.16;  212.20]      .              .   5.85 [0.16;  212.20]    .              .     .       .
        Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis  0    0  0.48 [0.07;    3.14]      .              .   0.48 [0.07;    3.14]    .              .     .       .
                           Erlotinib + MMP inhibitor:Placebo  0    0  4.18 [0.75;   23.43]      .              .   4.18 [0.75;   23.43]    .              .     .       .
                       Erlotinib + MMP inhibitor:Rociletinib  0    0  0.58 [0.09;    3.75]      .              .   0.58 [0.09;    3.75]    .              .     .       .
                    Erlotinib + MMP inhibitor:antiangiogenesis  0    0  0.57 [0.10;    3.43]      .              .   0.57 [0.10;    3.43]    .              .     .       .
                      Erlotinib + MMP inhibitor:Zorifertinib  0    0  3.07 [0.44;   21.43]      .              .   3.07 [0.44;   21.43]    .              .     .       .
                    Erlotinib + antiangiogenesis:Furmonertinib  0    0  1.04 [0.36;    2.97]      .              .   1.04 [0.36;    2.97]    .              .     .       .
                        Erlotinib + antiangiogenesis:Gefitinib  0    0  1.20 [0.56;    2.56]      .              .   1.20 [0.56;    2.56]    .              .     .       .
              Erlotinib + antiangiogenesis:Gefitinib/Erlotinib  0    0  1.22 [0.49;    3.07]      .              .   1.22 [0.49;    3.07]    .              .     .       .
           Erlotinib + antiangiogenesis:Gefitinib + chemotherapy  0    0  0.89 [0.24;    3.22]      .              .   0.89 [0.24;    3.22]    .              .     .       .
         Erlotinib + antiangiogenesis:Gefitinib + PARP inhibitor  0    0  0.39 [0.01;   10.73]      .              .   0.39 [0.01;   10.73]    .              .     .       .
                         Erlotinib + antiangiogenesis:Icotinib  0    0  0.17 [0.01;    3.63]      .              .   0.17 [0.01;    3.63]    .              .     .       .
                       Erlotinib + antiangiogenesis:Lazertinib  0    0  0.47 [0.16;    1.33]      .              .   0.47 [0.16;    1.33]    .              .     .       .
                      Erlotinib + antiangiogenesis:Osimertinib  0    0  0.51 [0.24;    1.07]      .              .   0.51 [0.24;    1.07]    .              .     .       .
         Erlotinib + antiangiogenesis:Osimertinib + chemotherapy  0    0  0.39 [0.17;    0.94]      .              .   0.39 [0.17;    0.94]    .              .     .       .
      Erlotinib + antiangiogenesis:Osimertinib + PD-L1 inhibitor  0    0  2.05 [0.08;   50.99]      .              .   2.05 [0.08;   50.99]    .              .     .       .
       Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  0.17 [0.06;    0.45]      .              .   0.17 [0.06;    0.45]    .              .     .       .
                          Erlotinib + antiangiogenesis:Placebo  0    0  1.47 [0.78;    2.75]      .              .   1.47 [0.78;    2.75]    .              .     .       .
                      Erlotinib + antiangiogenesis:Rociletinib  0    0  0.20 [0.08;    0.53]      .              .   0.20 [0.08;    0.53]    .              .     .       .
                   Erlotinib + antiangiogenesis:antiangiogenesis  1 0.18  0.20 [0.09;    0.43]   0.17 [0.03;   1.07]   0.21 [0.09;    0.48] 0.84 [0.11;   6.18] -0.18  0.8608
                     Erlotinib + antiangiogenesis:Zorifertinib  0    0  1.08 [0.36;    3.22]      .              .   1.08 [0.36;    3.22]    .              .     .       .
                                   Furmonertinib:Gefitinib  1 1.00  1.15 [0.56;    2.39]   1.15 [0.56;   2.39]      .               .    .              .     .       .
                         Furmonertinib:Gefitinib/Erlotinib  0    0  1.18 [0.35;    3.96]      .              .   1.18 [0.35;    3.96]    .              .     .       .
                      Furmonertinib:Gefitinib + chemotherapy  0    0  0.86 [0.24;    3.05]      .              .   0.86 [0.24;    3.05]    .              .     .       .
                    Furmonertinib:Gefitinib + PARP inhibitor  0    0  0.38 [0.01;   10.27]      .              .   0.38 [0.01;   10.27]    .              .     .       .
                                    Furmonertinib:Icotinib  0    0  0.16 [0.01;    3.47]      .              .   0.16 [0.01;    3.47]    .              .     .       .
                                  Furmonertinib:Lazertinib  0    0  0.45 [0.13;    1.58]      .              .   0.45 [0.13;    1.58]    .              .     .       .
                                 Furmonertinib:Osimertinib  0    0  0.49 [0.17;    1.44]      .              .   0.49 [0.17;    1.44]    .              .     .       .
                    Furmonertinib:Osimertinib + chemotherapy  0    0  0.38 [0.12;    1.23]      .              .   0.38 [0.12;    1.23]    .              .     .       .
                 Furmonertinib:Osimertinib + PD-L1 inhibitor  0    0  1.98 [0.07;   54.05]      .              .   1.98 [0.07;   54.05]    .              .     .       .
                  Furmonertinib:Osimertinib + antiangiogenesis  0    0  0.16 [0.05;    0.57]      .              .   0.16 [0.05;    0.57]    .              .     .       .
                                     Furmonertinib:Placebo  0    0  1.41 [0.51;    3.92]      .              .   1.41 [0.51;    3.92]    .              .     .       .
                                 Furmonertinib:Rociletinib  0    0  0.19 [0.05;    0.76]      .              .   0.19 [0.05;    0.76]    .              .     .       .
                              Furmonertinib:antiangiogenesis  0    0  0.19 [0.06;    0.65]      .              .   0.19 [0.06;    0.65]    .              .     .       .
                                Furmonertinib:Zorifertinib  0    0  1.04 [0.27;    4.00]      .              .   1.04 [0.27;    4.00]    .              .     .       .
                             Gefitinib:Gefitinib/Erlotinib  0    0  1.02 [0.39;    2.69]      .              .   1.02 [0.39;    2.69]    .              .     .       .
                          Gefitinib:Gefitinib + chemotherapy  3 1.00  0.74 [0.26;    2.10]   0.74 [0.26;   2.10]      .               .    .              .     .       .
                        Gefitinib:Gefitinib + PARP inhibitor  1 1.00  0.33 [0.01;    8.20]   0.33 [0.01;   8.20]      .               .    .              .     .       .
                                        Gefitinib:Icotinib  1 1.00  0.14 [0.01;    2.76]   0.14 [0.01;   2.76]      .               .    .              .     .       .
                                      Gefitinib:Lazertinib  1 0.32  0.39 [0.14;    1.09]   0.66 [0.11;   3.99]   0.30 [0.09;    1.05] 2.19 [0.24;  19.56]  0.70  0.4838
                                     Gefitinib:Osimertinib  0    0  0.43 [0.19;    0.94]      .              .   0.43 [0.19;    0.94]    .              .     .       .
                        Gefitinib:Osimertinib + chemotherapy  0    0  0.33 [0.13;    0.82]      .              .   0.33 [0.13;    0.82]    .              .     .       .
                     Gefitinib:Osimertinib + PD-L1 inhibitor  0    0  1.71 [0.07;   43.18]      .              .   1.71 [0.07;   43.18]    .              .     .       .
                      Gefitinib:Osimertinib + antiangiogenesis  0    0  0.14 [0.05;    0.39]      .              .   0.14 [0.05;    0.39]    .              .     .       .
                                         Gefitinib:Placebo  1 0.33  1.22 [0.60;    2.50]   0.98 [0.28;   3.41]   1.37 [0.57;    3.27] 0.71 [0.16;   3.28] -0.43  0.6647
                                     Gefitinib:Rociletinib  0    0  0.17 [0.05;    0.53]      .              .   0.17 [0.05;    0.53]    .              .     .       .
                                  Gefitinib:antiangiogenesis  1 0.12  0.17 [0.06;    0.44]   0.03 [0.00;   0.57]   0.21 [0.07;    0.58] 0.16 [0.01;   3.31] -1.18  0.2363
                                    Gefitinib:Zorifertinib  0    0  0.90 [0.29;    2.80]      .              .   0.90 [0.29;    2.80]    .              .     .       .
                Gefitinib/Erlotinib:Gefitinib + chemotherapy  0    0  0.72 [0.18;    3.00]      .              .   0.72 [0.18;    3.00]    .              .     .       .
              Gefitinib/Erlotinib:Gefitinib + PARP inhibitor  0    0  0.32 [0.01;    9.24]      .              .   0.32 [0.01;    9.24]    .              .     .       .
                              Gefitinib/Erlotinib:Icotinib  0    0  0.14 [0.01;    3.14]      .              .   0.14 [0.01;    3.14]    .              .     .       .
                            Gefitinib/Erlotinib:Lazertinib  0    0  0.38 [0.14;    1.02]      .              .   0.38 [0.14;    1.02]    .              .     .       .
                           Gefitinib/Erlotinib:Osimertinib  1 1.00  0.42 [0.24;    0.72]   0.42 [0.24;   0.72]      .               .    .              .     .       .
              Gefitinib/Erlotinib:Osimertinib + chemotherapy  0    0  0.32 [0.16;    0.65]      .              .   0.32 [0.16;    0.65]    .              .     .       .
           Gefitinib/Erlotinib:Osimertinib + PD-L1 inhibitor  0    0  1.68 [0.07;   40.04]      .              .   1.68 [0.07;   40.04]    .              .     .       .
            Gefitinib/Erlotinib:Osimertinib + antiangiogenesis  0    0  0.14 [0.06;    0.32]      .              .   0.14 [0.06;    0.32]    .              .     .       .
                               Gefitinib/Erlotinib:Placebo  0    0  1.20 [0.57;    2.49]      .              .   1.20 [0.57;    2.49]    .              .     .       .
                           Gefitinib/Erlotinib:Rociletinib  0    0  0.17 [0.05;    0.58]      .              .   0.17 [0.05;    0.58]    .              .     .       .
                        Gefitinib/Erlotinib:antiangiogenesis  0    0  0.16 [0.05;    0.50]      .              .   0.16 [0.05;    0.50]    .              .     .       .
                          Gefitinib/Erlotinib:Zorifertinib  1 1.00  0.88 [0.49;    1.60]   0.88 [0.49;   1.60]      .               .    .              .     .       .
           Gefitinib + chemotherapy:Gefitinib + PARP inhibitor  0    0  0.44 [0.02;   13.04]      .              .   0.44 [0.02;   13.04]    .              .     .       .
                           Gefitinib + chemotherapy:Icotinib  0    0  0.19 [0.01;    4.44]      .              .   0.19 [0.01;    4.44]    .              .     .       .
                         Gefitinib + chemotherapy:Lazertinib  0    0  0.52 [0.12;    2.26]      .              .   0.52 [0.12;    2.26]    .              .     .       .
                        Gefitinib + chemotherapy:Osimertinib  0    0  0.57 [0.15;    2.13]      .              .   0.57 [0.15;    2.13]    .              .     .       .
           Gefitinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.44 [0.11;    1.78]      .              .   0.44 [0.11;    1.78]    .              .     .       .
        Gefitinib + chemotherapy:Osimertinib + PD-L1 inhibitor  0    0  2.31 [0.08;   68.60]      .              .   2.31 [0.08;   68.60]    .              .     .       .
         Gefitinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.19 [0.04;    0.82]      .              .   0.19 [0.04;    0.82]    .              .     .       .
                            Gefitinib + chemotherapy:Placebo  0    0  1.65 [0.47;    5.84]      .              .   1.65 [0.47;    5.84]    .              .     .       .
                        Gefitinib + chemotherapy:Rociletinib  0    0  0.23 [0.05;    1.07]      .              .   0.23 [0.05;    1.07]    .              .     .       .
                     Gefitinib + chemotherapy:antiangiogenesis  0    0  0.23 [0.05;    0.94]      .              .   0.23 [0.05;    0.94]    .              .     .       .
                       Gefitinib + chemotherapy:Zorifertinib  0    0  1.21 [0.26;    5.66]      .              .   1.21 [0.26;    5.66]    .              .     .       .
                         Gefitinib + PARP inhibitor:Icotinib  0    0  0.43 [0.01;   34.10]      .              .   0.43 [0.01;   34.10]    .              .     .       .
                       Gefitinib + PARP inhibitor:Lazertinib  0    0  1.18 [0.04;   34.43]      .              .   1.18 [0.04;   34.43]    .              .     .       .
                      Gefitinib + PARP inhibitor:Osimertinib  0    0  1.29 [0.05;   35.35]      .              .   1.29 [0.05;   35.35]    .              .     .       .
         Gefitinib + PARP inhibitor:Osimertinib + chemotherapy  0    0  1.00 [0.04;   28.28]      .              .   1.00 [0.04;   28.28]    .              .     .       .
      Gefitinib + PARP inhibitor:Osimertinib + PD-L1 inhibitor  0    0  5.20 [0.05;  493.92]      .              .   5.20 [0.05;  493.92]    .              .     .       .
       Gefitinib + PARP inhibitor:Osimertinib + antiangiogenesis  0    0  0.42 [0.01;   12.40]      .              .   0.42 [0.01;   12.40]    .              .     .       .
                          Gefitinib + PARP inhibitor:Placebo  0    0  3.71 [0.14;   99.93]      .              .   3.71 [0.14;   99.93]    .              .     .       .
                      Gefitinib + PARP inhibitor:Rociletinib  0    0  0.51 [0.02;   15.55]      .              .   0.51 [0.02;   15.55]    .              .     .       .
                   Gefitinib + PARP inhibitor:antiangiogenesis  0    0  0.51 [0.02;   14.64]      .              .   0.51 [0.02;   14.64]    .              .     .       .
                     Gefitinib + PARP inhibitor:Zorifertinib  0    0  2.73 [0.09;   82.51]      .              .   2.73 [0.09;   82.51]    .              .     .       .
                                       Icotinib:Lazertinib  0    0  2.75 [0.12;   63.66]      .              .   2.75 [0.12;   63.66]    .              .     .       .
                                      Icotinib:Osimertinib  0    0  3.01 [0.14;   65.06]      .              .   3.01 [0.14;   65.06]    .              .     .       .
                         Icotinib:Osimertinib + chemotherapy  0    0  2.33 [0.10;   52.16]      .              .   2.33 [0.10;   52.16]    .              .     .       .
                      Icotinib:Osimertinib + PD-L1 inhibitor  0    0 12.12 [0.15;  972.57]      .              .  12.12 [0.15;  972.57]    .              .     .       .
                       Icotinib:Osimertinib + antiangiogenesis  0    0  0.99 [0.04;   22.93]      .              .   0.99 [0.04;   22.93]    .              .     .       .
                                          Icotinib:Placebo  0    0  8.66 [0.41;  183.66]      .              .   8.66 [0.41;  183.66]    .              .     .       .
                                      Icotinib:Rociletinib  0    0  1.19 [0.05;   28.84]      .              .   1.19 [0.05;   28.84]    .              .     .       .
                                   Icotinib:antiangiogenesis  0    0  1.19 [0.05;   27.05]      .              .   1.19 [0.05;   27.05]    .              .     .       .
                                     Icotinib:Zorifertinib  0    0  6.37 [0.26;  152.96]      .              .   6.37 [0.26;  152.96]    .              .     .       .
                                    Lazertinib:Osimertinib  1 0.83  1.09 [0.48;    2.48]   1.25 [0.51;   3.05]   0.57 [0.08;    4.20] 2.19 [0.24;  19.56]  0.70  0.4838
                       Lazertinib:Osimertinib + chemotherapy  0    0  0.85 [0.33;    2.16]      .              .   0.85 [0.33;    2.16]    .              .     .       .
                    Lazertinib:Osimertinib + PD-L1 inhibitor  0    0  4.41 [0.17;  111.58]      .              .   4.41 [0.17;  111.58]    .              .     .       .
                     Lazertinib:Osimertinib + antiangiogenesis  0    0  0.36 [0.13;    1.03]      .              .   0.36 [0.13;    1.03]    .              .     .       .
                                        Lazertinib:Placebo  0    0  3.15 [1.26;    7.86]      .              .   3.15 [1.26;    7.86]    .              .     .       .
                                    Lazertinib:Rociletinib  0    0  0.43 [0.11;    1.68]      .              .   0.43 [0.11;    1.68]    .              .     .       .
                                 Lazertinib:antiangiogenesis  0    0  0.43 [0.13;    1.46]      .              .   0.43 [0.13;    1.46]    .              .     .       .
                                   Lazertinib:Zorifertinib  0    0  2.31 [0.73;    7.31]      .              .   2.31 [0.73;    7.31]    .              .     .       .
                      Osimertinib:Osimertinib + chemotherapy  2 1.00  0.78 [0.49;    1.22]   0.78 [0.49;   1.22]      .               .    .              .     .       .
                   Osimertinib:Osimertinib + PD-L1 inhibitor  1 1.00  4.03 [0.18;   91.91]   4.03 [0.18;  91.91]      .               .    .              .     .       .
                    Osimertinib:Osimertinib + antiangiogenesis  2 1.00  0.33 [0.17;    0.64]   0.33 [0.17;   0.64]      .               .    .              .     .       .
                                       Osimertinib:Placebo  2 0.84  2.88 [1.76;    4.70]   2.86 [1.68;   4.88]   2.98 [0.86;   10.36] 0.96 [0.25;   3.72] -0.06  0.9524
                                   Osimertinib:Rociletinib  0    0  0.40 [0.13;    1.24]      .              .   0.40 [0.13;    1.24]    .              .     .       .
                                Osimertinib:antiangiogenesis  0    0  0.40 [0.15;    1.05]      .              .   0.40 [0.15;    1.05]    .              .     .       .
                                  Osimertinib:Zorifertinib  0    0  2.12 [0.94;    4.75]      .              .   2.12 [0.94;    4.75]    .              .     .       .
      Osimertinib + chemotherapy:Osimertinib + PD-L1 inhibitor  0    0  5.20 [0.22;  122.41]      .              .   5.20 [0.22;  122.41]    .              .     .       .
       Osimertinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.42 [0.19;    0.94]      .              .   0.42 [0.19;    0.94]    .              .     .       .
                          Osimertinib + chemotherapy:Placebo  0    0  3.71 [1.91;    7.24]      .              .   3.71 [1.91;    7.24]    .              .     .       .
                      Osimertinib + chemotherapy:Rociletinib  0    0  0.51 [0.15;    1.74]      .              .   0.51 [0.15;    1.74]    .              .     .       .
                   Osimertinib + chemotherapy:antiangiogenesis  0    0  0.51 [0.17;    1.49]      .              .   0.51 [0.17;    1.49]    .              .     .       .
                     Osimertinib + chemotherapy:Zorifertinib  0    0  2.73 [1.08;    6.89]      .              .   2.73 [1.08;    6.89]    .              .     .       .
    Osimertinib + PD-L1 inhibitor:Osimertinib + antiangiogenesis  0    0  0.08 [0.00;    1.99]      .              .   0.08 [0.00;    1.99]    .              .     .       .
                       Osimertinib + PD-L1 inhibitor:Placebo  0    0  0.71 [0.03;   16.92]      .              .   0.71 [0.03;   16.92]    .              .     .       .
                   Osimertinib + PD-L1 inhibitor:Rociletinib  0    0  0.10 [0.00;    2.74]      .              .   0.10 [0.00;    2.74]    .              .     .       .
                Osimertinib + PD-L1 inhibitor:antiangiogenesis  0    0  0.10 [0.00;    2.60]      .              .   0.10 [0.00;    2.60]    .              .     .       .
                  Osimertinib + PD-L1 inhibitor:Zorifertinib  0    0  0.53 [0.02;   13.27]      .              .   0.53 [0.02;   13.27]    .              .     .       .
                        Osimertinib + antiangiogenesis:Placebo  0    0  8.77 [3.85;   19.96]      .              .   8.77 [3.85;   19.96]    .              .     .       .
                    Osimertinib + antiangiogenesis:Rociletinib  0    0  1.21 [0.33;    4.49]      .              .   1.21 [0.33;    4.49]    .              .     .       .
                 Osimertinib + antiangiogenesis:antiangiogenesis  0    0  1.21 [0.37;    3.90]      .              .   1.21 [0.37;    3.90]    .              .     .       .
                   Osimertinib + antiangiogenesis:Zorifertinib  0    0  6.45 [2.27;   18.30]      .              .   6.45 [2.27;   18.30]    .              .     .       .
                                       Rociletinib:Placebo  0    0  7.25 [2.50;   21.05]      .              .   7.25 [2.50;   21.05]    .              .     .       .
                                    antiangiogenesis:Placebo  0    0  7.27 [2.98;   17.76]      .              .   7.27 [2.98;   17.76]    .              .     .       .
                                      Zorifertinib:Placebo  0    0  1.36 [0.53;    3.50]      .              .   1.36 [0.53;    3.50]    .              .     .       .
                                Rociletinib:antiangiogenesis  0    0  1.00 [0.31;    3.19]      .              .   1.00 [0.31;    3.19]    .              .     .       .
                                  Rociletinib:Zorifertinib  0    0  5.33 [1.32;   21.44]      .              .   5.33 [1.32;   21.44]    .              .     .       .
                               antiangiogenesis:Zorifertinib  0    0  5.35 [1.51;   18.92]      .              .   5.35 [1.51;   18.92]    .              .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

vascular_serious
Random effects model: 

                                               comparison  k prop    nma           95%-CI direct         95%-CI indir.           95%-CI  RoR         95%-CI     z p-value
                          Afatinib:Afatinib + Cetuximab  1 1.00   0.47 [0.08;     2.71]   0.47 [0.08;   2.71]      .                .    .              .     .       .
                                    Afatinib:Almonertinib  0    0   0.07 [0.00;     1.63]      .              .   0.07 [0.00;     1.63]    .              .     .       .
                        Afatinib:Amivantamab  +  Lazertinib  0    0   0.46 [0.10;     2.14]      .              .   0.46 [0.10;     2.14]    .              .     .       .
                                    Afatinib:Chemotherapy  2 0.34   1.04 [0.43;     2.53]   0.76 [0.16;   3.48]   1.22 [0.41;     3.65] 0.62 [0.09;   4.05] -0.50  0.6161
                                     Afatinib:Dacomitinib  0    0   1.64 [0.55;     4.89]      .              .   1.64 [0.55;     4.89]    .              .     .       .
                                  Afatinib:DHFR inhibitor  0    0   0.71 [0.05;    11.21]      .              .   0.71 [0.05;    11.21]    .              .     .       .
                                       Afatinib:Erlotinib  1 0.43   1.50 [0.66;     3.43]   1.23 [0.35;   4.34]   1.74 [0.58;     5.22] 0.71 [0.13;   3.75] -0.41  0.6841
                   Afatinib:Erlotinib + Autophagy inhibitor  0    0   4.63 [0.14;   151.88]      .              .   4.63 [0.14;   151.88]    .              .     .       .
                          Afatinib:Erlotinib + chemotherapy  0    0   1.90 [0.45;     8.04]      .              .   1.90 [0.45;     8.04]    .              .     .       .
                          Afatinib:Erlotinib + ER inhibitor  0    0   0.30 [0.01;     8.25]      .              .   0.30 [0.01;     8.25]    .              .     .       .
                        Afatinib:Erlotinib + HER3 inhibitor  0    0   3.05 [0.38;    24.77]      .              .   3.05 [0.38;    24.77]    .              .     .       .
                         Afatinib:Erlotinib + HGF inhibitor  0    0   0.47 [0.01;    16.80]      .              .   0.47 [0.01;    16.80]    .              .     .       .
                         Afatinib:Erlotinib + IGF-1R inhibitor  0    0   0.43 [0.08;     2.32]      .              .   0.43 [0.08;     2.32]    .              .     .       .
                         Afatinib:Erlotinib + MET inhibitor  0    0   1.50 [0.50;     4.46]      .              .   1.50 [0.50;     4.46]    .              .     .       .
                         Afatinib:Erlotinib + MMP inhibitor  0    0  14.09 [0.56;   353.74]      .              .  14.09 [0.56;   353.74]    .              .     .       .
                        Afatinib:Erlotinib + antiangiogenesis  0    0   0.44 [0.18;     1.12]      .              .   0.44 [0.18;     1.12]    .              .     .       .
                                       Afatinib:Gefitinib  1 0.39   1.53 [0.61;     3.83]   1.52 [0.35;   6.65]   1.53 [0.47;     4.95] 0.99 [0.15;   6.54] -0.01  0.9938
                             Afatinib:Gefitinib/Erlotinib  0    0   2.33 [0.38;    14.45]      .              .   2.33 [0.38;    14.45]    .              .     .       .
                          Afatinib:Gefitinib + chemotherapy  0    0   1.10 [0.30;     3.97]      .              .   1.10 [0.30;     3.97]    .              .     .       .
                        Afatinib:Gefitinib + antiangiogenesis  0    0   0.05 [0.01;     0.26]      .              .   0.05 [0.01;     0.26]    .              .     .       .
                                      Afatinib:Lazertinib  0    0   1.10 [0.29;     4.24]      .              .   1.10 [0.29;     4.24]    .              .     .       .
                                     Afatinib:Osimertinib  0    0   1.42 [0.42;     4.75]      .              .   1.42 [0.42;     4.75]    .              .     .       .
                        Afatinib:Osimertinib + chemotherapy  0    0   0.53 [0.08;     3.45]      .              .   0.53 [0.08;     3.45]    .              .     .       .
                      Afatinib:Osimertinib + antiangiogenesis  0    0   0.76 [0.14;     4.26]      .              .   0.76 [0.14;     4.26]    .              .     .       .
                                         Afatinib:Placebo  1 0.26   1.64 [0.65;     4.10]   3.86 [0.63;  23.53]   1.21 [0.42;     3.53] 3.18 [0.39;  25.94]  1.08  0.2800
                                     Afatinib:Rociletinib  0    0   4.51 [0.14;   146.94]      .              .   4.51 [0.14;   146.94]    .              .     .       .
                                  Afatinib:antiangiogenesis  0    0   0.27 [0.08;     0.88]      .              .   0.27 [0.08;     0.88]    .              .     .       .
                      Afatinib + Cetuximab:Almonertinib  0    0   0.15 [0.00;     5.46]      .              .   0.15 [0.00;     5.46]    .              .     .       .
          Afatinib + Cetuximab:Amivantamab  +  Lazertinib  0    0   0.98 [0.10;    10.12]      .              .   0.98 [0.10;    10.12]    .              .     .       .
                      Afatinib + Cetuximab:Chemotherapy  0    0   2.21 [0.31;    15.80]      .              .   2.21 [0.31;    15.80]    .              .     .       .
                       Afatinib + Cetuximab:Dacomitinib  0    0   3.50 [0.44;    27.63]      .              .   3.50 [0.44;    27.63]    .              .     .       .
                    Afatinib + Cetuximab:DHFR inhibitor  0    0   1.52 [0.06;    39.80]      .              .   1.52 [0.06;    39.80]    .              .     .       .
                         Afatinib + Cetuximab:Erlotinib  0    0   3.20 [0.46;    22.25]      .              .   3.20 [0.46;    22.25]    .              .     .       .
     Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor  0    0   9.85 [0.20;   490.39]      .              .   9.85 [0.20;   490.39]    .              .     .       .
            Afatinib + Cetuximab:Erlotinib + chemotherapy  0    0   4.06 [0.42;    39.25]      .              .   4.06 [0.42;    39.25]    .              .     .       .
            Afatinib + Cetuximab:Erlotinib + ER inhibitor  0    0   0.63 [0.01;    27.14]      .              .   0.63 [0.01;    27.14]    .              .     .       .
          Afatinib + Cetuximab:Erlotinib + HER3 inhibitor  0    0   6.49 [0.42;    99.80]      .              .   6.49 [0.42;    99.80]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + HGF inhibitor  0    0   1.01 [0.02;    53.79]      .              .   1.01 [0.02;    53.79]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor  0    0   0.91 [0.08;    10.43]      .              .   0.91 [0.08;    10.43]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + MET inhibitor  0    0   3.19 [0.40;    25.15]      .              .   3.19 [0.40;    25.15]    .              .     .       .
           Afatinib + Cetuximab:Erlotinib + MMP inhibitor  0    0  30.02 [0.77;  1177.60]      .              .  30.02 [0.77;  1177.60]    .              .     .       .
          Afatinib + Cetuximab:Erlotinib + antiangiogenesis  0    0   0.95 [0.13;     6.88]      .              .   0.95 [0.13;     6.88]    .              .     .       .
                         Afatinib + Cetuximab:Gefitinib  0    0   3.25 [0.45;    23.56]      .              .   3.25 [0.45;    23.56]    .              .     .       .
               Afatinib + Cetuximab:Gefitinib/Erlotinib  0    0   4.96 [0.39;    62.38]      .              .   4.96 [0.39;    62.38]    .              .     .       .
            Afatinib + Cetuximab:Gefitinib + chemotherapy  0    0   2.34 [0.27;    20.59]      .              .   2.34 [0.27;    20.59]    .              .     .       .
          Afatinib + Cetuximab:Gefitinib + antiangiogenesis  0    0   0.11 [0.01;     1.17]      .              .   0.11 [0.01;     1.17]    .              .     .       .
                        Afatinib + Cetuximab:Lazertinib  0    0   2.34 [0.26;    21.41]      .              .   2.34 [0.26;    21.41]    .              .     .       .
                       Afatinib + Cetuximab:Osimertinib  0    0   3.02 [0.36;    25.44]      .              .   3.02 [0.36;    25.44]    .              .     .       .
          Afatinib + Cetuximab:Osimertinib + chemotherapy  0    0   1.14 [0.09;    14.74]      .              .   1.14 [0.09;    14.74]    .              .     .       .
        Afatinib + Cetuximab:Osimertinib + antiangiogenesis  0    0   1.62 [0.14;    18.94]      .              .   1.62 [0.14;    18.94]    .              .     .       .
                           Afatinib + Cetuximab:Placebo  0    0   3.49 [0.48;    25.26]      .              .   3.49 [0.48;    25.26]    .              .     .       .
                       Afatinib + Cetuximab:Rociletinib  0    0   9.60 [0.19;   474.78]      .              .   9.60 [0.19;   474.78]    .              .     .       .
                    Afatinib + Cetuximab:antiangiogenesis  0    0   0.58 [0.07;     4.79]      .              .   0.58 [0.07;     4.79]    .              .     .       .
                    Almonertinib:Amivantamab  +  Lazertinib  0    0   6.69 [0.24;   187.69]      .              .   6.69 [0.24;   187.69]    .              .     .       .
                                Almonertinib:Chemotherapy  0    0  15.04 [0.65;   348.26]      .              .  15.04 [0.65;   348.26]    .              .     .       .
                                 Almonertinib:Dacomitinib  0    0  23.82 [1.00;   568.74]      .              .  23.82 [1.00;   568.74]    .              .     .       .
                              Almonertinib:DHFR inhibitor  0    0  10.34 [0.17;   617.24]      .              .  10.34 [0.17;   617.24]    .              .     .       .
                                   Almonertinib:Erlotinib  0    0  21.77 [0.95;   499.78]      .              .  21.77 [0.95;   499.78]    .              .     .       .
               Almonertinib:Erlotinib + Autophagy inhibitor  0    0  67.05 [0.66;  6791.99]      .              .  67.05 [0.66;  6791.99]    .              .     .       .
                      Almonertinib:Erlotinib + chemotherapy  0    0  27.61 [0.97;   783.86]      .              .  27.61 [0.97;   783.86]    .              .     .       .
                      Almonertinib:Erlotinib + ER inhibitor  0    0   4.30 [0.05;   384.79]      .              .   4.30 [0.05;   384.79]    .              .     .       .
                    Almonertinib:Erlotinib + HER3 inhibitor  0    0  44.18 [1.12;  1747.58]      .              .  44.18 [1.12;  1747.58]    .              .     .       .
                     Almonertinib:Erlotinib + HGF inhibitor  0    0   6.84 [0.06;   736.83]      .              .   6.84 [0.06;   736.83]    .              .     .       .
                     Almonertinib:Erlotinib + IGF-1R inhibitor  0    0   6.21 [0.19;   198.23]      .              .   6.21 [0.19;   198.23]    .              .     .       .
                     Almonertinib:Erlotinib + MET inhibitor  0    0  21.68 [0.87;   539.21]      .              .  21.68 [0.87;   539.21]    .              .     .       .
                     Almonertinib:Erlotinib + MMP inhibitor  0    0 204.26 [2.46; 16949.11]      .              . 204.26 [2.46; 16949.11]    .              .     .       .
                    Almonertinib:Erlotinib + antiangiogenesis  0    0   6.43 [0.27;   151.80]      .              .   6.43 [0.27;   151.80]    .              .     .       .
                                   Almonertinib:Gefitinib  1 1.00  22.13 [1.08;   455.39]  22.13 [1.08; 455.39]      .                .    .              .     .       .
                         Almonertinib:Gefitinib/Erlotinib  0    0  33.77 [1.03;  1111.19]      .              .  33.77 [1.03;  1111.19]    .              .     .       .
                      Almonertinib:Gefitinib + chemotherapy  0    0  15.90 [0.68;   373.19]      .              .  15.90 [0.68;   373.19]    .              .     .       .
                    Almonertinib:Gefitinib + antiangiogenesis  0    0   0.73 [0.03;    19.92]      .              .   0.73 [0.03;    19.92]    .              .     .       .
                                  Almonertinib:Lazertinib  0    0  15.94 [0.63;   403.88]      .              .  15.94 [0.63;   403.88]    .              .     .       .
                                 Almonertinib:Osimertinib  0    0  20.55 [0.82;   512.07]      .              .  20.55 [0.82;   512.07]    .              .     .       .
                    Almonertinib:Osimertinib + chemotherapy  0    0   7.74 [0.23;   260.37]      .              .   7.74 [0.23;   260.37]    .              .     .       .
                  Almonertinib:Osimertinib + antiangiogenesis  0    0  11.03 [0.35;   344.26]      .              .  11.03 [0.35;   344.26]    .              .     .       .
                                     Almonertinib:Placebo  0    0  23.72 [1.03;   547.96]      .              .  23.72 [1.03;   547.96]    .              .     .       .
                                 Almonertinib:Rociletinib  0    0  65.31 [0.65;  6581.97]      .              .  65.31 [0.65;  6581.97]    .              .     .       .
                              Almonertinib:antiangiogenesis  0    0   3.95 [0.16;    99.32]      .              .   3.95 [0.16;    99.32]    .              .     .       .
                    Amivantamab  +  Lazertinib:Chemotherapy  0    0   2.25 [0.54;     9.30]      .              .   2.25 [0.54;     9.30]    .              .     .       .
                     Amivantamab  +  Lazertinib:Dacomitinib  0    0   3.56 [0.74;    17.16]      .              .   3.56 [0.74;    17.16]    .              .     .       .
                  Amivantamab  +  Lazertinib:DHFR inhibitor  0    0   1.55 [0.08;    31.02]      .              .   1.55 [0.08;    31.02]    .              .     .       .
                       Amivantamab  +  Lazertinib:Erlotinib  0    0   3.26 [0.77;    13.82]      .              .   3.26 [0.77;    13.82]    .              .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor  0    0  10.03 [0.25;   400.57]      .              .  10.03 [0.25;   400.57]    .              .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + chemotherapy  0    0   4.13 [0.65;    26.36]      .              .   4.13 [0.65;    26.36]    .              .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + ER inhibitor  0    0   0.64 [0.02;    21.96]      .              .   0.64 [0.02;    21.96]    .              .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor  0    0   6.61 [0.59;    73.40]      .              .   6.61 [0.59;    73.40]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + HGF inhibitor  0    0   1.02 [0.02;    44.12]      .              .   1.02 [0.02;    44.12]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor  0    0   0.93 [0.12;     7.32]      .              .   0.93 [0.12;     7.32]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor  0    0   3.24 [0.65;    16.26]      .              .   3.24 [0.65;    16.26]    .              .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor  0    0  30.55 [0.99;   947.40]      .              .  30.55 [0.99;   947.40]    .              .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis  0    0   0.96 [0.21;     4.34]      .              .   0.96 [0.21;     4.34]    .              .     .       .
                       Amivantamab  +  Lazertinib:Gefitinib  0    0   3.31 [0.81;    13.49]      .              .   3.31 [0.81;    13.49]    .              .     .       .
             Amivantamab  +  Lazertinib:Gefitinib/Erlotinib  0    0   5.05 [0.86;    29.61]      .              .   5.05 [0.86;    29.61]    .              .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + chemotherapy  0    0   2.38 [0.45;    12.63]      .              .   2.38 [0.45;    12.63]    .              .     .       .
        Amivantamab  +  Lazertinib:Gefitinib + antiangiogenesis  0    0   0.11 [0.02;     0.76]      .              .   0.11 [0.02;     0.76]    .              .     .       .
                      Amivantamab  +  Lazertinib:Lazertinib  1 0.91   2.38 [0.75;     7.55]   2.22 [0.66;   7.41]   5.02 [0.11;   237.50] 0.44 [0.01;  25.11] -0.40  0.6916
                     Amivantamab  +  Lazertinib:Osimertinib  1 0.92   3.07 [1.00;     9.46]   3.28 [1.02;  10.56]   1.39 [0.02;    82.49] 2.36 [0.03; 165.45]  0.40  0.6916
        Amivantamab  +  Lazertinib:Osimertinib + chemotherapy  0    0   1.16 [0.19;     7.09]      .              .   1.16 [0.19;     7.09]    .              .     .       .
      Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis  0    0   1.65 [0.31;     8.70]      .              .   1.65 [0.31;     8.70]    .              .     .       .
                         Amivantamab  +  Lazertinib:Placebo  0    0   3.55 [0.84;    14.95]      .              .   3.55 [0.84;    14.95]    .              .     .       .
                     Amivantamab  +  Lazertinib:Rociletinib  0    0   9.77 [0.25;   387.68]      .              .   9.77 [0.25;   387.68]    .              .     .       .
                  Amivantamab  +  Lazertinib:antiangiogenesis  0    0   0.59 [0.11;     3.10]      .              .   0.59 [0.11;     3.10]    .              .     .       .
                                 Chemotherapy:Dacomitinib  0    0   1.58 [0.57;     4.39]      .              .   1.58 [0.57;     4.39]    .              .     .       .
                              Chemotherapy:DHFR inhibitor  0    0   0.69 [0.05;    10.40]      .              .   0.69 [0.05;    10.40]    .              .     .       .
                                   Chemotherapy:Erlotinib  8 0.62   1.45 [0.73;     2.88]   1.20 [0.50;   2.88]   1.96 [0.64;     5.97] 0.61 [0.15;   2.53] -0.68  0.4992
               Chemotherapy:Erlotinib + Autophagy inhibitor  0    0   4.46 [0.14;   142.05]      .              .   4.46 [0.14;   142.05]    .              .     .       .
                      Chemotherapy:Erlotinib + chemotherapy  1 0.33   1.84 [0.49;     6.83]   1.65 [0.17;  16.29]   1.94 [0.39;     9.61] 0.85 [0.05;  13.93] -0.11  0.9091
                      Chemotherapy:Erlotinib + ER inhibitor  0    0   0.29 [0.01;     7.70]      .              .   0.29 [0.01;     7.70]    .              .     .       .
                    Chemotherapy:Erlotinib + HER3 inhibitor  0    0   2.94 [0.38;    22.70]      .              .   2.94 [0.38;    22.70]    .              .     .       .
                     Chemotherapy:Erlotinib + HGF inhibitor  0    0   0.45 [0.01;    15.72]      .              .   0.45 [0.01;    15.72]    .              .     .       .
                     Chemotherapy:Erlotinib + IGF-1R inhibitor  0    0   0.41 [0.08;     2.10]      .              .   0.41 [0.08;     2.10]    .              .     .       .
                     Chemotherapy:Erlotinib + MET inhibitor  0    0   1.44 [0.53;     3.89]      .              .   1.44 [0.53;     3.89]    .              .     .       .
                     Chemotherapy:Erlotinib + MMP inhibitor  0    0  13.58 [0.56;   330.02]      .              .  13.58 [0.56;   330.02]    .              .     .       .
                    Chemotherapy:Erlotinib + antiangiogenesis  0    0   0.43 [0.19;     0.96]      .              .   0.43 [0.19;     0.96]    .              .     .       .
                                   Chemotherapy:Gefitinib  4 0.34   1.47 [0.63;     3.45]   1.97 [0.46;   8.52]   1.27 [0.44;     3.62] 1.56 [0.26;   9.44]  0.48  0.6294
                         Chemotherapy:Gefitinib/Erlotinib  0    0   2.25 [0.41;    12.43]      .              .   2.25 [0.41;    12.43]    .              .     .       .
                      Chemotherapy:Gefitinib + chemotherapy  0    0   1.06 [0.31;     3.66]      .              .   1.06 [0.31;     3.66]    .              .     .       .
                    Chemotherapy:Gefitinib + antiangiogenesis  0    0   0.05 [0.01;     0.24]      .              .   0.05 [0.01;     0.24]    .              .     .       .
                                  Chemotherapy:Lazertinib  0    0   1.06 [0.31;     3.67]      .              .   1.06 [0.31;     3.67]    .              .     .       .
                                 Chemotherapy:Osimertinib  1 0.52   1.37 [0.49;     3.83]   1.46 [0.35;   6.08]   1.27 [0.29;     5.64] 1.15 [0.15;   9.03]  0.13  0.8960
                    Chemotherapy:Osimertinib + chemotherapy  0    0   0.51 [0.09;     2.98]      .              .   0.51 [0.09;     2.98]    .              .     .       .
                  Chemotherapy:Osimertinib + antiangiogenesis  0    0   0.73 [0.15;     3.64]      .              .   0.73 [0.15;     3.64]    .              .     .       .
                                     Chemotherapy:Placebo  0    0   1.58 [0.67;     3.74]      .              .   1.58 [0.67;     3.74]    .              .     .       .
                                 Chemotherapy:Rociletinib  0    0   4.34 [0.14;   137.43]      .              .   4.34 [0.14;   137.43]    .              .     .       .
                              Chemotherapy:antiangiogenesis  0    0   0.26 [0.09;     0.78]      .              .   0.26 [0.09;     0.78]    .              .     .       .
                               Dacomitinib:DHFR inhibitor  0    0   0.43 [0.03;     6.89]      .              .   0.43 [0.03;     6.89]    .              .     .       .
                                    Dacomitinib:Erlotinib  2 0.54   0.91 [0.39;     2.16]   0.86 [0.26;   2.78]   0.98 [0.28;     3.47] 0.87 [0.16;   4.90] -0.15  0.8779
                Dacomitinib:Erlotinib + Autophagy inhibitor  0    0   2.82 [0.09;    93.19]      .              .   2.82 [0.09;    93.19]    .              .     .       .
                       Dacomitinib:Erlotinib + chemotherapy  0    0   1.16 [0.27;     5.07]      .              .   1.16 [0.27;     5.07]    .              .     .       .
                       Dacomitinib:Erlotinib + ER inhibitor  0    0   0.18 [0.01;     5.06]      .              .   0.18 [0.01;     5.06]    .              .     .       .
                     Dacomitinib:Erlotinib + HER3 inhibitor  0    0   1.85 [0.23;    15.28]      .              .   1.85 [0.23;    15.28]    .              .     .       .
                      Dacomitinib:Erlotinib + HGF inhibitor  0    0   0.29 [0.01;    10.31]      .              .   0.29 [0.01;    10.31]    .              .     .       .
                      Dacomitinib:Erlotinib + IGF-1R inhibitor  0    0   0.26 [0.05;     1.44]      .              .   0.26 [0.05;     1.44]    .              .     .       .
                      Dacomitinib:Erlotinib + MET inhibitor  0    0   0.91 [0.30;     2.78]      .              .   0.91 [0.30;     2.78]    .              .     .       .
                      Dacomitinib:Erlotinib + MMP inhibitor  0    0   8.58 [0.34;   217.19]      .              .   8.58 [0.34;   217.19]    .              .     .       .
                     Dacomitinib:Erlotinib + antiangiogenesis  0    0   0.27 [0.10;     0.70]      .              .   0.27 [0.10;     0.70]    .              .     .       .
                                    Dacomitinib:Gefitinib  1 0.40   0.93 [0.36;     2.43]   0.84 [0.19;   3.82]   0.99 [0.29;     3.44] 0.85 [0.12;   6.00] -0.17  0.8681
                          Dacomitinib:Gefitinib/Erlotinib  0    0   1.42 [0.22;     9.08]      .              .   1.42 [0.22;     9.08]    .              .     .       .
                       Dacomitinib:Gefitinib + chemotherapy  0    0   0.67 [0.18;     2.49]      .              .   0.67 [0.18;     2.49]    .              .     .       .
                     Dacomitinib:Gefitinib + antiangiogenesis  0    0   0.03 [0.01;     0.16]      .              .   0.03 [0.01;     0.16]    .              .     .       .
                                   Dacomitinib:Lazertinib  0    0   0.67 [0.17;     2.68]      .              .   0.67 [0.17;     2.68]    .              .     .       .
                                  Dacomitinib:Osimertinib  0    0   0.86 [0.25;     3.04]      .              .   0.86 [0.25;     3.04]    .              .     .       .
                     Dacomitinib:Osimertinib + chemotherapy  0    0   0.32 [0.05;     2.17]      .              .   0.32 [0.05;     2.17]    .              .     .       .
                   Dacomitinib:Osimertinib + antiangiogenesis  0    0   0.46 [0.08;     2.68]      .              .   0.46 [0.08;     2.68]    .              .     .       .
                                      Dacomitinib:Placebo  1 0.38   1.00 [0.40;     2.48]   1.21 [0.28;   5.28]   0.88 [0.28;     2.82] 1.37 [0.21;   8.92]  0.33  0.7443
                                  Dacomitinib:Rociletinib  0    0   2.74 [0.08;    90.16]      .              .   2.74 [0.08;    90.16]    .              .     .       .
                               Dacomitinib:antiangiogenesis  0    0   0.17 [0.05;     0.55]      .              .   0.17 [0.05;     0.55]    .              .     .       .
                                 DHFR inhibitor:Erlotinib  1 1.00   2.11 [0.15;    29.12]   2.11 [0.15;  29.12]      .                .    .              .     .       .
             DHFR inhibitor:Erlotinib + Autophagy inhibitor  0    0   6.48 [0.09;   473.37]      .              .   6.48 [0.09;   473.37]    .              .     .       .
                    DHFR inhibitor:Erlotinib + chemotherapy  0    0   2.67 [0.15;    48.26]      .              .   2.67 [0.15;    48.26]    .              .     .       .
                    DHFR inhibitor:Erlotinib + ER inhibitor  0    0   0.42 [0.01;    26.56]      .              .   0.42 [0.01;    26.56]    .              .     .       .
                  DHFR inhibitor:Erlotinib + HER3 inhibitor  0    0   4.27 [0.16;   110.95]      .              .   4.27 [0.16;   110.95]    .              .     .       .
                   DHFR inhibitor:Erlotinib + HGF inhibitor  0    0   0.66 [0.01;    51.59]      .              .   0.66 [0.01;    51.59]    .              .     .       .
                   DHFR inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.60 [0.03;    12.22]      .              .   0.60 [0.03;    12.22]    .              .     .       .
                   DHFR inhibitor:Erlotinib + MET inhibitor  0    0   2.10 [0.14;    31.89]      .              .   2.10 [0.14;    31.89]    .              .     .       .
                   DHFR inhibitor:Erlotinib + MMP inhibitor  0    0  19.75 [0.34;  1162.51]      .              .  19.75 [0.34;  1162.51]    .              .     .       .
                  DHFR inhibitor:Erlotinib + antiangiogenesis  0    0   0.62 [0.04;     8.91]      .              .   0.62 [0.04;     8.91]    .              .     .       .
                                 DHFR inhibitor:Gefitinib  0    0   2.14 [0.14;    33.56]      .              .   2.14 [0.14;    33.56]    .              .     .       .
                       DHFR inhibitor:Gefitinib/Erlotinib  0    0   3.27 [0.14;    76.38]      .              .   3.27 [0.14;    76.38]    .              .     .       .
                    DHFR inhibitor:Gefitinib + chemotherapy  0    0   1.54 [0.08;    27.84]      .              .   1.54 [0.08;    27.84]    .              .     .       .
                  DHFR inhibitor:Gefitinib + antiangiogenesis  0    0   0.07 [0.00;     1.51]      .              .   0.07 [0.00;     1.51]    .              .     .       .
                                DHFR inhibitor:Lazertinib  0    0   1.54 [0.08;    28.35]      .              .   1.54 [0.08;    28.35]    .              .     .       .
                               DHFR inhibitor:Osimertinib  0    0   1.99 [0.12;    34.05]      .              .   1.99 [0.12;    34.05]    .              .     .       .
                  DHFR inhibitor:Osimertinib + chemotherapy  0    0   0.75 [0.03;    17.94]      .              .   0.75 [0.03;    17.94]    .              .     .       .
                DHFR inhibitor:Osimertinib + antiangiogenesis  0    0   1.07 [0.05;    23.53]      .              .   1.07 [0.05;    23.53]    .              .     .       .
                                   DHFR inhibitor:Placebo  0    0   2.29 [0.15;    34.79]      .              .   2.29 [0.15;    34.79]    .              .     .       .
                               DHFR inhibitor:Rociletinib  0    0   6.32 [0.09;   458.55]      .              .   6.32 [0.09;   458.55]    .              .     .       .
                            DHFR inhibitor:antiangiogenesis  0    0   0.38 [0.02;     6.10]      .              .   0.38 [0.02;     6.10]    .              .     .       .
                  Erlotinib:Erlotinib + Autophagy inhibitor  1 1.00   3.08 [0.10;    91.57]   3.08 [0.10;  91.57]      .                .    .              .     .       .
                         Erlotinib:Erlotinib + chemotherapy  3 0.84   1.27 [0.38;     4.28]   1.17 [0.31;   4.40]   1.95 [0.09;    41.59] 0.60 [0.02;  16.81] -0.30  0.7635
                         Erlotinib:Erlotinib + ER inhibitor  1 1.00   0.20 [0.01;     4.95]   0.20 [0.01;   4.95]      .                .    .              .     .       .
                       Erlotinib:Erlotinib + HER3 inhibitor  1 1.00   2.03 [0.30;    13.91]   2.03 [0.30;  13.91]      .                .    .              .     .       .
                        Erlotinib:Erlotinib + HGF inhibitor  1 1.00   0.31 [0.01;    10.15]   0.31 [0.01;  10.15]      .                .    .              .     .       .
                        Erlotinib:Erlotinib + IGF-1R inhibitor  3 1.00   0.29 [0.07;     1.25]   0.29 [0.07;   1.25]      .                .    .              .     .       .
                        Erlotinib:Erlotinib + MET inhibitor  5 1.00   1.00 [0.49;     2.03]   1.00 [0.49;   2.03]      .                .    .              .     .       .
                        Erlotinib:Erlotinib + MMP inhibitor  1 1.00   9.38 [0.42;   211.46]   9.38 [0.42; 211.46]      .                .    .              .     .       .
                       Erlotinib:Erlotinib + antiangiogenesis 13 0.96   0.30 [0.19;     0.45]   0.27 [0.17;   0.41]   4.27 [0.45;    40.59] 0.06 [0.01;   0.62] -2.37  0.0180
                                      Erlotinib:Gefitinib  0    0   1.02 [0.45;     2.31]      .              .   1.02 [0.45;     2.31]    .              .     .       .
                            Erlotinib:Gefitinib/Erlotinib  0    0   1.55 [0.27;     8.86]      .              .   1.55 [0.27;     8.86]    .              .     .       .
                         Erlotinib:Gefitinib + chemotherapy  0    0   0.73 [0.22;     2.47]      .              .   0.73 [0.22;     2.47]    .              .     .       .
                       Erlotinib:Gefitinib + antiangiogenesis  0    0   0.03 [0.01;     0.16]      .              .   0.03 [0.01;     0.16]    .              .     .       .
                                     Erlotinib:Lazertinib  0    0   0.73 [0.21;     2.57]      .              .   0.73 [0.21;     2.57]    .              .     .       .
                                    Erlotinib:Osimertinib  0    0   0.94 [0.32;     2.78]      .              .   0.94 [0.32;     2.78]    .              .     .       .
                       Erlotinib:Osimertinib + chemotherapy  0    0   0.36 [0.06;     2.12]      .              .   0.36 [0.06;     2.12]    .              .     .       .
                     Erlotinib:Osimertinib + antiangiogenesis  0    0   0.51 [0.10;     2.60]      .              .   0.51 [0.10;     2.60]    .              .     .       .
                                        Erlotinib:Placebo  3 0.56   1.09 [0.54;     2.20]   0.61 [0.24;   1.55]   2.30 [0.80;     6.62] 0.26 [0.06;   1.08] -1.85  0.0643
                                    Erlotinib:Rociletinib  1 1.00   3.00 [0.10;    88.57]   3.00 [0.10;  88.57]      .                .    .              .     .       .
                                 Erlotinib:antiangiogenesis  2 0.65   0.18 [0.08;     0.44]   0.37 [0.12;   1.09]   0.05 [0.01;     0.22] 7.35 [1.17;  46.08]  2.13  0.0331
     Erlotinib + Autophagy inhibitor:Erlotinib + chemotherapy  0    0   0.41 [0.01;    15.12]      .              .   0.41 [0.01;    15.12]    .              .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + ER inhibitor  0    0   0.06 [0.00;     6.90]      .              .   0.06 [0.00;     6.90]    .              .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + HER3 inhibitor  0    0   0.66 [0.01;    32.56]      .              .   0.66 [0.01;    32.56]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + HGF inhibitor  0    0   0.10 [0.00;    13.12]      .              .   0.10 [0.00;    13.12]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.09 [0.00;     3.74]      .              .   0.09 [0.00;     3.74]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor  0    0   0.32 [0.01;    10.35]      .              .   0.32 [0.01;    10.35]    .              .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MMP inhibitor  0    0   3.05 [0.03;   304.75]      .              .   3.05 [0.03;   304.75]    .              .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis  0    0   0.10 [0.00;     2.93]      .              .   0.10 [0.00;     2.93]    .              .     .       .
                  Erlotinib + Autophagy inhibitor:Gefitinib  0    0   0.33 [0.01;    10.82]      .              .   0.33 [0.01;    10.82]    .              .     .       .
        Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib  0    0   0.50 [0.01;    22.82]      .              .   0.50 [0.01;    22.82]    .              .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy  0    0   0.24 [0.01;     8.72]      .              .   0.24 [0.01;     8.72]    .              .     .       .
   Erlotinib + Autophagy inhibitor:Gefitinib + antiangiogenesis  0    0   0.01 [0.00;     0.46]      .              .   0.01 [0.00;     0.46]    .              .     .       .
                 Erlotinib + Autophagy inhibitor:Lazertinib  0    0   0.24 [0.01;     8.85]      .              .   0.24 [0.01;     8.85]    .              .     .       .
                Erlotinib + Autophagy inhibitor:Osimertinib  0    0   0.31 [0.01;    10.78]      .              .   0.31 [0.01;    10.78]    .              .     .       .
   Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy  0    0   0.12 [0.00;     5.34]      .              .   0.12 [0.00;     5.34]    .              .     .       .
 Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis  0    0   0.16 [0.00;     7.10]      .              .   0.16 [0.00;     7.10]    .              .     .       .
                    Erlotinib + Autophagy inhibitor:Placebo  0    0   0.35 [0.01;    11.30]      .              .   0.35 [0.01;    11.30]    .              .     .       .
                Erlotinib + Autophagy inhibitor:Rociletinib  0    0   0.97 [0.01;   117.45]      .              .   0.97 [0.01;   117.45]    .              .     .       .
             Erlotinib + Autophagy inhibitor:antiangiogenesis  0    0   0.06 [0.00;     1.96]      .              .   0.06 [0.00;     1.96]    .              .     .       .
            Erlotinib + chemotherapy:Erlotinib + ER inhibitor  0    0   0.16 [0.00;     4.87]      .              .   0.16 [0.00;     4.87]    .              .     .       .
          Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor  0    0   1.60 [0.16;    15.59]      .              .   1.60 [0.16;    15.59]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + HGF inhibitor  0    0   0.25 [0.01;     9.84]      .              .   0.25 [0.01;     9.84]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor  0    0   0.22 [0.03;     1.52]      .              .   0.22 [0.03;     1.52]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + MET inhibitor  0    0   0.79 [0.19;     3.21]      .              .   0.79 [0.19;     3.21]    .              .     .       .
           Erlotinib + chemotherapy:Erlotinib + MMP inhibitor  0    0   7.40 [0.26;   209.58]      .              .   7.40 [0.26;   209.58]    .              .     .       .
          Erlotinib + chemotherapy:Erlotinib + antiangiogenesis  0    0   0.23 [0.06;     0.85]      .              .   0.23 [0.06;     0.85]    .              .     .       .
                         Erlotinib + chemotherapy:Gefitinib  0    0   0.80 [0.19;     3.36]      .              .   0.80 [0.19;     3.36]    .              .     .       .
               Erlotinib + chemotherapy:Gefitinib/Erlotinib  0    0   1.22 [0.15;     9.90]      .              .   1.22 [0.15;     9.90]    .              .     .       .
            Erlotinib + chemotherapy:Gefitinib + chemotherapy  0    0   0.58 [0.11;     3.13]      .              .   0.58 [0.11;     3.13]    .              .     .       .
          Erlotinib + chemotherapy:Gefitinib + antiangiogenesis  0    0   0.03 [0.00;     0.19]      .              .   0.03 [0.00;     0.19]    .              .     .       .
                        Erlotinib + chemotherapy:Lazertinib  0    0   0.58 [0.10;     3.20]      .              .   0.58 [0.10;     3.20]    .              .     .       .
                       Erlotinib + chemotherapy:Osimertinib  0    0   0.74 [0.15;     3.63]      .              .   0.74 [0.15;     3.63]    .              .     .       .
          Erlotinib + chemotherapy:Osimertinib + chemotherapy  0    0   0.28 [0.03;     2.35]      .              .   0.28 [0.03;     2.35]    .              .     .       .
        Erlotinib + chemotherapy:Osimertinib + antiangiogenesis  0    0   0.40 [0.05;     2.96]      .              .   0.40 [0.05;     2.96]    .              .     .       .
                           Erlotinib + chemotherapy:Placebo  0    0   0.86 [0.22;     3.43]      .              .   0.86 [0.22;     3.43]    .              .     .       .
                       Erlotinib + chemotherapy:Rociletinib  0    0   2.37 [0.06;    86.30]      .              .   2.37 [0.06;    86.30]    .              .     .       .
                    Erlotinib + chemotherapy:antiangiogenesis  0    0   0.14 [0.03;     0.64]      .              .   0.14 [0.03;     0.64]    .              .     .       .
          Erlotinib + ER inhibitor:Erlotinib + HER3 inhibitor  0    0  10.26 [0.24;   437.14]      .              .  10.26 [0.24;   437.14]    .              .     .       .
           Erlotinib + ER inhibitor:Erlotinib + HGF inhibitor  0    0   1.59 [0.01;   181.46]      .              .   1.59 [0.01;   181.46]    .              .     .       .
           Erlotinib + ER inhibitor:Erlotinib + IGF-1R inhibitor  0    0   1.44 [0.04;    49.81]      .              .   1.44 [0.04;    49.81]    .              .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MET inhibitor  0    0   5.04 [0.19;   136.29]      .              .   5.04 [0.19;   136.29]    .              .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MMP inhibitor  0    0  47.46 [0.54;  4188.32]      .              .  47.46 [0.54;  4188.32]    .              .     .       .
          Erlotinib + ER inhibitor:Erlotinib + antiangiogenesis  0    0   1.49 [0.06;    38.49]      .              .   1.49 [0.06;    38.49]    .              .     .       .
                         Erlotinib + ER inhibitor:Gefitinib  0    0   5.14 [0.19;   142.64]      .              .   5.14 [0.19;   142.64]    .              .     .       .
               Erlotinib + ER inhibitor:Gefitinib/Erlotinib  0    0   7.85 [0.20;   305.23]      .              .   7.85 [0.20;   305.23]    .              .     .       .
            Erlotinib + ER inhibitor:Gefitinib + chemotherapy  0    0   3.69 [0.12;   115.57]      .              .   3.69 [0.12;   115.57]    .              .     .       .
          Erlotinib + ER inhibitor:Gefitinib + antiangiogenesis  0    0   0.17 [0.00;     6.09]      .              .   0.17 [0.00;     6.09]    .              .     .       .
                        Erlotinib + ER inhibitor:Lazertinib  0    0   3.70 [0.12;   117.38]      .              .   3.70 [0.12;   117.38]    .              .     .       .
                       Erlotinib + ER inhibitor:Osimertinib  0    0   4.77 [0.16;   142.61]      .              .   4.77 [0.16;   142.61]    .              .     .       .
          Erlotinib + ER inhibitor:Osimertinib + chemotherapy  0    0   1.80 [0.05;    71.45]      .              .   1.80 [0.05;    71.45]    .              .     .       .
        Erlotinib + ER inhibitor:Osimertinib + antiangiogenesis  0    0   2.56 [0.07;    94.79]      .              .   2.56 [0.07;    94.79]    .              .     .       .
                           Erlotinib + ER inhibitor:Placebo  0    0   5.51 [0.20;   148.73]      .              .   5.51 [0.20;   148.73]    .              .     .       .
                       Erlotinib + ER inhibitor:Rociletinib  0    0  15.17 [0.14;  1622.32]      .              .  15.17 [0.14;  1622.32]    .              .     .       .
                    Erlotinib + ER inhibitor:antiangiogenesis  0    0   0.92 [0.03;    25.83]      .              .   0.92 [0.03;    25.83]    .              .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + HGF inhibitor  0    0   0.15 [0.00;     8.23]      .              .   0.15 [0.00;     8.23]    .              .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.14 [0.01;     1.59]      .              .   0.14 [0.01;     1.59]    .              .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor  0    0   0.49 [0.06;     3.82]      .              .   0.49 [0.06;     3.82]    .              .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor  0    0   4.62 [0.12;   180.03]      .              .   4.62 [0.12;   180.03]    .              .     .       .
        Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis  0    0   0.15 [0.02;     1.05]      .              .   0.15 [0.02;     1.05]    .              .     .       .
                       Erlotinib + HER3 inhibitor:Gefitinib  0    0   0.50 [0.06;     4.06]      .              .   0.50 [0.06;     4.06]    .              .     .       .
             Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib  0    0   0.76 [0.06;    10.25]      .              .   0.76 [0.06;    10.25]    .              .     .       .
          Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy  0    0   0.36 [0.04;     3.51]      .              .   0.36 [0.04;     3.51]    .              .     .       .
        Erlotinib + HER3 inhibitor:Gefitinib + antiangiogenesis  0    0   0.02 [0.00;     0.20]      .              .   0.02 [0.00;     0.20]    .              .     .       .
                      Erlotinib + HER3 inhibitor:Lazertinib  0    0   0.36 [0.04;     3.59]      .              .   0.36 [0.04;     3.59]    .              .     .       .
                     Erlotinib + HER3 inhibitor:Osimertinib  0    0   0.47 [0.05;     4.23]      .              .   0.47 [0.05;     4.23]    .              .     .       .
        Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy  0    0   0.18 [0.01;     2.42]      .              .   0.18 [0.01;     2.42]    .              .     .       .
      Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis  0    0   0.25 [0.02;     3.12]      .              .   0.25 [0.02;     3.12]    .              .     .       .
                         Erlotinib + HER3 inhibitor:Placebo  0    0   0.54 [0.07;     4.17]      .              .   0.54 [0.07;     4.17]    .              .     .       .
                     Erlotinib + HER3 inhibitor:Rociletinib  0    0   1.48 [0.03;    72.62]      .              .   1.48 [0.03;    72.62]    .              .     .       .
                  Erlotinib + HER3 inhibitor:antiangiogenesis  0    0   0.09 [0.01;     0.74]      .              .   0.09 [0.01;     0.74]    .              .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + IGF-1R inhibitor  0    0   0.91 [0.02;    39.57]      .              .   0.91 [0.02;    39.57]    .              .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MET inhibitor  0    0   3.17 [0.09;   110.03]      .              .   3.17 [0.09;   110.03]    .              .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MMP inhibitor  0    0  29.85 [0.28;  3175.65]      .              .  29.85 [0.28;  3175.65]    .              .     .       .
         Erlotinib + HGF inhibitor:Erlotinib + antiangiogenesis  0    0   0.94 [0.03;    31.19]      .              .   0.94 [0.03;    31.19]    .              .     .       .
                        Erlotinib + HGF inhibitor:Gefitinib  0    0   3.23 [0.09;   114.96]      .              .   3.23 [0.09;   114.96]    .              .     .       .
              Erlotinib + HGF inhibitor:Gefitinib/Erlotinib  0    0   4.94 [0.10;   240.77]      .              .   4.94 [0.10;   240.77]    .              .     .       .
           Erlotinib + HGF inhibitor:Gefitinib + chemotherapy  0    0   2.32 [0.06;    92.39]      .              .   2.32 [0.06;    92.39]    .              .     .       .
         Erlotinib + HGF inhibitor:Gefitinib + antiangiogenesis  0    0   0.11 [0.00;     4.83]      .              .   0.11 [0.00;     4.83]    .              .     .       .
                       Erlotinib + HGF inhibitor:Lazertinib  0    0   2.33 [0.06;    93.76]      .              .   2.33 [0.06;    93.76]    .              .     .       .
                      Erlotinib + HGF inhibitor:Osimertinib  0    0   3.00 [0.08;   114.36]      .              .   3.00 [0.08;   114.36]    .              .     .       .
         Erlotinib + HGF inhibitor:Osimertinib + chemotherapy  0    0   1.13 [0.02;    56.29]      .              .   1.13 [0.02;    56.29]    .              .     .       .
       Erlotinib + HGF inhibitor:Osimertinib + antiangiogenesis  0    0   1.61 [0.03;    74.99]      .              .   1.61 [0.03;    74.99]    .              .     .       .
                          Erlotinib + HGF inhibitor:Placebo  0    0   3.47 [0.10;   120.10]      .              .   3.47 [0.10;   120.10]    .              .     .       .
                      Erlotinib + HGF inhibitor:Rociletinib  0    0   9.55 [0.07;  1221.02]      .              .   9.55 [0.07;  1221.02]    .              .     .       .
                   Erlotinib + HGF inhibitor:antiangiogenesis  0    0   0.58 [0.02;    20.80]      .              .   0.58 [0.02;    20.80]    .              .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor  0    0   3.49 [0.68;    17.95]      .              .   3.49 [0.68;    17.95]    .              .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor  0    0  32.89 [1.05;  1032.08]      .              .  32.89 [1.05;  1032.08]    .              .     .       .
         Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis  0    0   1.04 [0.22;     4.81]      .              .   1.04 [0.22;     4.81]    .              .     .       .
                        Erlotinib + IGF-1R inhibitor:Gefitinib  0    0   3.56 [0.66;    19.26]      .              .   3.56 [0.66;    19.26]    .              .     .       .
              Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib  0    0   5.44 [0.56;    53.26]      .              .   5.44 [0.56;    53.26]    .              .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy  0    0   2.56 [0.38;    17.34]      .              .   2.56 [0.38;    17.34]    .              .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib + antiangiogenesis  0    0   0.12 [0.01;     1.01]      .              .   0.12 [0.01;     1.01]    .              .     .       .
                       Erlotinib + IGF-1R inhibitor:Lazertinib  0    0   2.57 [0.37;    17.80]      .              .   2.57 [0.37;    17.80]    .              .     .       .
                      Erlotinib + IGF-1R inhibitor:Osimertinib  0    0   3.31 [0.53;    20.59]      .              .   3.31 [0.53;    20.59]    .              .     .       .
         Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy  0    0   1.25 [0.12;    12.63]      .              .   1.25 [0.12;    12.63]    .              .     .       .
       Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis  0    0   1.78 [0.20;    16.04]      .              .   1.78 [0.20;    16.04]    .              .     .       .
                          Erlotinib + IGF-1R inhibitor:Placebo  0    0   3.82 [0.75;    19.54]      .              .   3.82 [0.75;    19.54]    .              .     .       .
                      Erlotinib + IGF-1R inhibitor:Rociletinib  0    0  10.51 [0.26;   422.00]      .              .  10.51 [0.26;   422.00]    .              .     .       .
                   Erlotinib + IGF-1R inhibitor:antiangiogenesis  0    0   0.64 [0.11;     3.54]      .              .   0.64 [0.11;     3.54]    .              .     .       .
          Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor  0    0   9.42 [0.39;   230.19]      .              .   9.42 [0.39;   230.19]    .              .     .       .
         Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis  0    0   0.30 [0.13;     0.68]      .              .   0.30 [0.13;     0.68]    .              .     .       .
                        Erlotinib + MET inhibitor:Gefitinib  0    0   1.02 [0.34;     3.03]      .              .   1.02 [0.34;     3.03]    .              .     .       .
              Erlotinib + MET inhibitor:Gefitinib/Erlotinib  0    0   1.56 [0.24;    10.23]      .              .   1.56 [0.24;    10.23]    .              .     .       .
           Erlotinib + MET inhibitor:Gefitinib + chemotherapy  0    0   0.73 [0.18;     3.01]      .              .   0.73 [0.18;     3.01]    .              .     .       .
         Erlotinib + MET inhibitor:Gefitinib + antiangiogenesis  0    0   0.03 [0.01;     0.19]      .              .   0.03 [0.01;     0.19]    .              .     .       .
                       Erlotinib + MET inhibitor:Lazertinib  0    0   0.74 [0.17;     3.12]      .              .   0.74 [0.17;     3.12]    .              .     .       .
                      Erlotinib + MET inhibitor:Osimertinib  0    0   0.95 [0.26;     3.46]      .              .   0.95 [0.26;     3.46]    .              .     .       .
         Erlotinib + MET inhibitor:Osimertinib + chemotherapy  0    0   0.36 [0.05;     2.44]      .              .   0.36 [0.05;     2.44]    .              .     .       .
       Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis  0    0   0.51 [0.09;     3.03]      .              .   0.51 [0.09;     3.03]    .              .     .       .
                          Erlotinib + MET inhibitor:Placebo  0    0   1.09 [0.40;     2.97]      .              .   1.09 [0.40;     2.97]    .              .     .       .
                      Erlotinib + MET inhibitor:Rociletinib  0    0   3.01 [0.09;    95.82]      .              .   3.01 [0.09;    95.82]    .              .     .       .
                   Erlotinib + MET inhibitor:antiangiogenesis  0    0   0.18 [0.06;     0.56]      .              .   0.18 [0.06;     0.56]    .              .     .       .
         Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis  0    0   0.03 [0.00;     0.73]      .              .   0.03 [0.00;     0.73]    .              .     .       .
                        Erlotinib + MMP inhibitor:Gefitinib  0    0   0.11 [0.00;     2.72]      .              .   0.11 [0.00;     2.72]    .              .     .       .
              Erlotinib + MMP inhibitor:Gefitinib/Erlotinib  0    0   0.17 [0.00;     5.87]      .              .   0.17 [0.00;     5.87]    .              .     .       .
           Erlotinib + MMP inhibitor:Gefitinib + chemotherapy  0    0   0.08 [0.00;     2.21]      .              .   0.08 [0.00;     2.21]    .              .     .       .
         Erlotinib + MMP inhibitor:Gefitinib + antiangiogenesis  0    0   0.00 [0.00;     0.12]      .              .   0.00 [0.00;     0.12]    .              .     .       .
                       Erlotinib + MMP inhibitor:Lazertinib  0    0   0.08 [0.00;     2.24]      .              .   0.08 [0.00;     2.24]    .              .     .       .
                      Erlotinib + MMP inhibitor:Osimertinib  0    0   0.10 [0.00;     2.72]      .              .   0.10 [0.00;     2.72]    .              .     .       .
         Erlotinib + MMP inhibitor:Osimertinib + chemotherapy  0    0   0.04 [0.00;     1.37]      .              .   0.04 [0.00;     1.37]    .              .     .       .
       Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis  0    0   0.05 [0.00;     1.82]      .              .   0.05 [0.00;     1.82]    .              .     .       .
                          Erlotinib + MMP inhibitor:Placebo  0    0   0.12 [0.00;     2.83]      .              .   0.12 [0.00;     2.83]    .              .     .       .
                      Erlotinib + MMP inhibitor:Rociletinib  0    0   0.32 [0.00;    31.82]      .              .   0.32 [0.00;    31.82]    .              .     .       .
                   Erlotinib + MMP inhibitor:antiangiogenesis  0    0   0.02 [0.00;     0.49]      .              .   0.02 [0.00;     0.49]    .              .     .       .
                       Erlotinib + antiangiogenesis:Gefitinib  0    0   3.44 [1.37;     8.62]      .              .   3.44 [1.37;     8.62]    .              .     .       .
             Erlotinib + antiangiogenesis:Gefitinib/Erlotinib  0    0   5.25 [0.87;    31.50]      .              .   5.25 [0.87;    31.50]    .              .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + chemotherapy  0    0   2.47 [0.68;     8.96]      .              .   2.47 [0.68;     8.96]    .              .     .       .
        Erlotinib + antiangiogenesis:Gefitinib + antiangiogenesis  0    0   0.11 [0.02;     0.58]      .              .   0.11 [0.02;     0.58]    .              .     .       .
                      Erlotinib + antiangiogenesis:Lazertinib  0    0   2.48 [0.66;     9.31]      .              .   2.48 [0.66;     9.31]    .              .     .       .
                     Erlotinib + antiangiogenesis:Osimertinib  0    0   3.19 [1.00;    10.19]      .              .   3.19 [1.00;    10.19]    .              .     .       .
        Erlotinib + antiangiogenesis:Osimertinib + chemotherapy  0    0   1.20 [0.19;     7.54]      .              .   1.20 [0.19;     7.54]    .              .     .       .
      Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0   1.71 [0.32;     9.27]      .              .   1.71 [0.32;     9.27]    .              .     .       .
                         Erlotinib + antiangiogenesis:Placebo  0    0   3.69 [1.63;     8.36]      .              .   3.69 [1.63;     8.36]    .              .     .       .
                     Erlotinib + antiangiogenesis:Rociletinib  0    0  10.15 [0.33;   307.85]      .              .  10.15 [0.33;   307.85]    .              .     .       .
                  Erlotinib + antiangiogenesis:antiangiogenesis  1 0.32   0.61 [0.24;     1.55]   0.16 [0.03;   0.81]   1.17 [0.38;     3.59] 0.14 [0.02;   0.98] -1.98  0.0475
                            Gefitinib:Gefitinib/Erlotinib  0    0   1.53 [0.27;     8.77]      .              .   1.53 [0.27;     8.77]    .              .     .       .
                         Gefitinib:Gefitinib + chemotherapy  3 1.00   0.72 [0.29;     1.77]   0.72 [0.29;   1.77]      .                .    .              .     .       .
                       Gefitinib:Gefitinib + antiangiogenesis  2 1.00   0.03 [0.01;     0.13]   0.03 [0.01;   0.13]      .                .    .              .     .       .
                                     Gefitinib:Lazertinib  1 0.61   0.72 [0.23;     2.25]   0.87 [0.20;   3.73]   0.54 [0.09;     3.36] 1.61 [0.15;  16.71]  0.40  0.6916
                                    Gefitinib:Osimertinib  0    0   0.93 [0.31;     2.77]      .              .   0.93 [0.31;     2.77]    .              .     .       .
                       Gefitinib:Osimertinib + chemotherapy  0    0   0.35 [0.06;     2.10]      .              .   0.35 [0.06;     2.10]    .              .     .       .
                     Gefitinib:Osimertinib + antiangiogenesis  0    0   0.50 [0.10;     2.57]      .              .   0.50 [0.10;     2.57]    .              .     .       .
                                        Gefitinib:Placebo  2 0.32   1.07 [0.46;     2.49]   1.66 [0.38;   7.37]   0.87 [0.31;     2.43] 1.91 [0.31;  11.65]  0.70  0.4826
                                    Gefitinib:Rociletinib  0    0   2.95 [0.09;    96.11]      .              .   2.95 [0.09;    96.11]    .              .     .       .
                                 Gefitinib:antiangiogenesis  1 0.24   0.18 [0.06;     0.55]   0.06 [0.01;   0.64]   0.25 [0.07;     0.88] 0.26 [0.02;   3.64] -1.00  0.3183
               Gefitinib/Erlotinib:Gefitinib + chemotherapy  0    0   0.47 [0.07;     3.37]      .              .   0.47 [0.07;     3.37]    .              .     .       .
             Gefitinib/Erlotinib:Gefitinib + antiangiogenesis  0    0   0.02 [0.00;     0.20]      .              .   0.02 [0.00;     0.20]    .              .     .       .
                           Gefitinib/Erlotinib:Lazertinib  0    0   0.47 [0.08;     2.67]      .              .   0.47 [0.08;     2.67]    .              .     .       .
                          Gefitinib/Erlotinib:Osimertinib  1 1.00   0.61 [0.16;     2.38]   0.61 [0.16;   2.38]      .                .    .              .     .       .
             Gefitinib/Erlotinib:Osimertinib + chemotherapy  0    0   0.23 [0.03;     1.65]      .              .   0.23 [0.03;     1.65]    .              .     .       .
           Gefitinib/Erlotinib:Osimertinib + antiangiogenesis  0    0   0.33 [0.05;     2.05]      .              .   0.33 [0.05;     2.05]    .              .     .       .
                              Gefitinib/Erlotinib:Placebo  0    0   0.70 [0.12;     3.97]      .              .   0.70 [0.12;     3.97]    .              .     .       .
                          Gefitinib/Erlotinib:Rociletinib  0    0   1.93 [0.04;    87.05]      .              .   1.93 [0.04;    87.05]    .              .     .       .
                       Gefitinib/Erlotinib:antiangiogenesis  0    0   0.12 [0.02;     0.80]      .              .   0.12 [0.02;     0.80]    .              .     .       .
          Gefitinib + chemotherapy:Gefitinib + antiangiogenesis  0    0   0.05 [0.01;     0.23]      .              .   0.05 [0.01;     0.23]    .              .     .       .
                        Gefitinib + chemotherapy:Lazertinib  0    0   1.00 [0.23;     4.29]      .              .   1.00 [0.23;     4.29]    .              .     .       .
                       Gefitinib + chemotherapy:Osimertinib  0    0   1.29 [0.31;     5.33]      .              .   1.29 [0.31;     5.33]    .              .     .       .
          Gefitinib + chemotherapy:Osimertinib + chemotherapy  0    0   0.49 [0.07;     3.62]      .              .   0.49 [0.07;     3.62]    .              .     .       .
        Gefitinib + chemotherapy:Osimertinib + antiangiogenesis  0    0   0.69 [0.11;     4.51]      .              .   0.69 [0.11;     4.51]    .              .     .       .
                           Gefitinib + chemotherapy:Placebo  0    0   1.49 [0.43;     5.13]      .              .   1.49 [0.43;     5.13]    .              .     .       .
                       Gefitinib + chemotherapy:Rociletinib  0    0   4.11 [0.11;   150.07]      .              .   4.11 [0.11;   150.07]    .              .     .       .
                    Gefitinib + chemotherapy:antiangiogenesis  0    0   0.25 [0.06;     1.05]      .              .   0.25 [0.06;     1.05]    .              .     .       .
                      Gefitinib + antiangiogenesis:Lazertinib  0    0  21.88 [3.76;   127.48]      .              .  21.88 [3.76;   127.48]    .              .     .       .
                     Gefitinib + antiangiogenesis:Osimertinib  0    0  28.22 [5.00;   159.33]      .              .  28.22 [5.00;   159.33]    .              .     .       .
        Gefitinib + antiangiogenesis:Osimertinib + chemotherapy  0    0  10.62 [1.13;    99.82]      .              .  10.62 [1.13;    99.82]    .              .     .       .
      Gefitinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  15.14 [1.82;   126.24]      .              .  15.14 [1.82;   126.24]    .              .     .       .
                         Gefitinib + antiangiogenesis:Placebo  0    0  32.57 [6.67;   159.09]      .              .  32.57 [6.67;   159.09]    .              .     .       .
                     Gefitinib + antiangiogenesis:Rociletinib  0    0  89.67 [2.14;  3749.01]      .              .  89.67 [2.14;  3749.01]    .              .     .       .
                  Gefitinib + antiangiogenesis:antiangiogenesis  0    0   5.43 [0.95;    31.14]      .              .   5.43 [0.95;    31.14]    .              .     .       .
                                   Lazertinib:Osimertinib  1 0.71   1.29 [0.44;     3.74]   1.48 [0.42;   5.24]   0.92 [0.13;     6.62] 1.61 [0.15;  16.71]  0.40  0.6916
                      Lazertinib:Osimertinib + chemotherapy  0    0   0.49 [0.08;     2.87]      .              .   0.49 [0.08;     2.87]    .              .     .       .
                    Lazertinib:Osimertinib + antiangiogenesis  0    0   0.69 [0.14;     3.51]      .              .   0.69 [0.14;     3.51]    .              .     .       .
                                       Lazertinib:Placebo  0    0   1.49 [0.42;     5.22]      .              .   1.49 [0.42;     5.22]    .              .     .       .
                                   Lazertinib:Rociletinib  0    0   4.10 [0.11;   151.59]      .              .   4.10 [0.11;   151.59]    .              .     .       .
                                Lazertinib:antiangiogenesis  0    0   0.25 [0.06;     1.10]      .              .   0.25 [0.06;     1.10]    .              .     .       .
                     Osimertinib:Osimertinib + chemotherapy  2 1.00   0.38 [0.09;     1.56]   0.38 [0.09;   1.56]      .                .    .              .     .       .
                   Osimertinib:Osimertinib + antiangiogenesis  3 1.00   0.54 [0.16;     1.83]   0.54 [0.16;   1.83]      .                .    .              .     .       .
                                      Osimertinib:Placebo  2 0.43   1.15 [0.40;     3.34]   1.58 [0.31;   8.03]   0.91 [0.22;     3.73] 1.73 [0.20;  14.87]  0.50  0.6167
                                  Osimertinib:Rociletinib  0    0   3.18 [0.09;   111.04]      .              .   3.18 [0.09;   111.04]    .              .     .       .
                               Osimertinib:antiangiogenesis  0    0   0.19 [0.05;     0.75]      .              .   0.19 [0.05;     0.75]    .              .     .       .
      Osimertinib + chemotherapy:Osimertinib + antiangiogenesis  0    0   1.42 [0.22;     9.31]      .              .   1.42 [0.22;     9.31]    .              .     .       .
                         Osimertinib + chemotherapy:Placebo  0    0   3.07 [0.52;    18.10]      .              .   3.07 [0.52;    18.10]    .              .     .       .
                     Osimertinib + chemotherapy:Rociletinib  0    0   8.44 [0.18;   387.82]      .              .   8.44 [0.18;   387.82]    .              .     .       .
                  Osimertinib + chemotherapy:antiangiogenesis  0    0   0.51 [0.07;     3.65]      .              .   0.51 [0.07;     3.65]    .              .     .       .
                       Osimertinib + antiangiogenesis:Placebo  0    0   2.15 [0.42;    10.90]      .              .   2.15 [0.42;    10.90]    .              .     .       .
                   Osimertinib + antiangiogenesis:Rociletinib  0    0   5.92 [0.14;   254.18]      .              .   5.92 [0.14;   254.18]    .              .     .       .
                Osimertinib + antiangiogenesis:antiangiogenesis  0    0   0.36 [0.06;     2.23]      .              .   0.36 [0.06;     2.23]    .              .     .       .
                                      Rociletinib:Placebo  0    0   0.36 [0.01;    11.52]      .              .   0.36 [0.01;    11.52]    .              .     .       .
                                   antiangiogenesis:Placebo  0    0   6.00 [2.01;    17.91]      .              .   6.00 [2.01;    17.91]    .              .     .       .
                               Rociletinib:antiangiogenesis  0    0   0.06 [0.00;     2.00]      .              .   0.06 [0.00;     2.00]    .              .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method

vascular_total
Random effects model: 

                                               comparison  k prop   nma          95%-CI direct        95%-CI indir.          95%-CI  RoR        95%-CI     z p-value
                          Afatinib:Afatinib + Cetuximab  1 1.00  1.05 [0.36;    3.09]   1.05 [0.36;  3.09]      .               .    .             .     .       .
                                    Afatinib:Almonertinib  0    0  0.53 [0.13;    2.10]      .             .   0.53 [0.13;    2.10]    .             .     .       .
                        Afatinib:Amivantamab  +  Lazertinib  0    0  0.19 [0.05;    0.65]      .             .   0.19 [0.05;    0.65]    .             .     .       .
                                    Afatinib:Chemotherapy  2 0.46  0.70 [0.34;    1.43]   0.49 [0.17;  1.42]   0.94 [0.36;    2.50] 0.52 [0.12;  2.20] -0.89  0.3751
                                     Afatinib:Dacomitinib  0    0  1.33 [0.52;    3.39]      .             .   1.33 [0.52;    3.39]    .             .     .       .
                                  Afatinib:DHFR inhibitor  0    0  0.58 [0.04;    8.41]      .             .   0.58 [0.04;    8.41]    .             .     .       .
                                       Afatinib:Erlotinib  1 0.38  1.23 [0.61;    2.48]   1.23 [0.39;  3.87]   1.22 [0.50;    2.98] 1.01 [0.24;  4.29]  0.01  0.9916
                   Afatinib:Erlotinib + Autophagy inhibitor  0    0  5.44 [1.17;   25.23]      .             .   5.44 [1.17;   25.23]    .             .     .       .
                          Afatinib:Erlotinib + chemotherapy  0    0  1.11 [0.34;    3.66]      .             .   1.11 [0.34;    3.66]    .             .     .       .
                        Afatinib:Erlotinib + COX2 inhibitor  0    0  0.24 [0.01;    6.29]      .             .   0.24 [0.01;    6.29]    .             .     .       .
                          Afatinib:Erlotinib + ER inhibitor  0    0  0.47 [0.12;    1.79]      .             .   0.47 [0.12;    1.79]    .             .     .       .
                        Afatinib:Erlotinib + HER3 inhibitor  0    0  2.49 [0.34;   18.06]      .             .   2.49 [0.34;   18.06]    .             .     .       .
                         Afatinib:Erlotinib + HGF inhibitor  0    0  1.53 [0.07;   34.73]      .             .   1.53 [0.07;   34.73]    .             .     .       .
                         Afatinib:Erlotinib + IGF-1R inhibitor  0    0  0.37 [0.11;    1.24]      .             .   0.37 [0.11;    1.24]    .             .     .       .
                         Afatinib:Erlotinib + MET inhibitor  0    0  1.26 [0.49;    3.26]      .             .   1.26 [0.49;    3.26]    .             .     .       .
                         Afatinib:Erlotinib + MMP inhibitor  0    0  6.81 [1.00;   46.58]      .             .   6.81 [1.00;   46.58]    .             .     .       .
                        Afatinib:Erlotinib + antiangiogenesis  0    0  0.30 [0.14;    0.65]      .             .   0.30 [0.14;    0.65]    .             .     .       .
                                       Afatinib:Gefitinib  1 0.34  1.19 [0.55;    2.57]   1.12 [0.30;  4.21]   1.22 [0.47;    3.17] 0.92 [0.18;  4.67] -0.10  0.9184
                             Afatinib:Gefitinib/Erlotinib  0    0  1.84 [0.43;    7.86]      .             .   1.84 [0.43;    7.86]    .             .     .       .
                          Afatinib:Gefitinib + chemotherapy  0    0  0.94 [0.35;    2.52]      .             .   0.94 [0.35;    2.52]    .             .     .       .
                          Afatinib:Gefitinib + ER inhibitor  0    0  0.29 [0.08;    1.06]      .             .   0.29 [0.08;    1.06]    .             .     .       .
                        Afatinib:Gefitinib + antiangiogenesis  0    0  0.10 [0.03;    0.35]      .             .   0.10 [0.03;    0.35]    .             .     .       .
                                      Afatinib:Lazertinib  0    0  0.85 [0.30;    2.46]      .             .   0.85 [0.30;    2.46]    .             .     .       .
                                     Afatinib:Osimertinib  0    0  1.14 [0.43;    3.03]      .             .   1.14 [0.43;    3.03]    .             .     .       .
                        Afatinib:Osimertinib + chemotherapy  0    0  0.74 [0.18;    2.96]      .             .   0.74 [0.18;    2.96]    .             .     .       .
                      Afatinib:Osimertinib + antiangiogenesis  0    0  0.14 [0.04;    0.51]      .             .   0.14 [0.04;    0.51]    .             .     .       .
                                 Afatinib:PD-L1 inhibitor  0    0  2.69 [0.17;   41.54]      .             .   2.69 [0.17;   41.54]    .             .     .       .
                                         Afatinib:Placebo  1 0.22  1.39 [0.62;    3.09]   3.86 [0.68; 21.77]   1.05 [0.42;    2.59] 3.69 [0.52; 26.00]  1.31  0.1901
                                     Afatinib:Rociletinib  0    0  3.68 [0.12;  112.28]      .             .   3.68 [0.12;  112.28]    .             .     .       .
                                  Afatinib:antiangiogenesis  0    0  0.18 [0.07;    0.48]      .             .   0.18 [0.07;    0.48]    .             .     .       .
                      Afatinib + Cetuximab:Almonertinib  0    0  0.50 [0.09;    2.89]      .             .   0.50 [0.09;    2.89]    .             .     .       .
          Afatinib + Cetuximab:Amivantamab  +  Lazertinib  0    0  0.18 [0.03;    0.92]      .             .   0.18 [0.03;    0.92]    .             .     .       .
                      Afatinib + Cetuximab:Chemotherapy  0    0  0.66 [0.18;    2.41]      .             .   0.66 [0.18;    2.41]    .             .     .       .
                       Afatinib + Cetuximab:Dacomitinib  0    0  1.26 [0.30;    5.25]      .             .   1.26 [0.30;    5.25]    .             .     .       .
                    Afatinib + Cetuximab:DHFR inhibitor  0    0  0.55 [0.03;    9.82]      .             .   0.55 [0.03;    9.82]    .             .     .       .
                         Afatinib + Cetuximab:Erlotinib  0    0  1.16 [0.32;    4.20]      .             .   1.16 [0.32;    4.20]    .             .     .       .
     Afatinib + Cetuximab:Erlotinib + Autophagy inhibitor  0    0  5.16 [0.79;   33.58]      .             .   5.16 [0.79;   33.58]    .             .     .       .
            Afatinib + Cetuximab:Erlotinib + chemotherapy  0    0  1.05 [0.21;    5.25]      .             .   1.05 [0.21;    5.25]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + COX2 inhibitor  0    0  0.23 [0.01;    7.09]      .             .   0.23 [0.01;    7.09]    .             .     .       .
            Afatinib + Cetuximab:Erlotinib + ER inhibitor  0    0  0.45 [0.08;    2.48]      .             .   0.45 [0.08;    2.48]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + HER3 inhibitor  0    0  2.36 [0.25;   22.50]      .             .   2.36 [0.25;   22.50]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + HGF inhibitor  0    0  1.46 [0.05;   39.44]      .             .   1.46 [0.05;   39.44]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + IGF-1R inhibitor  0    0  0.36 [0.07;    1.77]      .             .   0.36 [0.07;    1.77]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + MET inhibitor  0    0  1.20 [0.29;    5.02]      .             .   1.20 [0.29;    5.02]    .             .     .       .
           Afatinib + Cetuximab:Erlotinib + MMP inhibitor  0    0  6.46 [0.71;   58.46]      .             .   6.46 [0.71;   58.46]    .             .     .       .
          Afatinib + Cetuximab:Erlotinib + antiangiogenesis  0    0  0.28 [0.07;    1.06]      .             .   0.28 [0.07;    1.06]    .             .     .       .
                         Afatinib + Cetuximab:Gefitinib  0    0  1.13 [0.30;    4.24]      .             .   1.13 [0.30;    4.24]    .             .     .       .
               Afatinib + Cetuximab:Gefitinib/Erlotinib  0    0  1.74 [0.29;   10.63]      .             .   1.74 [0.29;   10.63]    .             .     .       .
            Afatinib + Cetuximab:Gefitinib + chemotherapy  0    0  0.89 [0.21;    3.83]      .             .   0.89 [0.21;    3.83]    .             .     .       .
            Afatinib + Cetuximab:Gefitinib + ER inhibitor  0    0  0.28 [0.05;    1.49]      .             .   0.28 [0.05;    1.49]    .             .     .       .
          Afatinib + Cetuximab:Gefitinib + antiangiogenesis  0    0  0.10 [0.02;    0.50]      .             .   0.10 [0.02;    0.50]    .             .     .       .
                        Afatinib + Cetuximab:Lazertinib  0    0  0.81 [0.18;    3.66]      .             .   0.81 [0.18;    3.66]    .             .     .       .
                       Afatinib + Cetuximab:Osimertinib  0    0  1.08 [0.25;    4.63]      .             .   1.08 [0.25;    4.63]    .             .     .       .
          Afatinib + Cetuximab:Osimertinib + chemotherapy  0    0  0.70 [0.12;    4.05]      .             .   0.70 [0.12;    4.05]    .             .     .       .
        Afatinib + Cetuximab:Osimertinib + antiangiogenesis  0    0  0.14 [0.03;    0.71]      .             .   0.14 [0.03;    0.71]    .             .     .       .
                   Afatinib + Cetuximab:PD-L1 inhibitor  0    0  2.56 [0.14;   48.30]      .             .   2.56 [0.14;   48.30]    .             .     .       .
                           Afatinib + Cetuximab:Placebo  0    0  1.31 [0.34;    5.03]      .             .   1.31 [0.34;    5.03]    .             .     .       .
                       Afatinib + Cetuximab:Rociletinib  0    0  3.49 [0.10;  125.62]      .             .   3.49 [0.10;  125.62]    .             .     .       .
                    Afatinib + Cetuximab:antiangiogenesis  0    0  0.17 [0.04;    0.73]      .             .   0.17 [0.04;    0.73]    .             .     .       .
                    Almonertinib:Amivantamab  +  Lazertinib  0    0  0.35 [0.07;    1.74]      .             .   0.35 [0.07;    1.74]    .             .     .       .
                                Almonertinib:Chemotherapy  0    0  1.31 [0.35;    4.99]      .             .   1.31 [0.35;    4.99]    .             .     .       .
                                 Almonertinib:Dacomitinib  0    0  2.50 [0.64;    9.84]      .             .   2.50 [0.64;    9.84]    .             .     .       .
                              Almonertinib:DHFR inhibitor  0    0  1.10 [0.06;   19.70]      .             .   1.10 [0.06;   19.70]    .             .     .       .
                                   Almonertinib:Erlotinib  0    0  2.31 [0.62;    8.55]      .             .   2.31 [0.62;    8.55]    .             .     .       .
               Almonertinib:Erlotinib + Autophagy inhibitor  0    0 10.23 [1.54;   67.77]      .             .  10.23 [1.54;   67.77]    .             .     .       .
                      Almonertinib:Erlotinib + chemotherapy  0    0  2.09 [0.41;   10.65]      .             .   2.09 [0.41;   10.65]    .             .     .       .
                    Almonertinib:Erlotinib + COX2 inhibitor  0    0  0.45 [0.01;   14.20]      .             .   0.45 [0.01;   14.20]    .             .     .       .
                      Almonertinib:Erlotinib + ER inhibitor  0    0  0.88 [0.17;    4.58]      .             .   0.88 [0.17;    4.58]    .             .     .       .
                    Almonertinib:Erlotinib + HER3 inhibitor  0    0  4.69 [0.49;   45.28]      .             .   4.69 [0.49;   45.28]    .             .     .       .
                     Almonertinib:Erlotinib + HGF inhibitor  0    0  2.89 [0.11;   78.98]      .             .   2.89 [0.11;   78.98]    .             .     .       .
                     Almonertinib:Erlotinib + IGF-1R inhibitor  0    0  0.71 [0.14;    3.59]      .             .   0.71 [0.14;    3.59]    .             .     .       .
                     Almonertinib:Erlotinib + MET inhibitor  0    0  2.37 [0.55;   10.18]      .             .   2.37 [0.55;   10.18]    .             .     .       .
                     Almonertinib:Erlotinib + MMP inhibitor  0    0 12.81 [1.39;  117.67]      .             .  12.81 [1.39;  117.67]    .             .     .       .
                    Almonertinib:Erlotinib + antiangiogenesis  0    0  0.56 [0.14;    2.15]      .             .   0.56 [0.14;    2.15]    .             .     .       .
                                   Almonertinib:Gefitinib  1 1.00  2.24 [0.72;    6.99]   2.24 [0.72;  6.99]      .               .    .             .     .       .
                         Almonertinib:Gefitinib/Erlotinib  0    0  3.45 [0.58;   20.67]      .             .   3.45 [0.58;   20.67]    .             .     .       .
                      Almonertinib:Gefitinib + chemotherapy  0    0  1.76 [0.48;    6.44]      .             .   1.76 [0.48;    6.44]    .             .     .       .
                      Almonertinib:Gefitinib + ER inhibitor  0    0  0.55 [0.11;    2.74]      .             .   0.55 [0.11;    2.74]    .             .     .       .
                    Almonertinib:Gefitinib + antiangiogenesis  0    0  0.19 [0.04;    0.85]      .             .   0.19 [0.04;    0.85]    .             .     .       .
                                  Almonertinib:Lazertinib  0    0  1.60 [0.39;    6.67]      .             .   1.60 [0.39;    6.67]    .             .     .       .
                                 Almonertinib:Osimertinib  0    0  2.15 [0.52;    8.97]      .             .   2.15 [0.52;    8.97]    .             .     .       .
                    Almonertinib:Osimertinib + chemotherapy  0    0  1.38 [0.24;    7.87]      .             .   1.38 [0.24;    7.87]    .             .     .       .
                  Almonertinib:Osimertinib + antiangiogenesis  0    0  0.27 [0.05;    1.39]      .             .   0.27 [0.05;    1.39]    .             .     .       .
                             Almonertinib:PD-L1 inhibitor  0    0  5.07 [0.27;   94.66]      .             .   5.07 [0.27;   94.66]    .             .     .       .
                                     Almonertinib:Placebo  0    0  2.61 [0.68;    9.98]      .             .   2.61 [0.68;    9.98]    .             .     .       .
                                 Almonertinib:Rociletinib  0    0  6.93 [0.19;  251.37]      .             .   6.93 [0.19;  251.37]    .             .     .       .
                              Almonertinib:antiangiogenesis  0    0  0.34 [0.08;    1.45]      .             .   0.34 [0.08;    1.45]    .             .     .       .
                    Amivantamab  +  Lazertinib:Chemotherapy  0    0  3.71 [1.19;   11.56]      .             .   3.71 [1.19;   11.56]    .             .     .       .
                     Amivantamab  +  Lazertinib:Dacomitinib  0    0  7.07 [1.99;   25.11]      .             .   7.07 [1.99;   25.11]    .             .     .       .
                  Amivantamab  +  Lazertinib:DHFR inhibitor  0    0  3.10 [0.18;   52.05]      .             .   3.10 [0.18;   52.05]    .             .     .       .
                       Amivantamab  +  Lazertinib:Erlotinib  0    0  6.53 [2.06;   20.68]      .             .   6.53 [2.06;   20.68]    .             .     .       .
   Amivantamab  +  Lazertinib:Erlotinib + Autophagy inhibitor  0    0 28.91 [4.84;  172.53]      .             .  28.91 [4.84;  172.53]    .             .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + chemotherapy  0    0  5.91 [1.32;   26.47]      .             .   5.91 [1.32;   26.47]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + COX2 inhibitor  0    0  1.28 [0.04;   37.93]      .             .   1.28 [0.04;   37.93]    .             .     .       .
          Amivantamab  +  Lazertinib:Erlotinib + ER inhibitor  0    0  2.49 [0.51;   12.19]      .             .   2.49 [0.51;   12.19]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + HER3 inhibitor  0    0 13.25 [1.49;  117.38]      .             .  13.25 [1.49;  117.38]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + HGF inhibitor  0    0  8.16 [0.32;  210.53]      .             .   8.16 [0.32;  210.53]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + IGF-1R inhibitor  0    0  1.99 [0.44;    8.97]      .             .   1.99 [0.44;    8.97]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MET inhibitor  0    0  6.70 [1.79;   25.05]      .             .   6.70 [1.79;   25.05]    .             .     .       .
         Amivantamab  +  Lazertinib:Erlotinib + MMP inhibitor  0    0 36.20 [4.31;  304.43]      .             .  36.20 [4.31;  304.43]    .             .     .       .
        Amivantamab  +  Lazertinib:Erlotinib + antiangiogenesis  0    0  1.58 [0.48;    5.24]      .             .   1.58 [0.48;    5.24]    .             .     .       .
                       Amivantamab  +  Lazertinib:Gefitinib  0    0  6.32 [2.08;   19.26]      .             .   6.32 [2.08;   19.26]    .             .     .       .
             Amivantamab  +  Lazertinib:Gefitinib/Erlotinib  0    0  9.76 [2.38;   40.00]      .             .   9.76 [2.38;   40.00]    .             .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + chemotherapy  0    0  4.99 [1.40;   17.80]      .             .   4.99 [1.40;   17.80]    .             .     .       .
          Amivantamab  +  Lazertinib:Gefitinib + ER inhibitor  0    0  1.56 [0.33;    7.29]      .             .   1.56 [0.33;    7.29]    .             .     .       .
        Amivantamab  +  Lazertinib:Gefitinib + antiangiogenesis  0    0  0.53 [0.12;    2.36]      .             .   0.53 [0.12;    2.36]    .             .     .       .
                      Amivantamab  +  Lazertinib:Lazertinib  1 0.92  4.53 [1.80;   11.42]   4.41 [1.68; 11.59]   6.09 [0.25;  147.63] 0.72 [0.03; 20.29] -0.19  0.8498
                     Amivantamab  +  Lazertinib:Osimertinib  1 0.93  6.08 [2.45;   15.08]   6.23 [2.42; 16.01]   4.45 [0.16;  125.86] 1.40 [0.04; 45.04]  0.19  0.8498
        Amivantamab  +  Lazertinib:Osimertinib + chemotherapy  0    0  3.91 [1.02;   15.02]      .             .   3.91 [1.02;   15.02]    .             .     .       .
      Amivantamab  +  Lazertinib:Osimertinib + antiangiogenesis  0    0  0.76 [0.23;    2.56]      .             .   0.76 [0.23;    2.56]    .             .     .       .
                 Amivantamab  +  Lazertinib:PD-L1 inhibitor  0    0 14.33 [0.95;  215.77]      .             .  14.33 [0.95;  215.77]    .             .     .       .
                         Amivantamab  +  Lazertinib:Placebo  0    0  7.37 [2.31;   23.54]      .             .   7.37 [2.31;   23.54]    .             .     .       .
                     Amivantamab  +  Lazertinib:Rociletinib  0    0 19.58 [0.57;  673.21]      .             .  19.58 [0.57;  673.21]    .             .     .       .
                  Amivantamab  +  Lazertinib:antiangiogenesis  0    0  0.95 [0.25;    3.62]      .             .   0.95 [0.25;    3.62]    .             .     .       .
                                 Chemotherapy:Dacomitinib  0    0  1.90 [0.80;    4.53]      .             .   1.90 [0.80;    4.53]    .             .     .       .
                              Chemotherapy:DHFR inhibitor  0    0  0.83 [0.06;   11.68]      .             .   0.83 [0.06;   11.68]    .             .     .       .
                                   Chemotherapy:Erlotinib  9 0.58  1.76 [0.99;    3.13]   1.18 [0.55;  2.52]   3.06 [1.25;    7.46] 0.39 [0.12;  1.24] -1.60  0.1105
               Chemotherapy:Erlotinib + Autophagy inhibitor  0    0  7.78 [1.77;   34.26]      .             .   7.78 [1.77;   34.26]    .             .     .       .
                      Chemotherapy:Erlotinib + chemotherapy  1 0.24  1.59 [0.53;    4.76]   1.65 [0.18; 15.33]   1.57 [0.45;    5.55] 1.05 [0.08; 13.58]  0.03  0.9724
                    Chemotherapy:Erlotinib + COX2 inhibitor  0    0  0.34 [0.01;    8.79]      .             .   0.34 [0.01;    8.79]    .             .     .       .
                      Chemotherapy:Erlotinib + ER inhibitor  0    0  0.67 [0.19;    2.44]      .             .   0.67 [0.19;    2.44]    .             .     .       .
                    Chemotherapy:Erlotinib + HER3 inhibitor  0    0  3.57 [0.51;   24.83]      .             .   3.57 [0.51;   24.83]    .             .     .       .
                     Chemotherapy:Erlotinib + HGF inhibitor  0    0  2.20 [0.10;   48.46]      .             .   2.20 [0.10;   48.46]    .             .     .       .
                     Chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  0.54 [0.17;    1.65]      .             .   0.54 [0.17;    1.65]    .             .     .       .
                     Chemotherapy:Erlotinib + MET inhibitor  0    0  1.81 [0.76;    4.27]      .             .   1.81 [0.76;    4.27]    .             .     .       .
                     Chemotherapy:Erlotinib + MMP inhibitor  0    0  9.75 [1.49;   63.96]      .             .   9.75 [1.49;   63.96]    .             .     .       .
                    Chemotherapy:Erlotinib + antiangiogenesis  0    0  0.42 [0.22;    0.83]      .             .   0.42 [0.22;    0.83]    .             .     .       .
                                   Chemotherapy:Gefitinib  5 0.29  1.70 [0.85;    3.41]   2.69 [0.74;  9.86]   1.42 [0.62;    3.23] 1.90 [0.41;  8.84]  0.82  0.4129
                         Chemotherapy:Gefitinib/Erlotinib  0    0  2.63 [0.68;   10.18]      .             .   2.63 [0.68;   10.18]    .             .     .       .
                      Chemotherapy:Gefitinib + chemotherapy  0    0  1.34 [0.53;    3.40]      .             .   1.34 [0.53;    3.40]    .             .     .       .
                      Chemotherapy:Gefitinib + ER inhibitor  0    0  0.42 [0.12;    1.44]      .             .   0.42 [0.12;    1.44]    .             .     .       .
                    Chemotherapy:Gefitinib + antiangiogenesis  0    0  0.14 [0.04;    0.48]      .             .   0.14 [0.04;    0.48]    .             .     .       .
                                  Chemotherapy:Lazertinib  0    0  1.22 [0.47;    3.18]      .             .   1.22 [0.47;    3.18]    .             .     .       .
                                 Chemotherapy:Osimertinib  1 0.53  1.64 [0.72;    3.71]   1.95 [0.64;  6.01]   1.34 [0.41;    4.42] 1.46 [0.28;  7.52]  0.45  0.6504
                    Chemotherapy:Osimertinib + chemotherapy  0    0  1.05 [0.29;    3.81]      .             .   1.05 [0.29;    3.81]    .             .     .       .
                  Chemotherapy:Osimertinib + antiangiogenesis  0    0  0.20 [0.06;    0.65]      .             .   0.20 [0.06;    0.65]    .             .     .       .
                             Chemotherapy:PD-L1 inhibitor  0    0  3.86 [0.26;   56.44]      .             .   3.86 [0.26;   56.44]    .             .     .       .
                                     Chemotherapy:Placebo  0    0  1.98 [0.95;    4.14]      .             .   1.98 [0.95;    4.14]    .             .     .       .
                                 Chemotherapy:Rociletinib  0    0  5.27 [0.18;  157.02]      .             .   5.27 [0.18;  157.02]    .             .     .       .
                              Chemotherapy:antiangiogenesis  0    0  0.26 [0.10;    0.63]      .             .   0.26 [0.10;    0.63]    .             .     .       .
                               Dacomitinib:DHFR inhibitor  0    0  0.44 [0.03;    6.40]      .             .   0.44 [0.03;    6.40]    .             .     .       .
                                    Dacomitinib:Erlotinib  2 0.45  0.92 [0.44;    1.95]   0.87 [0.29;  2.64]   0.97 [0.35;    2.67] 0.90 [0.20;  4.02] -0.14  0.8859
                Dacomitinib:Erlotinib + Autophagy inhibitor  0    0  4.09 [0.86;   19.38]      .             .   4.09 [0.86;   19.38]    .             .     .       .
                       Dacomitinib:Erlotinib + chemotherapy  0    0  0.84 [0.24;    2.87]      .             .   0.84 [0.24;    2.87]    .             .     .       .
                     Dacomitinib:Erlotinib + COX2 inhibitor  0    0  0.18 [0.01;    4.78]      .             .   0.18 [0.01;    4.78]    .             .     .       .
                       Dacomitinib:Erlotinib + ER inhibitor  0    0  0.35 [0.09;    1.35]      .             .   0.35 [0.09;    1.35]    .             .     .       .
                     Dacomitinib:Erlotinib + HER3 inhibitor  0    0  1.87 [0.25;   13.81]      .             .   1.87 [0.25;   13.81]    .             .     .       .
                      Dacomitinib:Erlotinib + HGF inhibitor  0    0  1.15 [0.05;   26.39]      .             .   1.15 [0.05;   26.39]    .             .     .       .
                      Dacomitinib:Erlotinib + IGF-1R inhibitor  0    0  0.28 [0.08;    0.96]      .             .   0.28 [0.08;    0.96]    .             .     .       .
                      Dacomitinib:Erlotinib + MET inhibitor  0    0  0.95 [0.35;    2.54]      .             .   0.95 [0.35;    2.54]    .             .     .       .
                      Dacomitinib:Erlotinib + MMP inhibitor  0    0  5.12 [0.74;   35.64]      .             .   5.12 [0.74;   35.64]    .             .     .       .
                     Dacomitinib:Erlotinib + antiangiogenesis  0    0  0.22 [0.10;    0.51]      .             .   0.22 [0.10;    0.51]    .             .     .       .
                                    Dacomitinib:Gefitinib  1 0.52  0.89 [0.42;    1.91]   0.87 [0.30;  2.49]   0.93 [0.31;    2.77] 0.94 [0.20;  4.28] -0.09  0.9312
                          Dacomitinib:Gefitinib/Erlotinib  0    0  1.38 [0.31;    6.11]      .             .   1.38 [0.31;    6.11]    .             .     .       .
                       Dacomitinib:Gefitinib + chemotherapy  0    0  0.71 [0.27;    1.88]      .             .   0.71 [0.27;    1.88]    .             .     .       .
                       Dacomitinib:Gefitinib + ER inhibitor  0    0  0.22 [0.06;    0.80]      .             .   0.22 [0.06;    0.80]    .             .     .       .
                     Dacomitinib:Gefitinib + antiangiogenesis  0    0  0.08 [0.02;    0.26]      .             .   0.08 [0.02;    0.26]    .             .     .       .
                                   Dacomitinib:Lazertinib  0    0  0.64 [0.22;    1.89]      .             .   0.64 [0.22;    1.89]    .             .     .       .
                                  Dacomitinib:Osimertinib  0    0  0.86 [0.31;    2.39]      .             .   0.86 [0.31;    2.39]    .             .     .       .
                     Dacomitinib:Osimertinib + chemotherapy  0    0  0.55 [0.13;    2.30]      .             .   0.55 [0.13;    2.30]    .             .     .       .
                   Dacomitinib:Osimertinib + antiangiogenesis  0    0  0.11 [0.03;    0.40]      .             .   0.11 [0.03;    0.40]    .             .     .       .
                              Dacomitinib:PD-L1 inhibitor  0    0  2.03 [0.13;   31.79]      .             .   2.03 [0.13;   31.79]    .             .     .       .
                                      Dacomitinib:Placebo  1 0.34  1.04 [0.47;    2.32]   1.21 [0.30;  4.79]   0.97 [0.36;    2.58] 1.25 [0.23;  6.79]  0.26  0.7967
                                  Dacomitinib:Rociletinib  0    0  2.77 [0.09;   85.26]      .             .   2.77 [0.09;   85.26]    .             .     .       .
                               Dacomitinib:antiangiogenesis  0    0  0.13 [0.05;    0.37]      .             .   0.13 [0.05;    0.37]    .             .     .       .
                                 DHFR inhibitor:Erlotinib  1 1.00  2.11 [0.16;   27.62]   2.11 [0.16; 27.62]      .               .    .             .     .       .
             DHFR inhibitor:Erlotinib + Autophagy inhibitor  0    0  9.32 [0.51;  171.73]      .             .   9.32 [0.51;  171.73]    .             .     .       .
                    DHFR inhibitor:Erlotinib + chemotherapy  0    0  1.90 [0.12;   30.05]      .             .   1.90 [0.12;   30.05]    .             .     .       .
                  DHFR inhibitor:Erlotinib + COX2 inhibitor  0    0  0.41 [0.01;   24.83]      .             .   0.41 [0.01;   24.83]    .             .     .       .
                    DHFR inhibitor:Erlotinib + ER inhibitor  0    0  0.80 [0.05;   13.88]      .             .   0.80 [0.05;   13.88]    .             .     .       .
                  DHFR inhibitor:Erlotinib + HER3 inhibitor  0    0  4.27 [0.18;  101.83]      .             .   4.27 [0.18;  101.83]    .             .     .       .
                   DHFR inhibitor:Erlotinib + HGF inhibitor  0    0  2.63 [0.05;  141.22]      .             .   2.63 [0.05;  141.22]    .             .     .       .
                   DHFR inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.64 [0.04;   10.05]      .             .   0.64 [0.04;   10.05]    .             .     .       .
                   DHFR inhibitor:Erlotinib + MET inhibitor  0    0  2.16 [0.15;   30.67]      .             .   2.16 [0.15;   30.67]    .             .     .       .
                   DHFR inhibitor:Erlotinib + MMP inhibitor  0    0 11.68 [0.51;  268.53]      .             .  11.68 [0.51;  268.53]    .             .     .       .
                  DHFR inhibitor:Erlotinib + antiangiogenesis  0    0  0.51 [0.04;    6.82]      .             .   0.51 [0.04;    6.82]    .             .     .       .
                                 DHFR inhibitor:Gefitinib  0    0  2.04 [0.14;   28.98]      .             .   2.04 [0.14;   28.98]    .             .     .       .
                       DHFR inhibitor:Gefitinib/Erlotinib  0    0  3.15 [0.17;   58.38]      .             .   3.15 [0.17;   58.38]    .             .     .       .
                    DHFR inhibitor:Gefitinib + chemotherapy  0    0  1.61 [0.11;   24.52]      .             .   1.61 [0.11;   24.52]    .             .     .       .
                    DHFR inhibitor:Gefitinib + ER inhibitor  0    0  0.50 [0.03;    8.46]      .             .   0.50 [0.03;    8.46]    .             .     .       .
                  DHFR inhibitor:Gefitinib + antiangiogenesis  0    0  0.17 [0.01;    2.92]      .             .   0.17 [0.01;    2.92]    .             .     .       .
                                DHFR inhibitor:Lazertinib  0    0  1.46 [0.09;   22.82]      .             .   1.46 [0.09;   22.82]    .             .     .       .
                               DHFR inhibitor:Osimertinib  0    0  1.96 [0.13;   29.57]      .             .   1.96 [0.13;   29.57]    .             .     .       .
                  DHFR inhibitor:Osimertinib + chemotherapy  0    0  1.26 [0.07;   22.68]      .             .   1.26 [0.07;   22.68]    .             .     .       .
                DHFR inhibitor:Osimertinib + antiangiogenesis  0    0  0.25 [0.01;    4.16]      .             .   0.25 [0.01;    4.16]    .             .     .       .
                           DHFR inhibitor:PD-L1 inhibitor  0    0  4.62 [0.11;  192.13]      .             .   4.62 [0.11;  192.13]    .             .     .       .
                                   DHFR inhibitor:Placebo  0    0  2.38 [0.17;   33.39]      .             .   2.38 [0.17;   33.39]    .             .     .       .
                               DHFR inhibitor:Rociletinib  0    0  6.32 [0.09;  429.77]      .             .   6.32 [0.09;  429.77]    .             .     .       .
                            DHFR inhibitor:antiangiogenesis  0    0  0.31 [0.02;    4.44]      .             .   0.31 [0.02;    4.44]    .             .     .       .
                  Erlotinib:Erlotinib + Autophagy inhibitor  1 1.00  4.43 [1.13;   17.33]   4.43 [1.13; 17.33]      .               .    .             .     .       .
                         Erlotinib:Erlotinib + chemotherapy  3 0.88  0.90 [0.34;    2.44]   0.85 [0.30;  2.44]   1.47 [0.08;   27.04] 0.58 [0.03; 12.88] -0.34  0.7304
                       Erlotinib:Erlotinib + COX2 inhibitor  1 1.00  0.20 [0.01;    4.75]   0.20 [0.01;  4.75]      .               .    .             .     .       .
                         Erlotinib:Erlotinib + ER inhibitor  1 0.69  0.38 [0.11;    1.29]   0.31 [0.07;  1.33]   0.63 [0.07;    5.50] 0.49 [0.04;  6.74] -0.54  0.5925
                       Erlotinib:Erlotinib + HER3 inhibitor  1 1.00  2.03 [0.32;   12.93]   2.03 [0.32; 12.93]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + HGF inhibitor  1 1.00  1.25 [0.06;   26.11]   1.25 [0.06; 26.11]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + IGF-1R inhibitor  3 1.00  0.31 [0.12;    0.80]   0.31 [0.12;  0.80]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + MET inhibitor  5 1.00  1.03 [0.54;    1.95]   1.03 [0.54;  1.95]      .               .    .             .     .       .
                        Erlotinib:Erlotinib + MMP inhibitor  1 1.00  5.55 [0.93;   33.22]   5.55 [0.93; 33.22]      .               .    .             .     .       .
                       Erlotinib:Erlotinib + antiangiogenesis 13 0.98  0.24 [0.17;    0.34]   0.24 [0.17;  0.33]   0.59 [0.05;    6.73] 0.41 [0.03;  4.78] -0.72  0.4735
                                      Erlotinib:Gefitinib  1 0.17  0.97 [0.51;    1.85]   0.66 [0.14;  3.09]   1.05 [0.52;    2.14] 0.63 [0.12;  3.44] -0.54  0.5925
                            Erlotinib:Gefitinib/Erlotinib  0    0  1.49 [0.38;    5.94]      .             .   1.49 [0.38;    5.94]    .             .     .       .
                         Erlotinib:Gefitinib + chemotherapy  0    0  0.76 [0.31;    1.86]      .             .   0.76 [0.31;    1.86]    .             .     .       .
                         Erlotinib:Gefitinib + ER inhibitor  1 0.67  0.24 [0.07;    0.76]   0.19 [0.05;  0.79]   0.37 [0.05;    2.80] 0.51 [0.04;  6.01] -0.54  0.5925
                       Erlotinib:Gefitinib + antiangiogenesis  0    0  0.08 [0.02;    0.27]      .             .   0.08 [0.02;    0.27]    .             .     .       .
                                     Erlotinib:Lazertinib  0    0  0.69 [0.27;    1.82]      .             .   0.69 [0.27;    1.82]    .             .     .       .
                                    Erlotinib:Osimertinib  0    0  0.93 [0.39;    2.20]      .             .   0.93 [0.39;    2.20]    .             .     .       .
                       Erlotinib:Osimertinib + chemotherapy  0    0  0.60 [0.16;    2.23]      .             .   0.60 [0.16;    2.23]    .             .     .       .
                     Erlotinib:Osimertinib + antiangiogenesis  0    0  0.12 [0.04;    0.38]      .             .   0.12 [0.04;    0.38]    .             .     .       .
                                Erlotinib:PD-L1 inhibitor  0    0  2.19 [0.15;   32.53]      .             .   2.19 [0.15;   32.53]    .             .     .       .
                                        Erlotinib:Placebo  3 0.59  1.13 [0.62;    2.05]   0.70 [0.32;  1.53]   2.22 [0.88;    5.64] 0.32 [0.09;  1.06] -1.86  0.0628
                                    Erlotinib:Rociletinib  1 1.00  3.00 [0.11;   85.02]   3.00 [0.11; 85.02]      .               .    .             .     .       .
                                 Erlotinib:antiangiogenesis  2 0.79  0.15 [0.07;    0.30]   0.16 [0.07;  0.36]   0.10 [0.02;    0.48] 1.55 [0.27;  8.74]  0.50  0.6197
     Erlotinib + Autophagy inhibitor:Erlotinib + chemotherapy  0    0  0.20 [0.04;    1.10]      .             .   0.20 [0.04;    1.10]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + COX2 inhibitor  0    0  0.04 [0.00;    1.42]      .             .   0.04 [0.00;    1.42]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Erlotinib + ER inhibitor  0    0  0.09 [0.01;    0.54]      .             .   0.09 [0.01;    0.54]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + HER3 inhibitor  0    0  0.46 [0.05;    4.57]      .             .   0.46 [0.05;    4.57]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + HGF inhibitor  0    0  0.28 [0.01;    7.90]      .             .   0.28 [0.01;    7.90]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.07 [0.01;    0.37]      .             .   0.07 [0.01;    0.37]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MET inhibitor  0    0  0.23 [0.05;    1.05]      .             .   0.23 [0.05;    1.05]    .             .     .       .
    Erlotinib + Autophagy inhibitor:Erlotinib + MMP inhibitor  0    0  1.25 [0.13;   11.89]      .             .   1.25 [0.13;   11.89]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Erlotinib + antiangiogenesis  0    0  0.05 [0.01;    0.22]      .             .   0.05 [0.01;    0.22]    .             .     .       .
                  Erlotinib + Autophagy inhibitor:Gefitinib  0    0  0.22 [0.05;    0.99]      .             .   0.22 [0.05;    0.99]    .             .     .       .
        Erlotinib + Autophagy inhibitor:Gefitinib/Erlotinib  0    0  0.34 [0.05;    2.35]      .             .   0.34 [0.05;    2.35]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + chemotherapy  0    0  0.17 [0.03;    0.88]      .             .   0.17 [0.03;    0.88]    .             .     .       .
     Erlotinib + Autophagy inhibitor:Gefitinib + ER inhibitor  0    0  0.05 [0.01;    0.32]      .             .   0.05 [0.01;    0.32]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Gefitinib + antiangiogenesis  0    0  0.02 [0.00;    0.11]      .             .   0.02 [0.00;    0.11]    .             .     .       .
                 Erlotinib + Autophagy inhibitor:Lazertinib  0    0  0.16 [0.03;    0.83]      .             .   0.16 [0.03;    0.83]    .             .     .       .
                Erlotinib + Autophagy inhibitor:Osimertinib  0    0  0.21 [0.04;    1.05]      .             .   0.21 [0.04;    1.05]    .             .     .       .
   Erlotinib + Autophagy inhibitor:Osimertinib + chemotherapy  0    0  0.14 [0.02;    0.90]      .             .   0.14 [0.02;    0.90]    .             .     .       .
 Erlotinib + Autophagy inhibitor:Osimertinib + antiangiogenesis  0    0  0.03 [0.00;    0.16]      .             .   0.03 [0.00;    0.16]    .             .     .       .
            Erlotinib + Autophagy inhibitor:PD-L1 inhibitor  0    0  0.50 [0.02;   10.17]      .             .   0.50 [0.02;   10.17]    .             .     .       .
                    Erlotinib + Autophagy inhibitor:Placebo  0    0  0.25 [0.06;    1.13]      .             .   0.25 [0.06;    1.13]    .             .     .       .
                Erlotinib + Autophagy inhibitor:Rociletinib  0    0  0.68 [0.02;   25.09]      .             .   0.68 [0.02;   25.09]    .             .     .       .
             Erlotinib + Autophagy inhibitor:antiangiogenesis  0    0  0.03 [0.01;    0.15]      .             .   0.03 [0.01;    0.15]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + COX2 inhibitor  0    0  0.22 [0.01;    6.10]      .             .   0.22 [0.01;    6.10]    .             .     .       .
            Erlotinib + chemotherapy:Erlotinib + ER inhibitor  0    0  0.42 [0.09;    2.02]      .             .   0.42 [0.09;    2.02]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + HER3 inhibitor  0    0  2.24 [0.27;   18.34]      .             .   2.24 [0.27;   18.34]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + HGF inhibitor  0    0  1.38 [0.06;   33.79]      .             .   1.38 [0.06;   33.79]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + IGF-1R inhibitor  0    0  0.34 [0.08;    1.35]      .             .   0.34 [0.08;    1.35]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + MET inhibitor  0    0  1.14 [0.35;    3.69]      .             .   1.14 [0.35;    3.69]    .             .     .       .
           Erlotinib + chemotherapy:Erlotinib + MMP inhibitor  0    0  6.13 [0.79;   47.46]      .             .   6.13 [0.79;   47.46]    .             .     .       .
          Erlotinib + chemotherapy:Erlotinib + antiangiogenesis  0    0  0.27 [0.09;    0.76]      .             .   0.27 [0.09;    0.76]    .             .     .       .
                         Erlotinib + chemotherapy:Gefitinib  0    0  1.07 [0.33;    3.43]      .             .   1.07 [0.33;    3.43]    .             .     .       .
               Erlotinib + chemotherapy:Gefitinib/Erlotinib  0    0  1.65 [0.31;    8.86]      .             .   1.65 [0.31;    8.86]    .             .     .       .
            Erlotinib + chemotherapy:Gefitinib + chemotherapy  0    0  0.84 [0.23;    3.15]      .             .   0.84 [0.23;    3.15]    .             .     .       .
            Erlotinib + chemotherapy:Gefitinib + ER inhibitor  0    0  0.26 [0.06;    1.21]      .             .   0.26 [0.06;    1.21]    .             .     .       .
          Erlotinib + chemotherapy:Gefitinib + antiangiogenesis  0    0  0.09 [0.02;    0.42]      .             .   0.09 [0.02;    0.42]    .             .     .       .
                        Erlotinib + chemotherapy:Lazertinib  0    0  0.77 [0.20;    2.99]      .             .   0.77 [0.20;    2.99]    .             .     .       .
                       Erlotinib + chemotherapy:Osimertinib  0    0  1.03 [0.28;    3.72]      .             .   1.03 [0.28;    3.72]    .             .     .       .
          Erlotinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.66 [0.13;    3.36]      .             .   0.66 [0.13;    3.36]    .             .     .       .
        Erlotinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.13 [0.03;    0.59]      .             .   0.13 [0.03;    0.59]    .             .     .       .
                   Erlotinib + chemotherapy:PD-L1 inhibitor  0    0  2.43 [0.14;   42.40]      .             .   2.43 [0.14;   42.40]    .             .     .       .
                           Erlotinib + chemotherapy:Placebo  0    0  1.25 [0.40;    3.93]      .             .   1.25 [0.40;    3.93]    .             .     .       .
                       Erlotinib + chemotherapy:Rociletinib  0    0  3.32 [0.10;  108.53]      .             .   3.32 [0.10;  108.53]    .             .     .       .
                    Erlotinib + chemotherapy:antiangiogenesis  0    0  0.16 [0.05;    0.54]      .             .   0.16 [0.05;    0.54]    .             .     .       .
          Erlotinib + COX2 inhibitor:Erlotinib + ER inhibitor  0    0  1.95 [0.06;   58.98]      .             .   1.95 [0.06;   58.98]    .             .     .       .
        Erlotinib + COX2 inhibitor:Erlotinib + HER3 inhibitor  0    0 10.34 [0.26;  412.04]      .             .  10.34 [0.26;  412.04]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + HGF inhibitor  0    0  6.37 [0.08;  520.27]      .             .   6.37 [0.08;  520.27]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + IGF-1R inhibitor  0    0  1.56 [0.06;   43.43]      .             .   1.56 [0.06;   43.43]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + MET inhibitor  0    0  5.23 [0.20;  134.87]      .             .   5.23 [0.20;  134.87]    .             .     .       .
         Erlotinib + COX2 inhibitor:Erlotinib + MMP inhibitor  0    0 28.26 [0.73; 1092.00]      .             .  28.26 [0.73; 1092.00]    .             .     .       .
        Erlotinib + COX2 inhibitor:Erlotinib + antiangiogenesis  0    0  1.23 [0.05;   30.31]      .             .   1.23 [0.05;   30.31]    .             .     .       .
                       Erlotinib + COX2 inhibitor:Gefitinib  0    0  4.94 [0.19;  127.41]      .             .   4.94 [0.19;  127.41]    .             .     .       .
             Erlotinib + COX2 inhibitor:Gefitinib/Erlotinib  0    0  7.62 [0.24;  245.19]      .             .   7.62 [0.24;  245.19]    .             .     .       .
          Erlotinib + COX2 inhibitor:Gefitinib + chemotherapy  0    0  3.89 [0.14;  106.44]      .             .   3.89 [0.14;  106.44]    .             .     .       .
          Erlotinib + COX2 inhibitor:Gefitinib + ER inhibitor  0    0  1.21 [0.04;   36.09]      .             .   1.21 [0.04;   36.09]    .             .     .       .
        Erlotinib + COX2 inhibitor:Gefitinib + antiangiogenesis  0    0  0.42 [0.01;   12.44]      .             .   0.42 [0.01;   12.44]    .             .     .       .
                      Erlotinib + COX2 inhibitor:Lazertinib  0    0  3.54 [0.13;   98.64]      .             .   3.54 [0.13;   98.64]    .             .     .       .
                     Erlotinib + COX2 inhibitor:Osimertinib  0    0  4.74 [0.18;  128.60]      .             .   4.74 [0.18;  128.60]    .             .     .       .
        Erlotinib + COX2 inhibitor:Osimertinib + chemotherapy  0    0  3.05 [0.10;   95.73]      .             .   3.05 [0.10;   95.73]    .             .     .       .
      Erlotinib + COX2 inhibitor:Osimertinib + antiangiogenesis  0    0  0.59 [0.02;   17.73]      .             .   0.59 [0.02;   17.73]    .             .     .       .
                 Erlotinib + COX2 inhibitor:PD-L1 inhibitor  0    0 11.18 [0.17;  726.31]      .             .  11.18 [0.17;  726.31]    .             .     .       .
                         Erlotinib + COX2 inhibitor:Placebo  0    0  5.75 [0.22;  147.08]      .             .   5.75 [0.22;  147.08]    .             .     .       .
                     Erlotinib + COX2 inhibitor:Rociletinib  0    0 15.29 [0.15; 1549.57]      .             .  15.29 [0.15; 1549.57]    .             .     .       .
                  Erlotinib + COX2 inhibitor:antiangiogenesis  0    0  0.74 [0.03;   19.44]      .             .   0.74 [0.03;   19.44]    .             .     .       .
          Erlotinib + ER inhibitor:Erlotinib + HER3 inhibitor  0    0  5.31 [0.58;   48.73]      .             .   5.31 [0.58;   48.73]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + HGF inhibitor  0    0  3.27 [0.12;   86.41]      .             .   3.27 [0.12;   86.41]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.80 [0.17;    3.78]      .             .   0.80 [0.17;    3.78]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MET inhibitor  0    0  2.69 [0.68;   10.63]      .             .   2.69 [0.68;   10.63]    .             .     .       .
           Erlotinib + ER inhibitor:Erlotinib + MMP inhibitor  0    0 14.51 [1.67;  126.49]      .             .  14.51 [1.67;  126.49]    .             .     .       .
          Erlotinib + ER inhibitor:Erlotinib + antiangiogenesis  0    0  0.63 [0.18;    2.23]      .             .   0.63 [0.18;    2.23]    .             .     .       .
                         Erlotinib + ER inhibitor:Gefitinib  1 0.81  2.54 [0.77;    8.32]   2.17 [0.58;  8.11]   4.94 [0.33;   74.63] 0.44 [0.02;  8.98] -0.54  0.5925
               Erlotinib + ER inhibitor:Gefitinib/Erlotinib  0    0  3.91 [0.66;   23.03]      .             .   3.91 [0.66;   23.03]    .             .     .       .
            Erlotinib + ER inhibitor:Gefitinib + chemotherapy  0    0  2.00 [0.52;    7.62]      .             .   2.00 [0.52;    7.62]    .             .     .       .
            Erlotinib + ER inhibitor:Gefitinib + ER inhibitor  1 1.00  0.62 [0.19;    2.03]   0.62 [0.19;  2.03]      .               .    .             .     .       .
          Erlotinib + ER inhibitor:Gefitinib + antiangiogenesis  0    0  0.21 [0.05;    1.00]      .             .   0.21 [0.05;    1.00]    .             .     .       .
                        Erlotinib + ER inhibitor:Lazertinib  0    0  1.82 [0.43;    7.61]      .             .   1.82 [0.43;    7.61]    .             .     .       .
                       Erlotinib + ER inhibitor:Osimertinib  0    0  2.44 [0.60;    9.95]      .             .   2.44 [0.60;    9.95]    .             .     .       .
          Erlotinib + ER inhibitor:Osimertinib + chemotherapy  0    0  1.57 [0.28;    8.77]      .             .   1.57 [0.28;    8.77]    .             .     .       .
        Erlotinib + ER inhibitor:Osimertinib + antiangiogenesis  0    0  0.30 [0.06;    1.54]      .             .   0.30 [0.06;    1.54]    .             .     .       .
                   Erlotinib + ER inhibitor:PD-L1 inhibitor  0    0  5.74 [0.31;  106.16]      .             .   5.74 [0.31;  106.16]    .             .     .       .
                           Erlotinib + ER inhibitor:Placebo  0    0  2.95 [0.81;   10.81]      .             .   2.95 [0.81;   10.81]    .             .     .       .
                       Erlotinib + ER inhibitor:Rociletinib  0    0  7.85 [0.22;  275.78]      .             .   7.85 [0.22;  275.78]    .             .     .       .
                    Erlotinib + ER inhibitor:antiangiogenesis  0    0  0.38 [0.09;    1.54]      .             .   0.38 [0.09;    1.54]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + HGF inhibitor  0    0  0.62 [0.02;   21.64]      .             .   0.62 [0.02;   21.64]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.15 [0.02;    1.22]      .             .   0.15 [0.02;    1.22]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MET inhibitor  0    0  0.51 [0.07;    3.59]      .             .   0.51 [0.07;    3.59]    .             .     .       .
         Erlotinib + HER3 inhibitor:Erlotinib + MMP inhibitor  0    0  2.73 [0.21;   35.92]      .             .   2.73 [0.21;   35.92]    .             .     .       .
        Erlotinib + HER3 inhibitor:Erlotinib + antiangiogenesis  0    0  0.12 [0.02;    0.78]      .             .   0.12 [0.02;    0.78]    .             .     .       .
                       Erlotinib + HER3 inhibitor:Gefitinib  0    0  0.48 [0.07;    3.39]      .             .   0.48 [0.07;    3.39]    .             .     .       .
             Erlotinib + HER3 inhibitor:Gefitinib/Erlotinib  0    0  0.74 [0.07;    7.42]      .             .   0.74 [0.07;    7.42]    .             .     .       .
          Erlotinib + HER3 inhibitor:Gefitinib + chemotherapy  0    0  0.38 [0.05;    2.94]      .             .   0.38 [0.05;    2.94]    .             .     .       .
          Erlotinib + HER3 inhibitor:Gefitinib + ER inhibitor  0    0  0.12 [0.01;    1.05]      .             .   0.12 [0.01;    1.05]    .             .     .       .
        Erlotinib + HER3 inhibitor:Gefitinib + antiangiogenesis  0    0  0.04 [0.00;    0.36]      .             .   0.04 [0.00;    0.36]    .             .     .       .
                      Erlotinib + HER3 inhibitor:Lazertinib  0    0  0.34 [0.04;    2.76]      .             .   0.34 [0.04;    2.76]    .             .     .       .
                     Erlotinib + HER3 inhibitor:Osimertinib  0    0  0.46 [0.06;    3.54]      .             .   0.46 [0.06;    3.54]    .             .     .       .
        Erlotinib + HER3 inhibitor:Osimertinib + chemotherapy  0    0  0.30 [0.03;    2.86]      .             .   0.30 [0.03;    2.86]    .             .     .       .
      Erlotinib + HER3 inhibitor:Osimertinib + antiangiogenesis  0    0  0.06 [0.01;    0.52]      .             .   0.06 [0.01;    0.52]    .             .     .       .
                 Erlotinib + HER3 inhibitor:PD-L1 inhibitor  0    0  1.08 [0.04;   28.48]      .             .   1.08 [0.04;   28.48]    .             .     .       .
                         Erlotinib + HER3 inhibitor:Placebo  0    0  0.56 [0.08;    3.90]      .             .   0.56 [0.08;    3.90]    .             .     .       .
                     Erlotinib + HER3 inhibitor:Rociletinib  0    0  1.48 [0.03;   67.61]      .             .   1.48 [0.03;   67.61]    .             .     .       .
                  Erlotinib + HER3 inhibitor:antiangiogenesis  0    0  0.07 [0.01;    0.52]      .             .   0.07 [0.01;    0.52]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + IGF-1R inhibitor  0    0  0.24 [0.01;    5.93]      .             .   0.24 [0.01;    5.93]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MET inhibitor  0    0  0.82 [0.04;   18.34]      .             .   0.82 [0.04;   18.34]    .             .     .       .
          Erlotinib + HGF inhibitor:Erlotinib + MMP inhibitor  0    0  4.44 [0.13;  150.98]      .             .   4.44 [0.13;  150.98]    .             .     .       .
         Erlotinib + HGF inhibitor:Erlotinib + antiangiogenesis  0    0  0.19 [0.01;    4.11]      .             .   0.19 [0.01;    4.11]    .             .     .       .
                        Erlotinib + HGF inhibitor:Gefitinib  0    0  0.78 [0.03;   17.33]      .             .   0.78 [0.03;   17.33]    .             .     .       .
              Erlotinib + HGF inhibitor:Gefitinib/Erlotinib  0    0  1.20 [0.04;   33.67]      .             .   1.20 [0.04;   33.67]    .             .     .       .
           Erlotinib + HGF inhibitor:Gefitinib + chemotherapy  0    0  0.61 [0.03;   14.51]      .             .   0.61 [0.03;   14.51]    .             .     .       .
           Erlotinib + HGF inhibitor:Gefitinib + ER inhibitor  0    0  0.19 [0.01;    4.94]      .             .   0.19 [0.01;    4.94]    .             .     .       .
         Erlotinib + HGF inhibitor:Gefitinib + antiangiogenesis  0    0  0.07 [0.00;    1.70]      .             .   0.07 [0.00;    1.70]    .             .     .       .
                       Erlotinib + HGF inhibitor:Lazertinib  0    0  0.56 [0.02;   13.46]      .             .   0.56 [0.02;   13.46]    .             .     .       .
                      Erlotinib + HGF inhibitor:Osimertinib  0    0  0.74 [0.03;   17.53]      .             .   0.74 [0.03;   17.53]    .             .     .       .
         Erlotinib + HGF inhibitor:Osimertinib + chemotherapy  0    0  0.48 [0.02;   13.13]      .             .   0.48 [0.02;   13.13]    .             .     .       .
       Erlotinib + HGF inhibitor:Osimertinib + antiangiogenesis  0    0  0.09 [0.00;    2.43]      .             .   0.09 [0.00;    2.43]    .             .     .       .
                  Erlotinib + HGF inhibitor:PD-L1 inhibitor  0    0  1.76 [0.03;  102.07]      .             .   1.76 [0.03;  102.07]    .             .     .       .
                          Erlotinib + HGF inhibitor:Placebo  0    0  0.90 [0.04;   19.99]      .             .   0.90 [0.04;   19.99]    .             .     .       .
                      Erlotinib + HGF inhibitor:Rociletinib  0    0  2.40 [0.03;  220.16]      .             .   2.40 [0.03;  220.16]    .             .     .       .
                   Erlotinib + HGF inhibitor:antiangiogenesis  0    0  0.12 [0.01;    2.65]      .             .   0.12 [0.01;    2.65]    .             .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MET inhibitor  0    0  3.36 [1.06;   10.71]      .             .   3.36 [1.06;   10.71]    .             .     .       .
          Erlotinib + IGF-1R inhibitor:Erlotinib + MMP inhibitor  0    0 18.16 [2.38;  138.85]      .             .  18.16 [2.38;  138.85]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Erlotinib + antiangiogenesis  0    0  0.79 [0.28;    2.20]      .             .   0.79 [0.28;    2.20]    .             .     .       .
                        Erlotinib + IGF-1R inhibitor:Gefitinib  0    0  3.17 [0.99;   10.14]      .             .   3.17 [0.99;   10.14]    .             .     .       .
              Erlotinib + IGF-1R inhibitor:Gefitinib/Erlotinib  0    0  4.89 [0.91;   26.38]      .             .   4.89 [0.91;   26.38]    .             .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + chemotherapy  0    0  2.50 [0.67;    9.32]      .             .   2.50 [0.67;    9.32]    .             .     .       .
           Erlotinib + IGF-1R inhibitor:Gefitinib + ER inhibitor  0    0  0.78 [0.17;    3.54]      .             .   0.78 [0.17;    3.54]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Gefitinib + antiangiogenesis  0    0  0.27 [0.06;    1.23]      .             .   0.27 [0.06;    1.23]    .             .     .       .
                       Erlotinib + IGF-1R inhibitor:Lazertinib  0    0  2.27 [0.58;    8.89]      .             .   2.27 [0.58;    8.89]    .             .     .       .
                      Erlotinib + IGF-1R inhibitor:Osimertinib  0    0  3.05 [0.84;   11.11]      .             .   3.05 [0.84;   11.11]    .             .     .       .
         Erlotinib + IGF-1R inhibitor:Osimertinib + chemotherapy  0    0  1.96 [0.38;   10.02]      .             .   1.96 [0.38;   10.02]    .             .     .       .
       Erlotinib + IGF-1R inhibitor:Osimertinib + antiangiogenesis  0    0  0.38 [0.08;    1.75]      .             .   0.38 [0.08;    1.75]    .             .     .       .
                  Erlotinib + IGF-1R inhibitor:PD-L1 inhibitor  0    0  7.19 [0.41;  126.00]      .             .   7.19 [0.41;  126.00]    .             .     .       .
                          Erlotinib + IGF-1R inhibitor:Placebo  0    0  3.70 [1.19;   11.51]      .             .   3.70 [1.19;   11.51]    .             .     .       .
                      Erlotinib + IGF-1R inhibitor:Rociletinib  0    0  9.82 [0.30;  319.20]      .             .   9.82 [0.30;  319.20]    .             .     .       .
                   Erlotinib + IGF-1R inhibitor:antiangiogenesis  0    0  0.48 [0.14;    1.58]      .             .   0.48 [0.14;    1.58]    .             .     .       .
          Erlotinib + MET inhibitor:Erlotinib + MMP inhibitor  0    0  5.40 [0.81;   36.12]      .             .   5.40 [0.81;   36.12]    .             .     .       .
         Erlotinib + MET inhibitor:Erlotinib + antiangiogenesis  0    0  0.24 [0.11;    0.48]      .             .   0.24 [0.11;    0.48]    .             .     .       .
                        Erlotinib + MET inhibitor:Gefitinib  0    0  0.94 [0.38;    2.34]      .             .   0.94 [0.38;    2.34]    .             .     .       .
              Erlotinib + MET inhibitor:Gefitinib/Erlotinib  0    0  1.45 [0.32;    6.66]      .             .   1.45 [0.32;    6.66]    .             .     .       .
           Erlotinib + MET inhibitor:Gefitinib + chemotherapy  0    0  0.74 [0.25;    2.23]      .             .   0.74 [0.25;    2.23]    .             .     .       .
           Erlotinib + MET inhibitor:Gefitinib + ER inhibitor  0    0  0.23 [0.06;    0.87]      .             .   0.23 [0.06;    0.87]    .             .     .       .
         Erlotinib + MET inhibitor:Gefitinib + antiangiogenesis  0    0  0.08 [0.02;    0.30]      .             .   0.08 [0.02;    0.30]    .             .     .       .
                       Erlotinib + MET inhibitor:Lazertinib  0    0  0.68 [0.21;    2.15]      .             .   0.68 [0.21;    2.15]    .             .     .       .
                      Erlotinib + MET inhibitor:Osimertinib  0    0  0.91 [0.31;    2.64]      .             .   0.91 [0.31;    2.64]    .             .     .       .
         Erlotinib + MET inhibitor:Osimertinib + chemotherapy  0    0  0.58 [0.14;    2.51]      .             .   0.58 [0.14;    2.51]    .             .     .       .
       Erlotinib + MET inhibitor:Osimertinib + antiangiogenesis  0    0  0.11 [0.03;    0.43]      .             .   0.11 [0.03;    0.43]    .             .     .       .
                  Erlotinib + MET inhibitor:PD-L1 inhibitor  0    0  2.14 [0.13;   34.12]      .             .   2.14 [0.13;   34.12]    .             .     .       .
                          Erlotinib + MET inhibitor:Placebo  0    0  1.10 [0.46;    2.64]      .             .   1.10 [0.46;    2.64]    .             .     .       .
                      Erlotinib + MET inhibitor:Rociletinib  0    0  2.92 [0.10;   87.92]      .             .   2.92 [0.10;   87.92]    .             .     .       .
                   Erlotinib + MET inhibitor:antiangiogenesis  0    0  0.14 [0.05;    0.37]      .             .   0.14 [0.05;    0.37]    .             .     .       .
         Erlotinib + MMP inhibitor:Erlotinib + antiangiogenesis  0    0  0.04 [0.01;    0.27]      .             .   0.04 [0.01;    0.27]    .             .     .       .
                        Erlotinib + MMP inhibitor:Gefitinib  0    0  0.17 [0.03;    1.17]      .             .   0.17 [0.03;    1.17]    .             .     .       .
              Erlotinib + MMP inhibitor:Gefitinib/Erlotinib  0    0  0.27 [0.03;    2.58]      .             .   0.27 [0.03;    2.58]    .             .     .       .
           Erlotinib + MMP inhibitor:Gefitinib + chemotherapy  0    0  0.14 [0.02;    1.02]      .             .   0.14 [0.02;    1.02]    .             .     .       .
           Erlotinib + MMP inhibitor:Gefitinib + ER inhibitor  0    0  0.04 [0.01;    0.36]      .             .   0.04 [0.01;    0.36]    .             .     .       .
         Erlotinib + MMP inhibitor:Gefitinib + antiangiogenesis  0    0  0.01 [0.00;    0.13]      .             .   0.01 [0.00;    0.13]    .             .     .       .
                       Erlotinib + MMP inhibitor:Lazertinib  0    0  0.13 [0.02;    0.96]      .             .   0.13 [0.02;    0.96]    .             .     .       .
                      Erlotinib + MMP inhibitor:Osimertinib  0    0  0.17 [0.02;    1.22]      .             .   0.17 [0.02;    1.22]    .             .     .       .
         Erlotinib + MMP inhibitor:Osimertinib + chemotherapy  0    0  0.11 [0.01;    0.99]      .             .   0.11 [0.01;    0.99]    .             .     .       .
       Erlotinib + MMP inhibitor:Osimertinib + antiangiogenesis  0    0  0.02 [0.00;    0.18]      .             .   0.02 [0.00;    0.18]    .             .     .       .
                  Erlotinib + MMP inhibitor:PD-L1 inhibitor  0    0  0.40 [0.02;   10.07]      .             .   0.40 [0.02;   10.07]    .             .     .       .
                          Erlotinib + MMP inhibitor:Placebo  0    0  0.20 [0.03;    1.34]      .             .   0.20 [0.03;    1.34]    .             .     .       .
                      Erlotinib + MMP inhibitor:Rociletinib  0    0  0.54 [0.01;   24.01]      .             .   0.54 [0.01;   24.01]    .             .     .       .
                   Erlotinib + MMP inhibitor:antiangiogenesis  0    0  0.03 [0.00;    0.18]      .             .   0.03 [0.00;    0.18]    .             .     .       .
                       Erlotinib + antiangiogenesis:Gefitinib  0    0  4.01 [1.94;    8.28]      .             .   4.01 [1.94;    8.28]    .             .     .       .
             Erlotinib + antiangiogenesis:Gefitinib/Erlotinib  0    0  6.19 [1.50;   25.58]      .             .   6.19 [1.50;   25.58]    .             .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + chemotherapy  0    0  3.16 [1.22;    8.18]      .             .   3.16 [1.22;    8.18]    .             .     .       .
          Erlotinib + antiangiogenesis:Gefitinib + ER inhibitor  0    0  0.99 [0.29;    3.31]      .             .   0.99 [0.29;    3.31]    .             .     .       .
        Erlotinib + antiangiogenesis:Gefitinib + antiangiogenesis  0    0  0.34 [0.10;    1.15]      .             .   0.34 [0.10;    1.15]    .             .     .       .
                      Erlotinib + antiangiogenesis:Lazertinib  0    0  2.87 [1.04;    7.95]      .             .   2.87 [1.04;    7.95]    .             .     .       .
                     Erlotinib + antiangiogenesis:Osimertinib  0    0  3.85 [1.53;    9.68]      .             .   3.85 [1.53;    9.68]    .             .     .       .
        Erlotinib + antiangiogenesis:Osimertinib + chemotherapy  0    0  2.48 [0.64;    9.61]      .             .   2.48 [0.64;    9.61]    .             .     .       .
      Erlotinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  0.48 [0.14;    1.64]      .             .   0.48 [0.14;    1.64]    .             .     .       .
                 Erlotinib + antiangiogenesis:PD-L1 inhibitor  0    0  9.08 [0.60;  137.41]      .             .   9.08 [0.60;  137.41]    .             .     .       .
                         Erlotinib + antiangiogenesis:Placebo  0    0  4.67 [2.36;    9.27]      .             .   4.67 [2.36;    9.27]    .             .     .       .
                     Erlotinib + antiangiogenesis:Rociletinib  0    0 12.42 [0.43;  357.79]      .             .  12.42 [0.43;  357.79]    .             .     .       .
                  Erlotinib + antiangiogenesis:antiangiogenesis  1 0.35  0.60 [0.29;    1.28]   0.51 [0.14;  1.81]   0.66 [0.26;    1.68] 0.76 [0.16;  3.69] -0.34  0.7376
                            Gefitinib:Gefitinib/Erlotinib  0    0  1.54 [0.39;    6.14]      .             .   1.54 [0.39;    6.14]    .             .     .       .
                         Gefitinib:Gefitinib + chemotherapy  4 1.00  0.79 [0.43;    1.46]   0.79 [0.43;  1.46]      .               .    .             .     .       .
                         Gefitinib:Gefitinib + ER inhibitor  1 0.79  0.25 [0.08;    0.76]   0.29 [0.08;  1.03]   0.13 [0.01;    1.62] 2.14 [0.13; 35.08]  0.54  0.5925
                       Gefitinib:Gefitinib + antiangiogenesis  2 1.00  0.08 [0.03;    0.23]   0.08 [0.03;  0.23]      .               .    .             .     .       .
                                     Gefitinib:Lazertinib  1 0.65  0.72 [0.30;    1.69]   0.76 [0.26;  2.20]   0.64 [0.15;    2.74] 1.19 [0.20;  7.20]  0.19  0.8498
                                    Gefitinib:Osimertinib  0    0  0.96 [0.41;    2.27]      .             .   0.96 [0.41;    2.27]    .             .     .       .
                       Gefitinib:Osimertinib + chemotherapy  0    0  0.62 [0.17;    2.30]      .             .   0.62 [0.17;    2.30]    .             .     .       .
                     Gefitinib:Osimertinib + antiangiogenesis  0    0  0.12 [0.04;    0.39]      .             .   0.12 [0.04;    0.39]    .             .     .       .
                                Gefitinib:PD-L1 inhibitor  0    0  2.26 [0.15;   33.58]      .             .   2.26 [0.15;   33.58]    .             .     .       .
                                        Gefitinib:Placebo  2 0.25  1.16 [0.57;    2.37]   1.63 [0.39;  6.79]   1.04 [0.46;    2.36] 1.57 [0.30;  8.12]  0.54  0.5917
                                    Gefitinib:Rociletinib  0    0  3.10 [0.10;   93.32]      .             .   3.10 [0.10;   93.32]    .             .     .       .
                                 Gefitinib:antiangiogenesis  1 0.17  0.15 [0.06;    0.38]   0.06 [0.01;  0.60]   0.18 [0.07;    0.49] 0.36 [0.03;  4.18] -0.82  0.4132
               Gefitinib/Erlotinib:Gefitinib + chemotherapy  0    0  0.51 [0.11;    2.32]      .             .   0.51 [0.11;    2.32]    .             .     .       .
               Gefitinib/Erlotinib:Gefitinib + ER inhibitor  0    0  0.16 [0.03;    0.91]      .             .   0.16 [0.03;    0.91]    .             .     .       .
             Gefitinib/Erlotinib:Gefitinib + antiangiogenesis  0    0  0.05 [0.01;    0.30]      .             .   0.05 [0.01;    0.30]    .             .     .       .
                           Gefitinib/Erlotinib:Lazertinib  0    0  0.46 [0.12;    1.81]      .             .   0.46 [0.12;    1.81]    .             .     .       .
                          Gefitinib/Erlotinib:Osimertinib  1 1.00  0.62 [0.21;    1.83]   0.62 [0.21;  1.83]      .               .    .             .     .       .
             Gefitinib/Erlotinib:Osimertinib + chemotherapy  0    0  0.40 [0.09;    1.74]      .             .   0.40 [0.09;    1.74]    .             .     .       .
           Gefitinib/Erlotinib:Osimertinib + antiangiogenesis  0    0  0.08 [0.02;    0.30]      .             .   0.08 [0.02;    0.30]    .             .     .       .
                      Gefitinib/Erlotinib:PD-L1 inhibitor  0    0  1.47 [0.09;   23.53]      .             .   1.47 [0.09;   23.53]    .             .     .       .
                              Gefitinib/Erlotinib:Placebo  0    0  0.76 [0.19;    3.00]      .             .   0.76 [0.19;    3.00]    .             .     .       .
                          Gefitinib/Erlotinib:Rociletinib  0    0  2.01 [0.05;   74.78]      .             .   2.01 [0.05;   74.78]    .             .     .       .
                       Gefitinib/Erlotinib:antiangiogenesis  0    0  0.10 [0.02;    0.45]      .             .   0.10 [0.02;    0.45]    .             .     .       .
            Gefitinib + chemotherapy:Gefitinib + ER inhibitor  0    0  0.31 [0.09;    1.13]      .             .   0.31 [0.09;    1.13]    .             .     .       .
          Gefitinib + chemotherapy:Gefitinib + antiangiogenesis  0    0  0.11 [0.03;    0.34]      .             .   0.11 [0.03;    0.34]    .             .     .       .
                        Gefitinib + chemotherapy:Lazertinib  0    0  0.91 [0.32;    2.61]      .             .   0.91 [0.32;    2.61]    .             .     .       .
                       Gefitinib + chemotherapy:Osimertinib  0    0  1.22 [0.42;    3.51]      .             .   1.22 [0.42;    3.51]    .             .     .       .
          Gefitinib + chemotherapy:Osimertinib + chemotherapy  0    0  0.78 [0.18;    3.35]      .             .   0.78 [0.18;    3.35]    .             .     .       .
        Gefitinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.15 [0.04;    0.58]      .             .   0.15 [0.04;    0.58]    .             .     .       .
                   Gefitinib + chemotherapy:PD-L1 inhibitor  0    0  2.87 [0.18;   45.65]      .             .   2.87 [0.18;   45.65]    .             .     .       .
                           Gefitinib + chemotherapy:Placebo  0    0  1.48 [0.58;    3.78]      .             .   1.48 [0.58;    3.78]    .             .     .       .
                       Gefitinib + chemotherapy:Rociletinib  0    0  3.93 [0.12;  125.05]      .             .   3.93 [0.12;  125.05]    .             .     .       .
                    Gefitinib + chemotherapy:antiangiogenesis  0    0  0.19 [0.06;    0.57]      .             .   0.19 [0.06;    0.57]    .             .     .       .
          Gefitinib + ER inhibitor:Gefitinib + antiangiogenesis  0    0  0.34 [0.08;    1.54]      .             .   0.34 [0.08;    1.54]    .             .     .       .
                        Gefitinib + ER inhibitor:Lazertinib  0    0  2.91 [0.73;   11.66]      .             .   2.91 [0.73;   11.66]    .             .     .       .
                       Gefitinib + ER inhibitor:Osimertinib  0    0  3.91 [1.00;   15.22]      .             .   3.91 [1.00;   15.22]    .             .     .       .
          Gefitinib + ER inhibitor:Osimertinib + chemotherapy  0    0  2.51 [0.47;   13.54]      .             .   2.51 [0.47;   13.54]    .             .     .       .
        Gefitinib + ER inhibitor:Osimertinib + antiangiogenesis  0    0  0.49 [0.10;    2.38]      .             .   0.49 [0.10;    2.38]    .             .     .       .
                   Gefitinib + ER inhibitor:PD-L1 inhibitor  0    0  9.21 [0.51;  166.46]      .             .   9.21 [0.51;  166.46]    .             .     .       .
                           Gefitinib + ER inhibitor:Placebo  0    0  4.74 [1.36;   16.47]      .             .   4.74 [1.36;   16.47]    .             .     .       .
                       Gefitinib + ER inhibitor:Rociletinib  0    0 12.59 [0.36;  434.16]      .             .  12.59 [0.36;  434.16]    .             .     .       .
                    Gefitinib + ER inhibitor:antiangiogenesis  0    0  0.61 [0.16;    2.35]      .             .   0.61 [0.16;    2.35]    .             .     .       .
                      Gefitinib + antiangiogenesis:Lazertinib  0    0  8.51 [2.29;   31.57]      .             .   8.51 [2.29;   31.57]    .             .     .       .
                     Gefitinib + antiangiogenesis:Osimertinib  0    0 11.41 [3.07;   42.42]      .             .  11.41 [3.07;   42.42]    .             .     .       .
        Gefitinib + antiangiogenesis:Osimertinib + chemotherapy  0    0  7.34 [1.41;   38.09]      .             .   7.34 [1.41;   38.09]    .             .     .       .
      Gefitinib + antiangiogenesis:Osimertinib + antiangiogenesis  0    0  1.43 [0.31;    6.67]      .             .   1.43 [0.31;    6.67]    .             .     .       .
                 Gefitinib + antiangiogenesis:PD-L1 inhibitor  0    0 26.90 [1.52;  475.88]      .             .  26.90 [1.52;  475.88]    .             .     .       .
                         Gefitinib + antiangiogenesis:Placebo  0    0 13.83 [4.09;   46.85]      .             .  13.83 [4.09;   46.85]    .             .     .       .
                     Gefitinib + antiangiogenesis:Rociletinib  0    0 36.77 [1.06; 1276.64]      .             .  36.77 [1.06; 1276.64]    .             .     .       .
                  Gefitinib + antiangiogenesis:antiangiogenesis  0    0  1.79 [0.46;    6.89]      .             .   1.79 [0.46;    6.89]    .             .     .       .
                                   Lazertinib:Osimertinib  1 0.70  1.34 [0.59;    3.06]   1.41 [0.53;  3.78]   1.19 [0.26;    5.36] 1.19 [0.20;  7.20]  0.19  0.8498
                      Lazertinib:Osimertinib + chemotherapy  0    0  0.86 [0.24;    3.14]      .             .   0.86 [0.24;    3.14]    .             .     .       .
                    Lazertinib:Osimertinib + antiangiogenesis  0    0  0.17 [0.05;    0.53]      .             .   0.17 [0.05;    0.53]    .             .     .       .
                               Lazertinib:PD-L1 inhibitor  0    0  3.16 [0.22;   46.34]      .             .   3.16 [0.22;   46.34]    .             .     .       .
                                       Lazertinib:Placebo  0    0  1.63 [0.61;    4.35]      .             .   1.63 [0.61;    4.35]    .             .     .       .
                                   Lazertinib:Rociletinib  0    0  4.32 [0.13;  140.28]      .             .   4.32 [0.13;  140.28]    .             .     .       .
                                Lazertinib:antiangiogenesis  0    0  0.21 [0.07;    0.68]      .             .   0.21 [0.07;    0.68]    .             .     .       .
                     Osimertinib:Osimertinib + chemotherapy  2 1.00  0.64 [0.24;    1.74]   0.64 [0.24;  1.74]      .               .    .             .     .       .
                   Osimertinib:Osimertinib + antiangiogenesis  3 1.00  0.13 [0.06;    0.28]   0.13 [0.06;  0.28]      .               .    .             .     .       .
                              Osimertinib:PD-L1 inhibitor  1 1.00  2.36 [0.18;   30.35]   2.36 [0.18; 30.35]      .               .    .             .     .       .
                                      Osimertinib:Placebo  2 0.42  1.21 [0.51;    2.86]   1.70 [0.45;  6.39]   0.94 [0.30;    2.93] 1.80 [0.32; 10.28]  0.66  0.5065
                                  Osimertinib:Rociletinib  0    0  3.22 [0.10;  101.79]      .             .   3.22 [0.10;  101.79]    .             .     .       .
                               Osimertinib:antiangiogenesis  0    0  0.16 [0.05;    0.47]      .             .   0.16 [0.05;    0.47]    .             .     .       .
      Osimertinib + chemotherapy:Osimertinib + antiangiogenesis  0    0  0.19 [0.05;    0.70]      .             .   0.19 [0.05;    0.70]    .             .     .       .
                 Osimertinib + chemotherapy:PD-L1 inhibitor  0    0  3.67 [0.24;   56.89]      .             .   3.67 [0.24;   56.89]    .             .     .       .
                         Osimertinib + chemotherapy:Placebo  0    0  1.89 [0.51;    7.02]      .             .   1.89 [0.51;    7.02]    .             .     .       .
                     Osimertinib + chemotherapy:Rociletinib  0    0  5.01 [0.14;  182.15]      .             .   5.01 [0.14;  182.15]    .             .     .       .
                  Osimertinib + chemotherapy:antiangiogenesis  0    0  0.24 [0.06;    1.07]      .             .   0.24 [0.06;    1.07]    .             .     .       .
               Osimertinib + antiangiogenesis:PD-L1 inhibitor  0    0 18.84 [1.29;  274.71]      .             .  18.84 [1.29;  274.71]    .             .     .       .
                       Osimertinib + antiangiogenesis:Placebo  0    0  9.69 [2.98;   31.50]      .             .   9.69 [2.98;   31.50]    .             .     .       .
                   Osimertinib + antiangiogenesis:Rociletinib  0    0 25.75 [0.74;  892.82]      .             .  25.75 [0.74;  892.82]    .             .     .       .
                Osimertinib + antiangiogenesis:antiangiogenesis  0    0  1.25 [0.32;    4.88]      .             .   1.25 [0.32;    4.88]    .             .     .       .
                                  PD-L1 inhibitor:Placebo  0    0  0.51 [0.03;    7.62]      .             .   0.51 [0.03;    7.62]    .             .     .       .
                              PD-L1 inhibitor:Rociletinib  0    0  1.37 [0.02;  100.31]      .             .   1.37 [0.02;  100.31]    .             .     .       .
                           PD-L1 inhibitor:antiangiogenesis  0    0  0.07 [0.00;    1.07]      .             .   0.07 [0.00;    1.07]    .             .     .       .
                                      Rociletinib:Placebo  0    0  0.38 [0.01;   11.24]      .             .   0.38 [0.01;   11.24]    .             .     .       .
                                   antiangiogenesis:Placebo  0    0  7.73 [3.11;   19.25]      .             .   7.73 [3.11;   19.25]    .             .     .       .
                               Rociletinib:antiangiogenesis  0    0  0.05 [0.00;    1.48]      .             .   0.05 [0.00;    1.48]    .             .     .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 prop       - Direct evidence proportion
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
Separate indirect from direct evidence (SIDE) using back-calculation method
